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PREFACE 
This thesis is about the climacteric years of women between the ages of 45 to 60 years. 
It is based on a cross-sectional population study and a longitudinal study in the same 
population. The climacteric is the period in which transition occurs from the fertile state 
into the infertile state. By hormonal change the menstrual cycles alter and finally cease. 
In figure 1 we see how this period is divided in a pre-, peri- and postmenopausal period, 
in which the menstruation is respectively regular, irregular and has ceased for more than 
12 months. 
peri menopause 
fertile state senium 
premenopause postmenopause 
Figure 1 menopause 
When a woman presents symptoms and lor complaints in the climacteric period, it is not 
easy to distinguish whether these symptoms and/or complaints are caused by endocrine 
changes, chronological aging, social or psychological factors, or by interactions 
between these factors. This is illustrated in fig 2. Since the mere presence of symptoms 
does not reflect the experience of them, we have chosen for the concept of well-being. 
Well-being can be operationally defined as the sum score of a set of measurement scales, 
evaluating one's bodily state, one's feelings and aspects of daily life. 
The power of well-being measures lies in the fact that different groups can be 
compared. We think there exists a relation between attitudes towards the climacteric 
and well-being in such a way that women with a more positive attitude towards 
menopause will experience the transition more positively. There are very few studies 
available which examined the use of hormone replacement therapy in relation to well-
being, attitude towards menopause, menopausal status and personal variables. 
Figure 2 
The main objectives of this thesis are: 
I. To study the relationship between well-being and menopausal status. 
II. To establish the relationship between women's attitude towards menopause and 
well-being. 
III. To examine the aspects in which women differ who do or do not use hormone 
replacement therapy. 
In chapter I of this thesis a review of the literature is given starting from the question 
whether there exists a climacteric syndrome in terms of symptoms and complaints, 
exclusively and independently connected with the climacteric status. Another question 
we try to answer is if there is an association between serum hormone levels and a 
possible climacteric syndrome, analogous to for example diabetes mellitus, 
hypothyroidism and Addison's disease. Furthermore we ask ourselves the question, does 
estrogen replacement therapy bring about relief in symptoms and complaints of this 
feasible syndrome? The concept of well-being will be discussed in this chapter. 
Methodological issues get emphasis, because methodological imperfections may lead 
to wrong conclusions. Also the attitudes towards menopause will be discussed. Aside 
the medical view of a possible climacteric syndrome, it is interesting to know from the 
women themselves their attitudes and beliefs towards the menopause. Finally the use 
of hormone replacement treatment among women is discussed. Chapter 2 describes the 
cross-sectional assessment of the relationship between menstrual age i.e. pre- peri- and 
postmenopausal women and well-being independent of differences in potential 
confounding variables in a population at large. Chapter 3 reports the relationship 
between vasomotor symptoms, well-being and menopausal status. In Chapter 4 is firstly 
described the attitude towards menopause of women aged between 45-60 years. 
Secondly the relationship between attitude towards menopause and well-being is 
assessed. Thirdly, the question about the relationship between medical attention and 
both well-being and attitude will be answered. Chapter 5 concentrates on the opinion 
of women on the continuation or re-induction of artificial cycles with hormone 
replacement therapy. In chapter 6 the cumulative incidence of HRT is described and the 
influences of women's well-being, attitude towards menopause, menopausal status and 
other variables on the initiation of HRT prescription in a population at large is studied 
during a 9 month follow-up period. Chapter 7 deals with the duration of HRT and its 
determinants in a 2 1/4 year follow-up period. Chapter 8 is a general discussion in which 
the implications of this thesis for the physician are given. 
Each chapter can be read independently from the others; together they form a picture 
of the climacteric years seen from a scientific point of view and from the women 
themselves. 
CHAPTER 1 
GENERAL INTRODUCTION: A LITERATURE REVIEW 
FPMJ Groeneveld 
Department of General Practice, Erasmus University Rotterdam, Rotterdam, The 
Netherlands. 
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IS THE CLIMACTERIC SYNDROME AN ENTITY ? 
1. 1 Introduction 
During the premenopausal years the cyclical events gradually decrease until 
postmenopausal amenorrhea is established. The primary process takes place in the 
ovaries as a gradual decline and final cessation of the generative and endocrine 
functions, although a certain non-cyclical endocrine activity of the ovaries is maintained 
until advanced age.
' 
Alexander found that the absence of ovarian steroids does not 
influence the hypothalamic secretion of gonadotropin releasing hormone (GnRH): the 
mean level of GnRH does not change with advanCing age. The lack of response of 
postmenopausal ovaries to endogenous gonadotropin stimulation is a result of primary 
age-related changes in the ovaries, not in the hypothalamus.2 As a result ofthe decrease 
in estrogens, the feed-back of ovarian estrogens on the hypothalamus diminishes, 
resulting in high FSH levels. A high serum FSH level is the only constant laboratory 
finding in the postmenopausal years. Apart from hormonal changes other effects of the 
aging do occur. No study so far has pointed out that in the climacteric years there is an 
acceleration of aging.3 
1.2 Symptomatology of the climacteric 
The climacteric years are associated with many symptoms. Consensus exists that severe 
(nocturnal) sweating and flushes (i.e. vasomotor symptoms) and menstrual disturbances 
are more frequent in the climacteric years than in other phases of life and therefore the 
symptoms are often qualified as typically climacteric. Dyspareunia caused by vaginal 
atrophia on the other hand, more frequently occurs in the postmenopause.4,5,6 These 
symptoms however are not pathognomonic of the climacteric. Hyperthyroidism, abuse 
of alcohol, carcinoid, nervousness, and drugs such as weight reducing drugs, vasodilatantia 
(nitrates) may mimic typical climacteric symptoms. Apart from these typical complaints, 
a variety of symptoms have been reported to be associated with the climacteric per se, 
i.e. to the change in steroid production of the ovaries. Incorrect attribution either by the 
doctor or the patient of symptoms in the climacteric to hormonal imbalance can cause 
unnecessary medicalization, a failure to recognize diagnoses and possible withholding 
of an appropriate treatment. In a very popular Dutch women's magazine 'Libel Ie', 
doctors recently wrote that in the years before and after the menopause, complaints like 
flushes, tachycardia, sleepingdisturbances, painful joints, listlessness, depression, and 
numbness in the limbs often occur and can be treated by hormone therapy.' Such 
unestablished remarks may be harmful, especially since women's magazines are proven 
to be the most important source of information on hormone replacement therapy.,,9 
Furthermorethere is 'The Cold-effect'. ProfessorT.Gold postulated that when hypothetical 
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ideas are formulated by authorities in a specific field, they become fixed views, which 
are very difficult to break through, especially when they are published in well-
established medical magazines. 'O Wilson with his book 'Feminine Forever' was harshly 
criticized for his disregard of the scientific procedure in his advocacy of HRT; yet there 
is no denying his impact. His clarion calls stirred millions of climacteric women.
'
!.l2 In 
the Netherlands the population of women aged between 45-60 years will increase to 
about 1,2 million women in the year 2000. Thus, incorrect attribution can augment to 
a notable extent.13 The true relationship between the climacteric and symptoms is a 
complex matter of determining the likelihood that alternative explanations such as 
chance, bias, or confounding could account for the findings. 
Aside from biological changes there are many other phenomena occurring in this age 
period, which may be causally related to these symptoms or their intensity.'4 In addition, 
inappropriate design strategies can distort the relationship between the climacteric and 
certain symptoms. 
The most important issues, which influence the evaluating of the cause and the pattern 
of symptoms and complaints will be discussed below. 
A. life events 
Life events such as diseases and death of family members, loss of job, the maturation of 
children and their departure from home, often co-occur in the climacteric period. 
Psychological symptoms were found to be directly and linearly related to stress arising 
from miscellaneous sources. Somatic symptoms were elevated only if such stress was 
accompanied by stress arising from exits. The results suggest that both additive and 
multiplicative relationships between life events and distress exist. 'S Cook found that 24% 
of the variance in psychological symptoms in the climacteric could be explained by 
independent life events, while the 27% of variance in somatic symptoms could be 
explained by the same variable. Furthermore, is argued that social relationships may 
modify detrimental effects of life events in a positive way.16 Some studies found that 
women whose children left home were generally more satisfied than women whose 
children remained. It looks as though the empty nest period is not a stressful one."·18 
B. Sociodemographic factors 
Factors such as education, marital status, work outside the home are related to 
symptoms. Krause found that work outside home can reduce negative effects of several 
types of marital stress, but not stress arising from the childcare role l9 McKinlay and 
Hunter found Single women less likely to be depressed, then married women, while 
those who were widowed or divorced were most likely to be depressed.2021 Hunter 
found that unemployment was a predictor of somatic symptoms.22 
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C. Personality 
The premorbid personality and coping behaviour have been reported to determine the 
experience of symptoms. Veeninga found that women visiting a menopause clinic 
compared to controls, attending a general practitioner for routine screening i.e. cervical 
smear did not differ in the total number of life events and exits. The women visiting 
menopause clinic experienced these life events more seriously.23 Holte found that 
women who reported that their mothers had perceived psychological complaints during 
menopause, expressed more vague somatic complaints themselves during menopause. 
Coping behaviour learnt from mother may play an important role.24 This indicates that 
a higher susceptibility to stressful life events rather than the occurrence of specific life 
events plays an important role in the experience of symptoms which are often attributed 
to the menopause. 
While not all studies, however, fully agree with the extent to which psychosocial 
variables influence the occurrence of symptoms. Yet, it is beyond dispute they do have 
an impact. 
D. Cultural factors 
Fourthly, cultural factors may determine the significance attached to concepts such as 
youth, menstruation, fertility, sexuality, menopause and aging. Muslim women for 
example regard menopause sometimes as a benefit since they are not allowed to perform 
religious rituals during their menstrual periods.2s Margaret Lock found that there is no 
particular word for hot flush in japanese. She suggested that this lack of perceived 
importance is due to the fact that menopause does not have any special social or ritual 
status in japan. In the majority of japanese women, menopause was seen more as an 
aging process than an important event.26 Of course language problems, the way some 
cultures express emotional changes in different ways, as well as bias introduced by the 
investigators may influence cross-cultural comparisons. 
E. Methodological strategies 
Other difficulties in establishing the association between symptoms and hormonal 
changes during normal menopausal development are methodological problems in 
detecting the possible association. Every stage of an investigation is susceptible to 
systemic errors. These are potentially serious, since the bias they cause may lead to 
invalid conclusions. Many earlier studies about the climacteric have had several 
methodological shortcomings 27: 
a) The recruitment of women from visitors to menopausal clinics. This may lead to 
selection bias and reduces the generalizabilty of the results.2829.30.31 
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b) Much attention has been paid in the questionnaire to the menopause 
(information bias: women could select from their experiences only those 
symptoms which they believe to be related to menopause).28,32 
c) Retrospective studies which may lead to faulty recall bias.3D 
d) The menopausal status was inappropriately categorized, leading to either an 
underestimation or overestimation of the association 2829 
e) Confounding variables were not taken into accQunt.28.29,3Q,3L32 
Confounding bias occurs whenever there are important differences between the groups 
being compared, which are also related to the variable of interest." For example a lower 
level of education is associated with a lower level of well-being. The average 
postmenopausal woman (an older woman) is less well-educated than the average 
premenopausal woman (a younger women). If there is no adjustment for difference in 
education, the fact that postmenopausal women experience a lower level of well-being 
than premenopausal women could be wrongly attributed to the climacteric. 
F. Statistical analysis 
The advancement of epidemiology corresponds with the fact that thinking about the 
causes of diseases from monocausal model, inherent to bacteriology, began slowly to 
make place for the multicausal model. One of the major essentials in family practice 
nowadays is to make an "integrated diagnosis" i.e. to record pathophysiological, social 
and personal factors of a particular patient at a definite moment. Till about 1975 only 
frequencies of symptoms were measured. Greene used factor analysis for the first time 
to get insight in the relationships between groups of symptoms and the climacteric.29 
Later on sophisticated statistical analysis together with advanced computer programmes 
came available. As a consequence, it is possible to investigate the joint influence of 
variables, the frequency of phenomena as a function of determinants, among large 
populations. 
Thus till about 1977 a climacteric syndrome was described on the basis of numerical 
scores and not always an adequate methodology was applied. Blatt expressed the 
climacteric syndrome in 13 symptoms, Jaszmann only in 9, Neugarten nO less than 41 
and Greene summarized 21 symptoms. Most of the information supplied to the general 
population about the climacteric has been based purely on symptoms and clinical 
experience. 2829 ,32,34 
1.3 WeI/-being 
By symptoms we mostly mean a sign we can objectively determine, for example 
coughing, sweating and vomiting. Complaints are the subjective experience of a patient, 
which are for the doctor hardly to objectify like headache and tiredness. On the other 
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hand not every objective 'diagnosed' symptom will be experienced in the same way by 
patients. Provided that there are symptoms caused by the hormonal changes in the 
climacteric, it is very difficult to measure the impact on women's health. F[ushes can be 
bothersome, but to be free from periods may be a relief. 
Ho[te found that the climacteric transition is also accompanied by relief; 40 to 51 % 
reported less headaches and 46 to 48% had less breast tenderness after menopause.35 
These changes were mainly due to the relief from premenstrual and menstrual 
complaints. A[though a significant increase was found in vasomotor symptoms, vaginal 
dryness, palpitations and social dysfunction, it was pointed out that 16 to 24% had fewer 
vasomotor complaints, 16 to 20% had less dryness of the vagina and 22 to 24% had 
less social dysfunction after menopause. Ho[te concluded that: the widely accepted 
perception of menopause as an event followed by uniformly negative change in health 
complaints is erroneous and that reality is far more complicated and involves large 
individual variation. 
Describing symptoms is a narrow spectered view on patients and from sociological 
sciences the concept of well-being has entered medical practice. Well-being can be 
defined as a multifactorial construct. The relevant well-being dimensions include36•37•38: 
a) subjective experience, self-assessed health, i.e illness. The way people perceive 
their complaints may differ considerably from the way the complaint should be 
viewed objectively. 
b) functional aspects in daily life such as social duties and intellectual functioning, i.e 
the sickness 
c) symptomatica[ aspects, the effects of diseases for instance the overwhelming ache 
with a heart attack, dyspnoea in case of asthmatic bronchitis i.e. the disease. 
Numerous earlier studies used psychometrically undocumented measures, making 
comparisons between different populations and/or studies difficult. [n the eighties many-
sided descriptions of the impact of postmenopausal complaints extending beyond that 
of pure symptomatic relief were developed. These measurement instruments used 
standard questionnaires with well documented re[iability and validity. However they 
often got different names such as well-being, quality of life and health status instruments, 
which are a[[ synonyms, but are not interchangeab[e.39 [t should be noted that for the 
validity there is a lack of generally acceptable criteria, or a 'gold standard' for such 
constructs as we[[-being.40 
1.4 Recent cross-sectional and longitudinal studies 
Studies of a representative sample of apparently healthy women experiencing normal 
aging are required to offset the biased portrait of the climacteric which was derived from 
studies in highly selective clinica[ populations. Studies of large unse[ected female 
populations using standardized methods of case detection and measurements of we[[-
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being were carried out in several countries such as USA, Canada, Norway, England, 
Japan and the Netherlands. In table 1 and 2 characteristics are shown of the most 
important recent cross-sectional and longitudinal studies. 
McKinlay included five measures of well-being, self-assessed health, measurement of 
chronic disease, daily activity, a sum score of common symptoms (such as persistent 
cough, diarrhoea, etc) and a list of symptoms of non-physical origin.41 In this study the 
utilization of formal and informal health was measured. The vast majority of peri- and 
postmenopausal women in this cross-sectional study did not report more symptoms or 
poorer health status and did not use more medical services than premenopausal women. 
The 'typical' menopausal woman is neither sick nor a high user of medical care. In a 
longitudinal study by the same author similar results were found, although insomnia was 
found to be associated with vasomotor symptoms.42 The symptom reporting however, 
appears to be transitory, with reported rates showing an increase in perimenopause and 
a compensatory decrease in the postmenopause. In the Mannitoba cross-sectional as 
well as in the longitudinal study no significant increase in emotional symptoms in 
women throughout the different menopausal status was found.27A3 In order to avoid 
emphasis on menopausal symptoms Hunter studied women in the climacteric period 
naming the questionnaire used 'The Women's Health Questionnaire'." Thirty six 
symptoms were rated, a factor analysis was carried out resulting in the identification of 
the following groups of symptoms: somatic symptoms, depressed mood, cognitive 
difficulties, anxiety and fears, sexual functioning, vasomotor symptoms, sleep problems, 
menstrual symptoms. No significant change in sexual interest, sexual satisfaction, 
somatic symptoms or anxiety during menopause was found. However, the sum score on 
the symptom group 'sleep problems' and 'depressed mood' was higher in peri- and 
postmenopausal women compared to premenopausal women, but was of modest 
proportion. In the cross-sectional part in Hunter's study, menopausal status and 
socioeconomic status accounted for only 4% of the variation in the occurrence of 
depressed mood. In the longitudinal part of the study premenopausal depression was the 
strongest predictor of depressed mood during the menopause, accounting for 34% of the 
variance.44 No association was found between vasomotor symptoms and concurrent 
mood. Holte concluded from a cross-sectional study that menopausal development 
played only a modest role, if any, in explaining variance of many measures of well-being 
such as vague somatic complaints, nervous complaints, mood and urogenital complaints." 
In Holte's prospective study only a significant increase in social dysfunction after 
menopause was detected.35 This may be caused by vasomotor symptoms as was shown 
by the regression analysis. A remarkably substantial number of women reported an 
improvement in well-being following menopause. Lock, using a 57 item symptom 
checklist, found that Japanese women who had stopped menstruating did not report any 
more emotional symptoms than women who were still menstruating.26 
Matthews investigated 541 initially premenopausal healthy women.46 After three 
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years of follow-up, 69 women had ceased cycling for 12 months. A battery of sum score 
measures were used, evaluating for example anxiety, anger, self-consciousness, perceived 
stress, depression, job dissatisfaction and Neugarten's symptomlist. Comparison among 
groups at the baseline and follow-up examination showed an increase in hot flushes 
during menopause. Further, natural menopause led to few changes in psychological 
characteristics. 
In a Danish eleven year prospective study it was not possible to demonstrate a 
significant correlation between menopausal status and sexual desire4 ? In this study the 
only significant predictor of decreased sexual desire at the age of 51 was the 40-year old 
women's anticipation of decreased sexuality as a consequence of menopause. This 
means for women that their negative anticipation towards their own sexuality in this 
period of life turned into a self-fulfilling prophecy. 
Olden have in a cross-sectional study found no clear relationship between menopausal 
status and well-being.4S Well-being was measured by a list of 21 atypical complaints, 
which correlated with a well-being measure, 'The General Health Questionnaire'. 
However, in the presence of vasomotor symptoms a more negative impact on well-bei ng 
was apparent; a relationship between the severity of vasomotor symptoms and the 
severity of atypical complaints was established. This could support the 'domino-
hypothesis' which regards certain psychological complaints as secondary manifestations 
of disabling vasomotor symptoms (hot flushes, sweating) and not causally related with 
the hormonal changes associated with menopause. It should be stressed, however, that 
in a cross-sectional study one can only study the association between vasomotor 
symptoms and atypical complaints, whereas a causal relation is difficult to discern in the 
absence of a longitudinal design. For example the relationship between night sweats and 
sleepingdisturbances may be explained in two ways. On one hand the night sweats can 
wake up the women in the night. On the other hand sleepingproblems, lying awake at 
night may magnify a woman's perception of night sweats. Moreover, potential 
confounding variables such as education and marital status were not taken into account 
in this study. 
In the longitudinal study of Hunter there was a tendency for women who were 
depressed in the premenopause to develop vasomotor symptoms in the peri-and 
postmenopause. Ballinger found that women attending menopause clinics did suffer 
from significantly more life stress, symptoms and depression than a matched grouP"of 
women who did not come to the clinic.49 The clinic patients perceived the same events 
more distressing compared to the non-clinic patients. Moreover significantly more clinic 
patients had suffered from depression prior to the climacteric. There was no difference 
in the occurrence of hot flushes between these two groups (70-80%). However hospital 
patients reported hot flushes of Significantly greater severity. In short, the relationship 
between flushes and other symptoms can be confounded by underlying factQrs such as 
depressed mood and I ife stress. 
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Table2. OvelView of recent longitudinal studies about the relationship between the climacteric and symptoms/well-being. IV IV 
Study Recruitment Ageof Follow up Variables induded in the Measurement instru- Analysis Major outcomes 
women period analysis apart from age ments 
approached and menopausal status 
McKinlayt2 N=2,570 45-55 5 year smoking see cross-sectional - regression - significant increase of vasomotor 
Massachusetts premenopausal parity study analysis symptoms and insomnia. 
1982 continuation of educational level - sleep disturbance associated with 
cross-sectional body mass index vasomotor symptoms 
study 
Cl 
HolleJs N=200 45-55 5 year see cross-sectional study 24-ilem symptom list - regression - significant increase in vasomotor m Z No"vay randomly Personality test analysis symptoms, vaginal dl)'ness, heart m 
1982 selected Psychosocial defence ~ analysis of palpitations and social ~ premenopausal test variance dysfunctioning following the , 
continuation of Sex-role indentifica- - summary menopause. Z 
cross-sectional tion measurements - further analysis indicated that -i 
study Self-esteem procedure vasomotor symptoms caused the 
'" 0 increase in social dysfunction 0 
C 
KaufertU N=477 40-59 3 year marital status CES-D - factor analysis - only association bet>.'Jeen meno- Q 
Mannitoba premenopausal education level pausal status and vasomotor 6 
1982 continuation of employment status symptoms if' 
cross-sectional )-
study 
, 
=1 
m 
Hunter4-1 N=200 >47 3 year marital status WHQ=;:36-item - factor analysis - vasomotor symptoms, ~ 
England premenopausal social class symptom list - multiple sleepprobJem and to a lesser C 
'" 1983 continuation of employment status GHQ (General regression extent depressed mood increase m 
cross-sectional Health Question- significantly during peri- and 
'" m study naire): mood disturb- postmenopause. peri. and ::; 
ance postmenopausal women do not m 
more frequently visiting their doc- ~ 
tors compared to premenopausal 
women. 
- no changes in sexual interest. 
sexual satisfaction, somatic symp-
toms or anXiety. 
Table 2. (continued) 
Study Recruitment Age of Follow up Variables included in the 
women period analysis apart from age 
approached and menopausal status 
Matthews46 N=541 42-50 5 year marital status 
Pennsylvania premenopausal educational level 
1983 sample of driving current religion 
license list 
Kosterl1 N=621 40 11 year marital status 
Denmark social status 
1976 
Measurement instru- Analysis 
ments 
Spielberger trait - analysis of 
anxiety and anger variance 
SCI private Self- . analysis of co-
Consciousness variance 
SCI public Self-con-
sdousness 
Cohen perceived 
stress 
Beck depression 
InventOlY 
Paid Job dissatis-
faction 
Number of symptoms 
sexual items - multiple log is-
tic regression 
Major outcomes 
- increase of hot flushes 
- natural menopause led to few 
changes in psychological charae-
teristics, only a decline in 
i otros pectiveness. 
- the 51-year-old women's experi-
ence of frequency or change in 
sexual desire was not related to 
menopausal status. 
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1.5 Conclusions 
Most large scale cross-sectional and longitudinal studies found that vasomotor symptoms 
and vaginal dryness are significantly related to menopausal status. The two vasomotor 
symptoms, hot flushes and night sweats, which are strongly associated with menopausal 
status in Western research literature, had a relative low incidence in Japanese women. 
In general these studies showed that the menopausal transition does not have an 
important impact on well-being, including sexuality. Some studies did report a relation 
between complaints (sleepingdisturbances, social dysfunction) and the presence of 
vasomotor symptoms. Most complaints in the climacteric years were not associated with 
menopausal development, but could be explained by a mixture of other biological, 
psychological and social variables. Given the available recent evidence, apart from 
typical complaints, there are too few indications to speak of a well-defined climacteric 
syndrome. 
2 THE ASSOCIATION BETWEEN HORMONE CHANGES AND SYMPTOM 
REPORTING 
Many hormones, their metabolites and gonadotropins like FSH, LH, estrogen, epinefrine, 
norepinephrine, prolactin, 5-hydroxy-indole acetic acid (5-HlAA), androstendion have 
been studied in their relationship to vasomotor symptoms and other complaints. None 
of these have any value in predicting either the duration or the severity of symptoms and 
complaints. Although the drop in estrogen production at menopause is characteristic, 
levels of all hormones are similar in flushers and non_flushers."o.51 
3 EFFECTS OF ESTROGEN REPLACEMENT THERAPY DURING THE CLIMACTERIC 
The question whether estrogen replacement therapy brings about relief in symptoms and 
complaints and does improve well-being, should be resolved by a randomized double 
blind placebo controlled trial, especially since vasomotor symptoms have been shown 
to be highly responsive to placebo. A randomized double blind placebo controlled trial 
has several methodological limitations. 
(i) In the seventies it became clear that the incidence of endometrium cancer is higher 
in postmenopausal women when estrogens are used.52 .53 There is sufficient evidence 
that when progestogen is added to estrogen the risk of endometrium cancer 
decreases.54~s. Nowadays, a combination of estrogen with periodic progestogens is 
considered a safe hormonal therapy. Such a combination induces withdrawal 
bleedings in most women.56 For women with irregular menses, such a hormonal 
schedule induces regular bleedings and for women who had stopped menstruating 
the periods start again. For these women it seems impossible to ensure a blind 
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comparison. 
(ij) Estrogens can alleviate vasomotor symptoms substantially, but often give tension in 
the mammae.57~8 This further reduces the possibility of blinding; the women may 
become aware of the effect of the hormone. 
(iii) By adding progestogens to estrogen treatment, the separate attribution of estrogens 
to the improvement of symptoms and complaints can not be measured. 
(iv) Another problem is the difficulty of defining and measuring the outcome measures 
which assess the efficacy of estrogen replacement therapy. In case of osteoporosis 
and heart disease the endpoints are quite pathophysiologically defined, however the 
problem then is the long follow-up period for 1 0-20 years. Vasomotor symptoms and 
vaginal dryness may be relatively easy to measure. However, to measure depression 
and the level of well-being it is necessary to use sensitive, valid and reliable 
psychometric tests. 
It is disappointing to find, that quasi-experimental designs have dominated this research 
area. The most common study design applied is the single-group pre- versus posttest 
design. Wiklund used several measures of well-being and mood, which are 
psychometrically correct, such as the Psychological General Well-Being index (PGWB), 
the Sleep dysfunction Scale and the Women's Health Questionnaire.38 From the 136 
women in his 9-month follow-up study to assess the efficacy of HRT 110 completed the 
study. An open study design without a placebo control group is always questionable as 
Wiklund recognized himself, but he argued that the placebo effect disappears within a 
few months, so that if the follow up period is long enough this may compensate for the 
lack of a placebo controlled study. He simply passed the fact that without randomization, 
including a control group (irrespective of a placebo) there is no adjusting for the natural 
course of complaints. The severity of flushes varies enormously from time to time in the 
same woman. The author concludes cautiously that women using transdermal estrogen! 
progestogen therapy experienced relief from vasomotor symptoms and also enjoyed 
secondary beneficial effects on sleep disturbances and mood. 
It appeared to be almost impossible to design a study to assess whether well-being is 
improved by estrogen therapy by means of a randomized double-blind placebo 
controlled study. Some investigators found a solution to the problem of blinding by 
performing studies among hysterectomized women. An additional profit is that only 
estrogen can be used, because there is no more intact uterus. However hysterectomized 
women are a selected group. 
Dennerstein (N=49) performed a double blind cross-over study in hysterectomized 
bilateral oophorectomized women.'9 Ethynyloestradiol had a beneficial effect on mood 
as measured by the Hamilton depression rating scale scores and interview ratings of 
general well-being, fatigue, anxiety, irritability and insomnia. 
Paterson (N=23) also studied hysterectomized women and found a significant 
reduction in hot flushes and night sweats. There was a slight improvement in insomnia 
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and an increase in energy.60 No alteration in depression, anxiety, memory and even 
vaginal dryness was established. 
Ditkoff (N=36) randomly assigned asymptomatic hysterectomized women to a 
double blind treatment regimen.61 He found a significant improvement in depression 
scores on the Beck Depression Inventory, although there was no dose-response effect. 
Another way to maintain blinding is to use only estrogen therapy, which alone will 
mostly give no withdrawal bleedings. Only two studies are reported. 
Campbell (N=64) found estrogen to be more effective than placebo in alleviating 
symptoms such as hot flushes, vaginal dryness, poor memory, anxiety.62 This effect was 
similar in women without flushes, indicating a direct positive effect of estrogen on 
mental status. Wiklund (N=223) blindly and randomly allocated to either estradiol or 
placeboM The duration of the study was only 12 weeks and no progestogen was given. 
In this study several quality of life measurement scales were applied: Nottingham Health 
Profile, Psychological General Well-Being, Women's Health Questionnaire, McCoy 
sex scale and self-rated symptoms. Quality of life improved after both therapies, but was 
more pronounced for estradiol. However, it looks as though estradiol therapy is 
statistically significantly superior to placebo, no comment is given to the clinical 
relevance. Nevertheless, some studies pointed out that the beneficial effects of estrogens 
on mood and sexual functioning were reduced by progestogens.59•60.64 
Walling made an extensive review of studies in which the impact of hormonal 
replacement therapy on sexual behaviour and functioning in postmenopausal women 
was examined.65 With estrogen, gynaecologic improvement i.e. reduction in atrophic 
vaginitis occurs. Specific effects of sexual behaviour (e.g., increase in coital frequency) 
are less often found, but there is a consistent trend of global improvements in sexual 
desire. It is difficult to know wether the sexual improvements are the result of the 
reduction of atrophic vaginitis or the direct effects on sexuality. 
3.1 Conclusion 
The best scientifically accepted design to establish the effect of estrogen therapy in 
relieving symptoms, complaints and improving well-being is a randomized double-
blind placebo controlled trial. The major problem in the design is blinding, caused by 
the presence of withdrawal bleedings as a result of the combination of estrogens with 
progestogens. To maintain blinding, some studies were performed in hysterectomized 
women, of which the generalizability of the results are of course questionable. Other 
studies used estrogen only. Furthermore, different modifications in therapies have been 
used: different hormones, dosages and modes of administration. 
In conclusion from the few randomized double blind control trials it was apparent that 
estrogen therapy (i) has a significantly and substantially effect in relieving vasomotor 
symptoms and vaginal dryness (ii) has a modest beneficial effect on mood, sleep 
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problems, sexual functioning and well-being; however, these may be reduced by adding 
progestogens (iii) has an outspoken placebo impact on these symptoms, complaints and 
well-bei ng. 
4 THE ATTITUDES OF WOMEN TOWARDS MENOPAUSE 
4.1 Introduction 
By attitudes towards menopause we mean the beliefs, feelings, and action tendencies 
of a group of women towards menopause. The opinion of the women themselves is of 
importance to the doctor in order to see the women's symptoms and complaints in the 
perspective of understanding. Attributions made about symptoms have important health 
consequences66: 
a) When women tend to attribute symptoms to the menopause, which are not related 
to the menopause, this may lead to an unjustified emphasis on the climacteric origin 
of these complaints. As a consequence, another possible cause of the complaints 
may remain unrecognized leading to patient's or doctor's delay and to unsuitable 
treatment or unnecessary prescription of medicines. 
b) In contrast, women may refuse beneficial hormone replacement therapy to reduce 
hot flushes, vaginal dryness, menstrual disturbances and for the prevention of 
osteoporosis and cardiovascular diseases as a repercussion oftheir attitudes towards 
menopause. 
In the Netherlands, the general practitioner is the first physician a 'climacteric' women 
will turn to for help. Van de Kar found that apart from the efficacy of the general 
practitioner's care and the perceived severity of complaints, the efficacy of self care, 
knowledge aboutthe complaint and the need for information are important determinants 
in consulting the general practitioner67 
Anderson found that 79 of the 100 women reported physical symptoms and 63 
reported emotional symptoms as the primary reason for seeking medical attention at the 
Academic Menopause Clinic.68 This selected group of women knew little about the 
menopause, but they had gained helpful new information about the menopause. To 
successfully break through the self-labelling processes, it is necessary to gain insight into 
attitudes of the women towards the menopause in populations at large. In the study of 
Frick-Bruder 60% of the women expressed the need for more information about the 
climacteric.69 Surveys show a discrepancy between the doctor's perception of the 
attention and care he gives to his patients and the women's perception of the care he 
provides. Feeling of ignorance can increase both anxiety and symptoms70 
Barlow found that 27% of the consultations related to menopause included advice and 
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discussion only, illustrating the role of doctors in informing and reassuring menopausal 
women.7l In general, anxiety reduction is also possible by giving clear information about 
the illness under discussion.'2 
4.2 Attitudes towards menopause in general 
Only a few studies assessed the women's attitude towards the climacteric concerning 
general statements.41M,69,73,?4.75 Neugarten found that the majority of women did not hold 
a negative attitude and that younger women had a more negative attitude than 
postmenopausal womenJ3 
Frick·Bruder studied 1127 women of which 908 had a positive attitude towards the 
menopause and 167 a negative attitude. The women older than 50 years had a more 
positive attitude compared to women under 50 years.69 
Leiblum administered a 10·item Menopause Attitude Questionnaire to a sample of 
244 pre·, peri·, postmenopausal and hysterectomized women, recruited from a variety 
of settings.'4 The majority of women in this study, especially women with a lower 
educational level and older women, felt that the menopause should be viewed as a 
medical condition and treated as such. They did not subscribe to the notion however, 
that it was a particularly malevolent one. Although women in this study tend to agree 
that menopausal symptoms are brought about by changes in estrogen levels, they 
nevertheless prefer 'natural' treatments over estrogen replacementtherapy for alleviation 
of menopausal complaints. This is probably caused by the general anxiety about the 
possible causal role of estrogen use in the deveJopment of endometrial· and breast 
cancer following publications in the seventies and late eighties respectively. From these 
studies it was apparent that women are united in their belief that their sexuality is 
undiminished subsequent to the menopause, this being even more strongly endorsed by 
postmenopausal women. 
The studies mentioned above are based on small and usually non·representative 
samples of women. The study of Avis is an example of an excellent study on certain 
aspects of attitudes towards the menopause i.e. feelings about cessation of menses'and 
statements about menopause (statements concerning HRT were not included).75 The 
study was based on a large community sample (N=2,565). Further, a longitudinal 
analysis was performed taking into account some confounding variables including age, 
marital status, employment status, number of children. There was a classification of 
women into menopausal status according to the last menstrual bleeding excluding 
women who had undergone hysterectomy.2? Another advantage of this study was the 
fact that the same statements concerning the menopause were used in two other studies, 
one in Japan and one in Canada, providing the opportunity to compare women's 
responses across cultures. Avis established that (j) The majority of women report relief 
or neutral feelings about the cessation of menses; (ij) The attitude of women who were 
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premenopausal at the beginning of the study changed towards more positive attitudes 
when they became post-menopausal; (iii) The variables that significantly discriminated 
between positive and negative feelings concerning the climacteric years were 
psychological symptoms, education, depression and physical symptoms. Negative 
attitudes towards menopause prior to experiencing menopause were related to higher 
symptom reporting during menopause. Also Holte found that nervous complaints are 
associated with negative expectations regarding 'the change'.24 This supports the 
existence of a self-fulfilling prophecy as advocated by some authors. Avis, for example, 
stated that the so-called menopause syndrome may be more related to personal 
characteristics than to menopause per se. 
4.3 Attitudes towards HRT 
Apart from women's general attitudes towards menopause, it is interesting to know their 
desirability about starting hormone replacement. Women's own views on HRT have 
rarely been investigated. 
The study of Ferguson and Sinclair estimated attitudes towards HRT in the USA and 
England respectively.76.77 Both studies used the same questions to measure attitude and 
showed: 
Ii) Women taking HRT compared to women who have never taken HRT were far more 
likely to view menopause as a medical condition and were less likely to favour non-
medical approaches. 
(ii) Women currently taking HRT are neutral to the statement 'sexual interest and 
comfort increase after menopause', while women who have never taken HRT are 
more often in agreement with this statement. 
(iii) Women on HRT more often agreed with the statement that one cannot control 
menopausal changes inside one's body. 
Rothert and Robert found that women are mainly concerned about hot flushes and 
disruption of their daily life and this was for many women a more important consideration 
than morbidity and mortality of osteoporosis and cardiovascular diseases9 .78 
Hunskaar pointed out that most women have already collected some information and 
have formed an opinion about the menopause before consulting their physician.' Thus 
the role of the general practitioner consists of sensing the situation, discussing the 
subject, advising and if necessary correcting the views of the women. Hunskaar further 
argued that women follow their doctor's recommendations, suggesting that simple 
communication could significantly alter the use of HRT. Many women were concerned 
about the risks of HRT, but their opinions on the actual risk profile did not correspond 
with present scientific knowledge of HRT. There was a strong association between a 
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negative attitude towards using hormones and belief in an increased risk of serious 
disease such as heart infarction, stroke, breast cancer and cancer in general. 
4.4 Conclusions 
Most women have a neutral to positive attitude towards menopause, evidently women 
who already experienced menopause are more positive than premenopausal women. 
Negative attitudes are clearly related to complaints. Women generally believe that 
sexuality is not influenced negatively by the menopause. 
The women are divided regarding the issue of hormone replacement therapy. Only 
women who view menopause as a medical condition show a clear tendency to start the 
use of HRT. 
An interesting but yet unresolved scientific question is how women acquire these 
different attitudes towards HRT. 
5 HRT USE 
5.1 Introduction 
Figures about the prevalence and compliance with HRT will vary in time and differ in 
various countries. These figures give an impression of the doctor's agreement to 
prescribe HRT and to woman's willingness to start and comply with HRT. 
5.2 Prevalence HRT 
Relatively few women use hormone replacement therapy between the age of 40 to 70 
years. Data about the prevalence of HRT use in some countries is shown in table 3. The 
prevalence in European countries is in Italy is 3%, UK 7%, France 13%, Germany 25% 
and in Denmark 16%. In South Australia the prevalence was 14% among women aged 
40-65 years. In California current estrogen use was 32% among women aged 50-60 
years. A clear discrepancy between the intention to prescribe HRT and the actual use 
Table 3. Prevalence of estrogen replacement therapy 
Country Prevalence of estrogen use Country Prevalence of estrogen use 
Italy 3% Denmark 16% 
United Kingdom 7% South Austral ia 14% 
France 13% California 32% 
Germany 25% 
GENERAL INTRODUCTION:A LITERA TLlRE REVIEW 31 
of HRT has been reported in this study namely 75-95% of the gynaecologists would 
prescribe estrogen therapy to most of their patients.79•80,S1.82.83 
5.3 Physicians attitude towards HRT 
In the Netherlands Stouthamer studied the view of 195 GPs as to the climacteric.84 
Ninety-five percent of the GPs were of the opinion that women with climacteric 
complaints need some kind of medical help, 62% prescribed some kind of medication 
for climacteric complaints, 24% prescribed no treatment at all. Remarkably, 75% of all 
GPs were of the opinion that prescribing HRT for climacteric complaints is a form of 
medicalization. In case of preventive treatment 32% of the GPs said they would 
prescribe HRT for a period longer than 5 years. 
In the UK Bryce studied the view of 1 000 Gps, 31 a returned cornpleted questionnaires.as 
Less than 25% of the GPs were sympathetic to the idea of prophylactic HRT and only 
7% routinely discussed this possibility with menopausal patients, while the majority felt 
that the duration of therapy should be limited to 2 years or less. 
In Finland Hemminki studied the opinion of gynaecologists, internists, general 
practitioners and non-specialists on HRT prescription (n~500; response rate 74%).86 
Gynaecologist were far more favourable towards hormone therapy than were other 
physicians.One fourth of the physicians said HRT should be preventively given to all or 
to all those at risk from osteoporosis. Most agreed as to the benefits of HRT for the 
prevention of osteoporosis, but opinions as to other benefits and disadvantages varied. 
Furthermore, many physicians seemed to have difficulties in giving general opinions and 
preferred using individual judgement for each patient. In Norway, a questionnaire was 
mailed to a random sample of approximately 10% of the general practitioners in order 
to investigate attitudes to prescription of HRT. GPs indicated restrained attitude towards 
prescription of HRT.87 
5.4 Determinants of HRT 
It was established in the USA that both gynaecologists and family physicians were 
influenced in their prescribing by cancer risk and by severity of vasomotor symptoms in 
their patients. The variation among physicians however was large.Be 
A policy-capturing study of 283 perimenopausal women showed that the factor of 
frequent concern was relief from hot flushes.78 Cauley found thatthe primary determinant 
of HRT was for women with surgical menopause.89 Other determinants were higher 
levels of education, less obese women, more alcohol use and participation in sports and 
recreation compared to never users of HRT. Ringa found that surgical menopause and 
higher education were major determinants of HRT use.eo Cigarette smoking was not 
associated with use of HRT, which is consistent with the American studies. In a study 
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among women in Massachusetts the only constant finding is that surgically menopausal 
women and women with symptoms are overrepresented among estrogen users. 
5.5 Compliance with HRT 
The compliance with HRT is deplorably poor. Utian cited data from a review of 200 
American pharmacies in which 50% of those given new HRT prescription had stopped 
taking their medicine within one year; 49% of repeat prescriptions were never filled out, 
the average duration of HRT was nine months.90 The occurrence of withdrawal bleeding, 
fear of cancer and side effects such as edema, bloating, premenstrual irritability, lower 
abdominal cramps, breast tenderness, all limit compliance with hormonal therapy91 
Apparently the decision for women to stay on HRT is complex, because even when there 
is no withdrawal bleeding as is the case with hysterectomized women compliance is also 
paor.92 
5.6 Conclusions 
Hormone replacementtherapy use rates especially in Europe are in general low and vary 
between countries from 3 to 13%. GPs in the various countries are cautious to prescribes 
HRT. 
There is a wide gap between CPs own perceived prescribing practice and the actual 
prescribing practice. Less than 25% of the CPs in UK, Netherlands and Finland said 
hormones should be preventively given. Surgical menopause, educational level, former 
use of anticonceptiva, menopausal status and vasomotor complaints are determinants 
for HRT use. The compliance with HRT is low; most studies indicate that more than 50% 
of women take H RT no longer than one year. 
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INTRODUCTION 
The climacteric years are associated with a variety of physiological and psychological 
symptoms that may influence the level of well-being of women.'" However, because 
the climacteric is accompanied by other changes in life, it is important to assess the 
independent relationship between the climacteric and well-being. 
Typical physiological symptoms related to the hormonal changes during the climacteric 
include hot flushes, night sweats and dyspareunia caused by vaginal atrophy. Many 
women report vasomotoric symptoms with the peak of complaints occurring in the first 
year after menopause.' However, these symptoms are not restricted to the climacteric 
period, but may also occur during other periods in life. 
Many psychological symptoms have been reported to accompany this phase of life, 
e.g. nervousness, sleeping problems and irritability.9.lD The few published population-
based studies suggest that the so-called 'climacteric symptoms' may be related more to 
personal characteristics than to menopause per 5e. 11 ,3 
Further, several studies have shown that menopause is associated with a whole range 
of changes in sociodemographic variables, e.g. work outside the home and marital 
status.S.'2 In addition, both the nature and frequency of symptoms are known to be 
influenced by cultural and/or racial factors.'s For example, hot flushes are less frequently 
reported among Japanese women than among western women. l4 
Although several studies have evaluated the occurrence of symptoms in the climacteric 
period, the interpretation of these results is hampered by a couple of reasons. First, most 
studies did not distinguish between symptoms believed to be related to the climacteric 
period and the feeling of general well-being. Nevertheless, this distinction is fundamental, 
as the presence of symptoms such as flushes may point at the climacteric, whereas the 
change in the level of the woman's well-being reflects the impact of the climacteric. 
Moreover the mere presence of symptoms is not indicative of a low level of well-being. 
Well-being can be defined as a multifactorial construct. The relevant well-being 
dimensions include: (a) subjective experiences i.e. self-assessed health (b) functioning 
aspects in daily life like social duties and intellectual functioning (c) symptomatic 
aspects i.e. the effects of disease.'s Second, only few studies adjusted their findings for 
variables which could distort the relationship between general well-being and menopausal 
status, i.e. confounding variables. When adjustments were made, they were mostly 
limited to age', social class and marital status.s 
The objective of our study was to assess the relationship between menstrual age, i.e. 
pre-, peri- and postmenopausal and general well-being independent of differences in 
potential confounding variables. Apart from age, education and way of cohabitation we 
also adjusted for Body Mass Index (kglm2), smoking behaviour, work outside the home, 
parity, difference in age with the partner and partner's employment. 
The assessment of the independent influence of menopause on well-being rather than 
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on the well-known symptoms, may contribute to a better understanding of the 
climacteric. 
METHODS 
Recruitment 
From the municipal authorities of Krimpen aan den Ijssel, a commuter suburb of 
Rotterdam with approximately 28.000 inhabitants, names and addresses of all 2729 
women aged between 45 and 60 years were obtained. In May 1990 they were sent a 
questionnaire and 1947 women responded (response 71.3%). A random sample (N=55) 
was taken of the non-respondents in order to evaluate the representativity of the 
respondent group. They were approached by telephone and 52 participated (response 
95%). 
The main principles of Dillman's Total Design Method were used to maximize 
response. 16 In cases where the questionnaire was not returned within three weeks, a 
reminder was sent. To avoid emphasis on menopausal symptoms the questionnaire was 
named 'Health Questionnaire for Women' and questions about the menopause were 
placed in the second part. 
The climacteric status of women was classified into six categories according to 
menstrual pattern characteristics and the number of months or years since the last 
menstrual bleeding (LMB) prior to the completion of the questionnaire (see Appendix II; 
question B.7.). Women having had a menstruation within twelve months prior to the 
survey (part a and part b of question B.7.) and a menstrual pattern which did not change 
(part c) formed one group: the premenopausal group. Women who had had a change 
in the menstrual cycles in the preceding year were categorized into two peri menopausal 
groups according to the number of months since the last LMB: three months or less 
(perimenopausall) and four to twelve months (perimenopausal II). Women whose LMB 
had occurred over twelve months previous to the survey were categorized into three 
postmenopausal groups according to the 'number of years since the last LMB; 1- 21;' years 
(postmenopausal I), 2'12- 4V, years (postmenopausal II) and 4'12 or more years 
(postmenopausal III). As some women filled out the year of the LMB only and not the 
exact month, a classification was chosen which coincides with the calendar year. 
Women who had undergone hysterectomy and women who used estrogen therapy in 
the 6 months preceding answering the questionnaire, were excluded from the analyses 
(Figure 1). 
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Figure 1. Selection oftarget population. Total register population n= 2729; response N=1947 (71 .3%). The 
segments placed apart are left out of consideration in theanalyses. 
Pre= Premenopausal; Peri= Peri menopausal; Post= Postmenopausal; Hyst= Hysterectomized; Est= Estrogen use. 
Thestudyreceived approval fromtheMedical Ethical Commiteeofthe Ersmus University Medical School and 
Academic Hospital Dijkzicht in Rotterdam. 
Assessment of well-being 
General well-being was measured by two validated inventories, namely the 'Inventory 
of Subjective Health' (ISH) and the 'Sickness Impact Profile' (SIP). 
The ISH has proven to be a sensitive instrument to detect health problems. In recent 
years it has been used in several Dutch surveys to quantify subjective health status."·18·19 
In a large representative study in the Netherlands Cronbach's "equalled .87 and the ratio 
of the eigenvalues of the first and second principal component equalled 16.2/4.4=3.7, 
both reflecting a strong unidimensional scale.'" The ISH includes 49 items, concerning 
the experience in the past two weeks of complaints like pains in the chest, shaking hands, 
headache, sneezing and less appetite (see Appendix II; part A). On every item the 
respondent is asked whether she has experienced it during the last two weeks. All items 
must be answered with either 'yes' or 'no'o The sum score of all responses is computed, 
the maximum score being 49. 
The SIP was developed in the United States as a behaviourally based measure of the 
impact of sickness." The Dutch validated version was used in this study.2223 Both SIP 
overall scores and SIP category scores can discriminate between subsamples. To limit 
the time needed for filling out the questionnaire we chose three category scores which 
measure psycho-social impact on well-being: emotions, feelings and sensations (9 
items), social interaction (18 items) and intellectual functioning (10 items). All items are 
rated a scaling factor. This scaling permits the calculation of three SIP percent category 
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scores. A percentage of 100 means maximal impairment on the corresponding category 
score. 
The validated inventories formed the first part of the questionnaire. Furthermore, the 
women were asked to answer questions on social factors, smoking, body weight and 
length, menstrual pattern, medical consumption during the last two weeks, attitude 
towards menopause and knowledge of menopause-related problems. 
Analysis 
Variables that are related to both well-being and menopause can distort the relationship 
between well-being and menopause. Therefore, multivariate linear regression analysis 
which can adjust forthese confounding variables, was used to compute the independent 
relationship between menopausal status and general well-being. Dummy variables for 
all nominal and ordinal variables were constructed to detect possible non linear effects. 
Separate analyses were performed for the ISH and the three categories of the SIP. As 
a first step the relationship was computed adjusting for age only. As menopausal status 
inheres age, age was always adjusted for. 
Further, variables that according to literature could be related to both well-being and 
menopausal status were selected. Body mass and smoking behaviour can influence 
menopausal status,24·26 and may be related to well-being as well. About the association 
between education, parity and work outside the home on one side and symptom 
reporting on the other, results are equivocal.2718 Instead of marital status adjustment is 
made for the way of cohabitation as in the Netherlands a considerable number of people 
live together without being married. As the age-difference between the partners 
increases, women report more vague somatic complaints. 12 Finally, it is interesting to 
know whether the partner's employment status confounds the relationship between 
menopausal status and well-being. The measurement scales used for these variables are 
embodied in table 2. 
Next, the relationship between these eight potential confounders and well-being was 
determined, while adjusting for age, by applying linear regression analysis. If a variable 
contributed on a p< 0.10 level to the explanation of one or more of the four measures 
of well-being it was selected as a potential confounder and included in the multivariate 
analyses. 
Finally, to compute the independent relationship between menopause and the 
measures of well-being, again four separate linear regression analyses were carried out, 
with all selected confounders included in the regression equations. 
RESULTS 
The results of the comparison between respondents and non-respondents are shown in 
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table 1. No marked differences between respondents and non-respondents could be 
demonstrated. 
After exclusion of all women with hysterectomy and/or estrogen therapy, 1343 
women could be categorized according to menopausal status: 274 premenopausal 
women, 309 perimenopausal women (226 peri 1+ 83 peri II) and 760 postmenopausal 
(140 post I + 153 post II + 467 post III) women. Some characteristics of the participants 
are given in table 2. The median menopausal age (the age at which 50% of the women 
have stopped menstruating) was 50.5 years. In comparable studies in the Netherlands 
51.2 years and 51.5 years were reported.'29 
Table 1. Comparison of respondents (n=1947) and non-respondents (n=52) 
Respondent Non-respondent 
o· 0 p-value 
Menopausal status 1343 '8 .75 
P" 274 20% 6 16% 
peri I + peri II 309 23% 10 26% 
post I + post II + post III 760 57% 22 58% 
Hysterectomy 1930 48 .75 
yo> 273 l4% 6 13% 
00 1657 86% 42 88% 
Estrogen therapy 1946 48 .41 
y" 238 12% 4 8% 
00 1708 88% 44 92% 
Mean age (years) 1893 52.4 49 53.2 .21 
Level of education 1906 SO .23 
lower 894 47% 20 40% 
middle 694 36% 24 48% 
higher 318 17% 6 12% 
Work outside the home 1791 49 .16 
yo> 630 35% 22 45% 
00 1161 65% 27 55% 
Visit to general practitioner 
last year 1879 SO .14 
y" 1198 64% 37 74% 
00 681 36% 13 26% 
... The n differs as the number of women that give a valid answer differs per question. 
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Table 2_ Some characteristics of the participating women (aged 45-60 years)_ 
Total number of women of which the menopausal status is known is 1343_ 
0' Total Pee Peri I Peri II Post 1 Post 11 Post III 
Mean age (year:» 1314 52.6 48.0 49.4 51.3 53.1 54.6 56.4 
Mean Body Mass Index Ckg/m2) 1270 24.7 24.5 24.3 24,1 24.7 24.6 25.1 
Severe sweating 1280 26% 16% 22% 43% 3S% 33% 2S% 
Vaginal dryne~ 1274 21% 4% 14% 18% 30% 31% 30% 
Smoking (cigarettes/day) 1303 
Never smoked 50% 46% 49% 52% 54% 56% 49% 
Ever smoked 27% 35% 27% 31% 20% 22% 25% 
:05 5% 5% 7% 4% 5% 4% 6% 
6,'5 10% 7% 9% 5% 13% 10% 11% 
>16 8% 7% 9% 9% 5% 8% 9% 
Education 1321 
Low 16% 9% 10% 13% 23% 22% 21% 
Middle 66% 67% 68% 63% 62% 65% 66% 
High 18% 24% 22% 23% 15% 14% 13% 
Work outside the home 1241 
No work 65% 45% 52% 65% 71% 74% 78% 
Working <20 hrs 23% 33% 29% 21% 22% 21% 14% 
Working;:::: 20 hrs 13% 22% 19% 15% 7% 6% 7% 
Parity 1343 
None 7% 4% 6% 8% 9% 5% 9% 
0" 12% 11% 12% 13% 16% 12% 11% 
Two 44% 51% 50% 40% 41% 43% 40% 
Three 22% 20% 22% 29% 19% 24% 23% 
Four and more 15% 14% 11% 10% 15% 16% 17% 
Way of cohabitation 1340 
living apart 7% 4% 4% 4% 9% 12% 8% 
living with husband/partner 39% 21% 24% 34% 41% 44% 55% 
Living with children 6% 4% 6% 5% 6% 7% 5% 
living with partner & child 48% 70% 65% 58% 43% 37% 31% 
Me<ln age of the partner (years) 
" 63 54.6 49.9 515 53.7 55.S 56.6 58.3 
Employment partner 1157 
Working 75% 93% 90% 76% 81% 68% 56% 
Retired 15% 2% 4% 9% 13% 22% 29% 
Other 10% 5% 6% 15% 6% 10% 14% 
Measures of well-being: mean (sd)b 
ISH 1020 9.6 8.7 9.7 10.6 9.8 10.1 9.8 
(6.7) (65) (6.4) (6.8) (6.5) (6.8) (6.9) 
SIP social interaction 1088 11.3 8.8 11.7 lOA 1104 10.9 13.0 
(11.9) (9.9) (12.5) (10.1) (10.0) (12.6) (13.1) 
SIP emotions, feelings and 1227 75 6.1 9.2 8.3 9.9 6.3 72 
sensations (13.7) (11.7) (1504) (14.9) (15.9) (14.0) (12.8) 
SIP intellectual functioning 1177 10.0 8.0 12.2 9.7 10.7 6.7 11.0 
(1704) (16.3) (1904) (15.8) (18.5) (1404) (17.7) 
~ The n differ.; as the number of women that give a valid answer differ.; perquestion. 
b The standard deviation is placed in parentheses under the mean. 
Table 3. The relationship between menopausal status and four measures of well-being, adjusted for differences in age. 
Regression weights of menopausal status. 
Measure of Pre· Peri· Peri- Post· Post- Post-
well-being menopausal menopausal I menopausal I[ menopausal I menopausal 11 menopausal III 
0 B' 0 B 95% Clb P 0 B 95%(1 P 0 B 95%(1 P 
" 
B 95%(1 P 0 B 95%CI 
15H 220 0 177 1.2 (-0.1,2.5) .08 58 2.2 (0.3,4.2) .03 lOB 1.B (0.1,3.4) .04 111 2.0 (03,3.B) .02 328 1.9 (0.3,3.5) 
SIP·social' 235 0 183 3.0 (0.7,5.3) .01 67 2.0 (-1.3,5.3) .24 109 33 (0.3,6.2) .03 121 2.7 (-0.3,5.8) .08 353 5.1 (2.3,8.0) 
SJP·emotlons~ 253 0 200 3.5- (1.0,6.1) .01 73 3.2 (-004,6.9) .08 127 5.3 (2.1,8.4) .00 140 1.7 (-1.6,5.0) 31 409 33 (0.2,6.4) 
SIP-inteJ!ectuaIC 242 0 19S 4.2 (0.9,7.S) .01 74 1.9 (-2.7,6.6) .41 120 3.1 (-1.1,7.3) .15 136 -',2 (-5.5,3.1) .58 390 3.5 (·0.5,7.6) 
'In all regression analyses the premenopausal group is taken as reference (ategol)'. Therefore the regression weight (noted by 6) of this group is fixed at 0.0. The other regression weights 
reflect the difference between the peri V5 pre·menopausal group or the post vs pre-menopausal group_ 
b 95% CI: 95% confidence interval of B. 
, SIP social: SIP social functioning; SIP emotions: SIP emotions and feelings; SIP intellectual: SIP intellectual functioning and alertness. 
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The relationship between menopausal status and the four d·,fferent measures of well-
being, adjusted for differences in age, is reported in table 3_ 
Early peri menopausal women (peri I) score statistically significantly higher -thus 
experience a lower level of we"-being- on all measures but the ISH as compared to 
premenopausal women. Late peri menopausal women (peri II) report a lower level of 
well-being on the ISH only. 
Early postmenopausal women (post I) have a statistically significantly reduced level 
of well-being on all measures but the SIP intellectual functioning again compared to 
premenopausal women_ Intermediate postmenopausal women (post II) show a lower 
level of well-being on the ISH only. Late postmenopausal women (post III) have a 
diminished level of well-being on all scales except for the SIP intellectual functioning. 
By applying linear regression analysis the influence of eight potential confounders on 
well-being was determined. The results are reported in table 4. Five potential confounders 
met the criteria as outlined in the method section and were included in the multivariate 
analyses: Body Mass Index, smoking behaviour, education, way of cohabitation and 
partner's employment. 
Table 4. The influence of potential confounders on well-being: multiple regression 
coefficients. 
ISH SIP social SIP emotions, SIP intellectual 
interaction feelings and functioning 
sensations 
Potential confounder R'. F' e'. ,'. e'. 
change~ change change change 
Body Mass Index .02 18,1 *"~ .01 5.8"" .00 02 .00 1.0 
Smoking .01 1.8 .01 2.6*" .00 2.4" .01 2.8"* 
Education .01 2.4"" .02 4.'*** .01 2.6"" .00 1.1 
Work outside the home .00 0.3 .00 0.1 .00 0.9 .00 0.5 
Parity .00 0.9 .01 1.7 .00 0.7 .00 0.1 
Way of cohabitation .01 2.4" .00 1.7 .01 2.3" .01 2.3* 
Age difference between .00 0.2 .00 0.7 .00 0.2 .00 0.1 
partners 
Employment partner .01 4.0"" .01 2.7" .01 3.2H .00 12 
• R?-change denotes the change of the multiple regression coefficient when the variable is removed from the regression 
equationi the regression equation always includes age. 
b Significance:" p < ,10; ** P < .05; *** P < .01. 
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The results of the multivariate regression analyses are shown in table 5. In general, the 
differences in the level of well-being between the six menopausal status become less 
pronounced after adjustment for selected potential confounders, compared to the 
analysis where only differences in age are taken into account. However, the majority of 
results remain statistically significant (p <0.05), except for the lower level of well-being 
of early postmenopausal women (post I) on the SIP social functioning. Three other 
statistically Significant results seem to disappear as a consequence of a reduced number 
of women, whereas the regression weight B is about the same: the decreased level of 
well-being of late perimenopausal women (peri II), early postmenopausal women (post 
I) and of late postmenopausal women (post III) on the ISH. 
Table S. The relationship between menopausal status and four measures of well-being, adjusted for differences in age and 
selected confounders'. Regression weights of menopausal status. 
Measure of Pre- Peri- Peri- Post- Post- Post-
well·being menopausal menopausal I menopausal II menopausal J menopausal II menopausallH 
" " " 
, 95%(1' P 
" 
, 95%(1 P 
" 
, 95%(1 P 
" 
, 95%(1 P 
" 
, 95%(1 
ISH 20S 0 166 0.9 (-004,2.3) .18 53 2.1 (0.0,4.1) .05 101 1.6 (-0.1,3.4) .07 102 2.1 (0.3,3.9) .Q2 301 1.7 (0.0,3.4) 
SIP-socfald 219 0 171 2.5 (0.1,4.9) .04 63 1.8 (-1.6,5.4) .30 103 2.3 (-0.8,5.4) .14 111 1.9 (-1.3,5.1) .25 316 4.4 (1.4,7.4) 
SIP-emotionsd 232 0 188 3.5 (0.8,6.1) .01 69 2.7 (-1.1,6.5) .16 117 4.9 (1.6,8.3) .00 126 2.1 (-1.4,5.6) .25 367 3.4 (0.1,6.8) 
SIP-intel!ectuald 223 0 181 4.1 (0.7,7.5) .02 69 2.4 (-2.5,7.2) .34 111 2.3 (-2.1. 6.7) .30 122 -2.1 (-6.6,2.5) .3, 35l 3.0 (-1.3,7.3) 
• Selected confounders: Body Mass index, smoking behaviour, education, way of cohabitation and partner's employment. 
b In all regression analyses the premenopausal group is taken as reference category. There'fore the regression weight (noted by B) ofthi5 group is fixed at 0.0. The other regression weights 
reflect the difference behveen the peri vs pre-menopau5al group or the post V5 pre-menopausal group. 
'95% 0: 95% confidence interval of B. 
d SIP social: SIP social functioning; SIP emotions: SIP emotions and feelings; SIP intellectual: SIP intellectual functioning and alertness. 
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DISCUSSION 
Our findings among women with natural menopause and without estrogen therapy 
suggest that in general, women in the climacteric report a lower level of well-being 
compared to women in the premenopausal period, even after adjusting for confounders. 
In the early peri-, early post- and late postmenopausal period a difference is mainly found 
on the SIP scales. In the intermediate postmenopausal period a difference is found on 
the ISH. The pattern is not constant over the six periods. Therefore future research should 
consider menopausal status as a nominal variable rather than an ordinal one_ Although 
these differences are statistically significant, they are rather small. The question arises 
whether these small differences represent clinically significant differences. 
It is difficult to compare the findings of this study with those of other studies because 
no uniform approach exists to study the influence of the climacteric on health. Some 
studies use a diversity of symptoms as outcome measures,3 others search for symptom-
clusters,3D or look for differences on already existing scales. '27 In this study the measure 
of well-being best comparable to the measurements by other authors is the ISH as it 
consists of health complaints. In this respect our results are in accordance with other 
studies: for most women health is not much adversely affected by the climacteric. 
Further, most studies indicate that other factors, for example social class, may have more 
influence on well-being than menopause per se.3 
In our view the results are based on a well controlled methodological design.3l As to 
the generalizability of the results, our study group encompassed a population at large 
and women were not selected according to the presence of medical complaints. No 
selection bias seems to be present, given the minor differences between respondents and 
non-respondents and the response rate (71.3%). This is a plus-point in contrast to other 
studies which were performed in highly selected populations, e.g_ visitors of menopause 
clinics or women attending a routine ovarian screening clinic. 
Efforts were made to avoid emphaSiS on the climacteric by naming the questionnaire 
'Health Questionnaire for Women'. Questions on menstruation and menopause were 
included towards the end of the questionnaire. Thus the detection signal bias was 
minimized. 
In order to classify menopausal status correctly, hysterectomized women and women 
using estrogens or having used estrogens in the past six months were excluded. As a 
consequence, it is not known whether ourfindings may be extrapolated to these women_ 
Since the menstrual pattern can fluctuate over time it is possible, for instance, that 
women once classified as postmenopausal, start menstruating again. However, it seems 
plausible that the incidence of such phenomena is 10w.32.33 
Confounding is a serious danger in all types of epidemiological research. When there 
is a suspicion of confounding, the next three steps must be made: (a) identification of the 
confounders (b) evaluation ofthe presence of confounding (c) adjustmentforconfounders.34 
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Therefore identification of potential confounders is a cruc',al step in this process. We 
identified confounders on the basis of literature on factors related to well-being, 
menopause or both. It is remarkable that in our study working outside the home, parity 
and age difference with the partner did not appear to confound the relationship between 
menopausal status and well-being, whereas Body Mass Index, smoking behaviour and 
the partner's employment did. In our view, future research on well-being in the 
climacteric should take these latter variables into account. 
One might attribute the differences in well-being between the different menopausal 
status to the so-called 'consensus' complaints, i.e. flushes, severe sweating and vaginal 
dryness. The ISH is the only measure of well-being in this study that contains one of these 
consensus complaints, namely severe sweating. When severe sweating is included in the 
regression equation as a confounder the differences in well-being, as expressed by the 
regression weight B, decrease. As a consequence, the 6's of early perimenopausal 
women on the SIP social functioning and of late postmenopausal women on the SIP 
emotions, feelings and sensations are no longer statistically significant. The only 
statistically significant B of the ISH for intermediate postmenopausal women also 
disappears. However, despite this correction, the other differences remain. Furthermore, 
one should note that as the item 'severe sweating' is a component of the ISH, this 
correction may suppress the relationship between climacteric and well-being itself. 
The ISH reflects one's tendency to express a lower level of well-being in vague somatic 
complaints. Hence, our findings indicate that the somatic aspects of well-being are not 
much influenced by the menopausal status per se. Nota bene: there may be complaints 
caused by the climacteric, but well-being is not much influenced by them. 
The main differences are found on measurements of well-being that focus on. the 
impact of menopause on daily life functioning. Social interaction is significantly worse 
in early peri and late postmenopausal women. The women in this study reported to be 
less interested in their family members and friends and acted less friendly towards them. 
Emotions, feelings and sensations are significantly lower in early peri-, early post- and 
late postmenopausal women. Women may feel more nervous, tense or depressive. 
Finally, the level of intellectual functioning is lower in early peri menopausal women 
only. On average women seem to be less able to concentrate and more forgetful during 
this period. 
In conclusion, our results suggest that the independent influence of the climacteric on 
well-being is found in a small negative influence on behavioural functioning in the daily 
life of a woman. 
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INTRODUCTION 
Early studies of the climacteric reported a range of symptoms that occur more frequent 
among women whose menstrual cycles have changed. These include hot flushes, night 
sweats, lethargy, forgetfulness, tiredness, crying spells, irritability and headache.
'
·
4 Later 
studies differentiated between typical symptoms that are strongly related to the 
climacteric (i.e. vasomotor symptoms and vaginal dryness) and atypical symptoms that 
are weakly associated. These atypical symptoms appeared to be more related to co-
occurring social, psychological and physically bothersome changes than totheclimacteric 
per 5e.5-7 Since the study of mere symptoms may give a limited view of the experiences 
of women in the climacteric years, other studies have addressed the association between 
climacteric and measures of well-being. These studies pOinted out that (emotional) well-
being is not much adversely affected by the climacteric.8-11 
However, Olden have et al '2 recently concluded that the prevalence of vasomotor 
symptoms was highest in the late premenopause and early postmenopause (about 85%) 
and that this increase of vasomotor symptoms was related to an overall reduced level 
of well-being. In contrast, Matthews established that despite experiencing more 
vasomotor symptoms, women perceived lower levels of stress.'3 Apparently, there are 
equivocal conceptions of the association between vasomotor symptoms and well-being. 
The aim of our study was to examine more closely the relationship between vasomotor 
symptoms, well-being and climacteric status according to the last menstrual bleeding. 
As this association may depend on the perception of the climacteric status, another aim 
was to examine this relationship for climacteric status according to the women 
themselves. 
METHODS 
This study is part of a larger study aimed at assessing the relationships between the 
climacteric, well-being, women's attitude towards menopause, medical attention and 
the use of hormone replacement therapy. The methodology of this study has been 
reported in detail elsewhere." In short, from the municipal authorities of Krimpen aan 
den IJssel, a commuter suburb of Rotterdam with approximately 28000 inhabitants, 
names and addresses of all 2729 women aged 45 to 60 years were obtained. In May 1990 
they were sent a questionnaire; 1947 women responded (response 71.3%). The 
comparison between respondents and a sample of 55 non-respondents did not reveal 
any statistically significant differences in age, menopausal status, hysterectomy, estrogen 
therapy, level of education, work outside the home or medical attention. 
The study received approval from the Medical Ethical Committee of the Erasmus 
University and Academic Hospital Dijkzigt in Rotterdam. 
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Measurements 
Well-being was measured by two validated inventories: the 'Inventory of Subjective 
Health' (ISH) and the 'Sickness Impact Profile' (SIP). The ISH has proven to be a sensitive 
instrument to detect health problems.14 The ISH includes 49 items, concerning the 
experience in the past two weeks of, for example, pains in the chest, shaking hands, 
headache, sneezing and lessening of appetite. With every item the respondent is asked 
whether she has experienced it during the last two weeks. All items must be answered 
with either 'yes' or 'no'. The sum score of all responses is computed, the maximum score 
being 49. The SIP was developed in the United States as a behaviourally based measure 
ofthe impact of sickness.lSln this study, the Dutch validated version was used. Both SIP 
overall scores and SIP category scores can discriminate between subsamples. To limit 
the time needed to fill outthe questionnaire we have chosen three category scores which 
measure psycho-social impact on well-being: emotions, feelings and sensations (9 
items), social interaction (18 items) and intellectual functioning (10 items). All items are 
rated a scaling factor. This scaling permits the calculation of three SIP percent category 
scores. A percentage of 100 means maximal impairment on the corresponding category 
score. 
Women were categorized as having vasomotor symptoms when they reported severe 
sweating and/or hot flushes in the questionnaire. The presence of severe sweating was 
assessed by using both a closed question and an open question, whereas hot flushes were 
asked by using an open question only, to avoid emphasis on the climacteric. 
The climacteric status of women was classified according to menstrual pattern 
characteristics and to the number of months or years since the last menstrual bleeding 
prior to the completion of the questionnaire. We defined six categories:1O women who 
had had a menstruation within twelve months and whose menstrual pattern did not 
change (premenopausal), women who had experienced a change in the menstrual 
cycles in the preceding year with a last menstrual bleeding occurring three months or 
less (peri menopausal I) or four to twelve months ago (peri menopausal II), women whose 
last menstrual bleeding occurred 1-2'12 years ago (postmenopausal I), 2'12-4'12 years ago 
(postmenopausal II) and more than 4'12 years ago (postmenopausal III). As some women 
filled out the year of the last menstrual bleeding only and not the exact month, a 
classification was chosen which coincided with the calendar year. Women who had 
undergone hysterectomy and women who had used estrogen therapy in the 6 months 
prior to answering the questionnaire, were excluded from the analyses as they can not 
be classified according to climacteric status. 
The women were also asked to rate their climacteric phase themselves by choosing 
one of the following five categories: 'I have not reached the menopause', 'I have just 
reached the menopause', 'I am in the middle of the menopause', 'I have reached the end 
of the menopause', 'I reached the menopause long ago'. 
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Data analysis 
Prevalences of vasomotor symptoms were computed for women in the different 
climacteric categories. Subsequently, a logistic regression analysis was performed with 
the dichotomized scores of well-being as the dependent variable and the presence of 
vasomotor symptoms as independent variable. Well-being scores were dichotomized 
around the median. In an earlier study we reported on the relationship between well-
being and body mass index, smoking, education, the woman's employment status, 
parity, the way of cohabitation, age difference between the partners and the employment 
status ofthe partner." In this analysis age, education and body mass index were related 
on a p< .01 level to one or more of the four measures of well-being and were therefore 
entered in the logistic regression equation. Odds ratios with 95% confidence intervals 
were computed for the six menopausal status defined according to last menstrual 
bleeding as well as for the five categories of menopausal status according to the women 
themselves. In this study the odds ratios express the likelihood of women with vasomotor 
symptoms compared to women without these symptoms of having a score of well-being 
above the median. A relatively high score means a relatively low level of well-being. 
RESULTS 
In Table lA, the prevalence of vasomotor symptoms is shown for the six climacteric 
status according to last menstrual bleeding. The prevalence varied from 25.0% in 
premenopause, to 69.1% in late perimenopause (peri II) and was 38.9% in late 
postmenopause. 
The odds ratios of women with vasomotor symptoms as compared to women without 
these symptoms of experiencing a level of well-being below the median are shown in 
Table 1 B. 
Premenopausal women with vasomotor symptoms more often experienced a lower 
level on all four measures of well-being compared to women without these symptoms. 
Women with vasomotor symptoms had 4.8 (95% CI 2.3-9.7) times more often a lower 
level of well-being on the ISH. The corresponding odds ratio for the SIP emotions, 
feelings and sensations was 2.2 (95% Cl1.2-4.0) and for SIP intellectual functioning and 
alertness 2.7 (95% CI 1.4-5.0). 
Early peri menopausal women (peri I) with vasomotor symptoms were somewhat more 
likely to experience a lower level of well-being than women without these symptoms: 
the odds ratios being slightly higherthan 1.0, exceptforthe ISH (odds ratio 2.1; 95% CI 
1.4-4.0). In contrast, late peri menopausal women (peri II) with vasomotor symptoms less 
often report a relatively low level of well-being on all scales. However, none of these 
odds ratios were statistically significant. 
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Table lA. Prevalence of vasomotor symptoms for menopausal status according to 
last menstrual bleeding. 
(N) 
Prevalence 
Menopausal status according to last menstrual bleeding 
Pee 
(274) 
25.0% 
Peri I 
(226) 
41.0% 
Peri II 
(83) 
69,1% 
Post I 
(140) 
61.3% 
Post II 
(1S3) 
58.4% 
Post III 
(466) 
38.9% 
Table 1 B. Odds ratio of women with vasomotor symptoms compared to women 
without these symptoms of being above the medium on four measures of well • being. 
A score above the medium means a relatively lower level of well-being. Figures are 
presented separately for menopausal status according to last menstrual bleeding'. 
Measure of wei I . being 
ISH Odds Ratio 4.8 2.1 0.6 1.9 5.8 2.1 
95%CI (2.3;9.7) (1.1;4.0) (0.2;2.3) (0.8;4.8) (2.4;14.0) (1.3;3.4) 
SIP social functioning Odds Ratio 1.9 1.0 0.4 2.9 1.4 1.9 
95%CI (1.0;3.5) (05;1.8) (0.1;1.2) <1.2;7.1) (0.6;3.0) (1.2;3.1) 
SIP emotions, feelings Odds Ratio 22 1.5 0.5 0.8 2.0 1.4 
and sensations 95% CI (1.2;4.0) (0.8;2.7) (0.2;1.6) (004;1.9) (0.8;4.7) (0.9;2.1) 
SIP intellectual func- Odds Ratio 2.7 12 0.8 1.0 1.5 1.3 
tioning and alertne% 95% CI (1.4;5.0) (0.6;2.1) (0.3;2.5) (0.4;2.3) (0.7;3.5) (0.8;2.0) 
" Odds ratios are adjusted for differences in age, education and body mass index. 
For early postmenopausal women (post I) no association between vasomotor symptoms 
and the SIP intellectual functioning and alertness and the SIP emotions, feelings and 
sensations was found, whereas for the ISH and the SIP social functioning odds ratios of 
1.9 (95% CI 0.8-4.8) and 2.9 (95% CI 1.2-7.1) respectively were found. Among middle 
postmenopausal women (post II) all women with vasomotor symptoms reported a 
relatively lower level of well-being. Finally, for late postmenopausal women (post III) 
with vasomotor symptoms all measures showed an odds ratio higher than 1.0. 
Statistically significant odds ratios were established on the ISH (odds ratio 2.1; 95% CI 
1.3-3.4) and the SIP social functioning (odds ratio 1.9; 95% CI 1.2-3.1) only. 
In Table 2 the relationship between vasomotor symptoms and the level of well-being 
is shown for the menopausal phases categorized according to the women themselves. 
The same pattern emerged. Here too, women with vasomotor symptoms who perceive 
themselves as not menopausal or menopausal long ago had significantly more often a 
relatively low level of well-being, whereas women with vasomotor symptoms who 
perceive themselves as in the middle of menopause had odds ratios that are notably 
lower. 
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Table 2A. Prevalence of vasomotor symptoms for menopausal status according to 
the women themselves. 
Measure of well-being Menopausal status according to the women themselves 
Not reached Just reached Middle of End of Menopause 
menopause menopause menopause menopause long ago 
(N) (265) (242) (324) (224) (354) 
Prevalence 172% 45.4% 68.3% 58.8% 27.7% 
Table 2B. Odds ratio of women with vasomotor symptoms compared to women 
withoutthesesymptoms of being above the median on four measures of well· being. 
A score above the median means a relatively lower level of well·being. Figures are 
presented separately for menopausal status according to the women themselves'. 
ISH Odds Riltio 4.4 2.1 1.5 1.4 2.8 
95%CI (2.0;9.6) (1.1;3.9) (0.8;2.8) (0.7;2.8) (1.5;52) 
SIP social functioning Odds Ratio 2.3 0.7 12 1.7 1.8 
95%(1 (1.1;4.9) (0.4;104) (0.7;2.1) (0.8;3.3) (1,0;32) 
SIP emotions, feelings Odds Ratio 2.6 1.0 0.8 1.0 1.8 
and sensations 95% CI (1.3;5.3) (0.5;1.7) (0.4;1.3) (0.5;1.8) (1.0;3.1) 
SIP intellectual func- Odds Ratio 3.8 0.9 0.9 1.3 1.4 
tioning and alertness 95%0 (1.8;7.8) (0.5;1,7) (0.5;1.5) (0.7;2.5) (0.8;2.4) 
" Odds ratios are adjusted for differences in age, education and body mass index. 
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DISCUSSION 
Population based studies established no major difference in well-being between pre-, 
peri- and postmenopausal women.6-10 Studies in which a distinction was made between 
women with or without vasomotor symptoms showed a considerably lower level of 
well-being for women with these symptoms. 12•16 In this cross-sectional study we also 
found a clear relationship between vasomotor symptoms and well-being which 
depended on climacteric status. Pre- and (middle and late) postmenopausal women with 
vasomotor symptoms more often experienced a relatively low level of well-being 
compared to women without these symptoms. However, in contrast to the above 
mentioned studies, when the prevalence of vasomotor symptoms is at its top, i.e. in late 
peri menopause, a difference in the level of well-being between women with and 
without vasomotor symptoms was absent. 
An explanation for the fact that Olden have did not detect an absence of the 
relationship in perimenopausal women may be found in the differences between the 
measurement instruments applied to quantify health status. Furthermore, in the 
questionnaire Oldenhave first explained the meaning of vasomotor symptoms in order 
to quantify them, thereby drawing attention to the climacteric. In our study we tried to 
avoid any emphasis on the climacteric by calling the questionnaire 'Health Questionnaire 
for Women' and measuring vasomotor symptoms either in a list of several symptoms or 
using open questions. 
In Daly's recently published study, it was concluded that the quality of life of women 
with menopausal symptoms may be severely compromised and that perceived 
improvements in quality of life in users of hormone replacement therapy seem to be 
substantial. '6 In that study a sample was recruited of 31 women was recruited from a 
specialist menopause clinic and 32 women consulting their general practitioner of 
which 9 women had menopausal problems. Apart from vasomotor symptoms, the 
participating women were asked ,to imagine menopausal symptoms such as tiredness, 
lack of concentration and confidence and less interest in sex. Subsequently they were 
asked how these experiences would influence their quality of life. The effect of hormone 
replacement therapy was measured by asking women actually using or having used this 
therapy to compare their quality of life before and after therapy. 
The methodology of that study is hampered by several imperfections. Firstly, selection 
was present in the sample as mainly women were recruited who suffered from 
bothersome complaints which they labelled climacteric. Secondly, the validity of 
imagination of complaints is doubtful. Thirdly it is uncertain that, apart from the 
vasomotor ones, the 'menopausal complaints' are caused by the climacteric. Fourthly, 
any conclusion about the efficacy of hormone replacement therapy is inappropriate 
without a randomized, double blinded, and placebo controlled design. 
The absence of modification by vasomotor symptoms in late peri menopausal women, 
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that we observed in this study, constitutes a puzzling phenomenon. Although the 
prevalence of vasomotor symptoms depends on the climacteric status, it is not obvious 
why in late perimenopausal women vasomotor symptoms were not related to well-
being, whereas in pre- and postmenopausal women they were. 
No study thus far has shown a clear relationship between serum hormone levels and 
vasomotor symptoms." Even if such a relationship exists it would still be difficult to 
explain the absence of a negative impact of vasomotor symptoms on well-being in 
peri menopausal women. Apart from a biological approach a social scientific explanation 
may be worthwhile. Social scientists stress the importance of the context in which a 
symptom is experienced. 18-19 Aubuchon et al concludes that social expectancies 
influence the report of peri menstrual discomfort. Zola stated that there are two ways in 
which symptoms indicated in one part of a population may be ignored in another part. 
Firstly, when a symptom's prevalence is high, this condition may be perceived as the 
normal state. Secondly, it is the fit of certain symptoms with a society's major values 
(75% of the women in this study agreed with the statement 'physical changes in the 
climacteric are natural')20, which accounts for the degree of attention they receive. This 
theory implies that vasomotor symptoms will be experienced as 'normal' in 
peri menopause, whereas the presence of vasomotor symptoms in pre- and postmenopausal 
women will be more difficult to understand. This line of reasoning is only valid when 
peri menopausal women according to last menstrual bleeding perceive themselves as 
such. In fact the results about the relationship between vasomotor symptoms and well-
being forthe climacteric status as perceived by the women themselves confirm this view. 
An advantage of this study lies in its representativity_ This study was performed in a 
non-selected population. The response rate was adequate and a sample of non-
respondents did not differ from the respondents on a number of characteristics. No 
emphasis was placed on the climacteric. A limitation of this study is its cross-sectional 
design. To assess whether vasomotor symptoms induce a lower level of well-being or 
vice versa, longitudinal studies are necessary. 
It is beyond question that hormone replacement therapy relieves vasomotor symptoms 
and thereby may improve a woman's well-being. Placebo's also proved to be beneficial, 
albeit to a lesser degree than hormone replacement, in the treatment of vasomotor 
symptoms.21 Presumably vasomotor symptoms can be influenced by other than 
pharmacological approaches. This is also supported by Whitehead's study,22 in which 
he claims that explanation and reassurance were sufficient helpful for 40% of women 
seeking help at menopausal clinics. The results of this study suggest that well-being may 
improve considerably when women would know more aboutthe presence of vasomotor 
symptoms in pre- and postmenopause. 
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INTRODUCTION 
Attitudes and well-being are both known to be related to medical attention.' However, 
little is known about this association for women in the climacteric years. 
Doctors should be actively involved with their patients' beliefs and explanations about 
what determines their health and their interest in treatment. A patient-oriented approach 
may keep referrals to a specialist and prescribing of non-specific medicines to a 
minimum.' Moreover, lack of knowledge of a patient's attitudes may give rise to 
dissatisfaction of the patient with the consultation.' A few studies report that the majority 
of women have a neutral or positive attitude towards menopause. In these studies 
women disagree with statements like "A woman feels less like a woman".4 Besides this, 
the attitude appears to be positively linked to the actual menopausal status of women: 
the opinion towards menopause tends to be more positive from pre- through peri- to 
postmenopausal women.s Knowing the attitudes of women in the climacteric may also 
clarify the reported reluctance of women to the use of hormone replacement therapy 
(HRT), despite the fact that several studies have suggested that HRT may reduce the 
incidence of osteoporosis and ischaemic heart disease6 
The climacteric years are accompanied by an increased incidence of the so-called 
consensus complaints i.e. hot flushes, disturbances in menstrual pattern, dyspareunia. 
Nonetheless, the mere presence of these symptoms does not necessarily result in a low 
level of well-being. The relationship between climacteric and well-being has been 
reported elsewhere and showed that well-being is not much adversely affected by 
menopausal status per se.',8 Yet, a considerable number of women consult their GP for 
problems believed to be climacteric.9,1Q 
Firstly, this study will explore the attitude towards menopause of women aged 45-60 
years. Secondly, the relation between attitude towards menopause and well-being will 
be assessed. Thirdly, the question is answered on the relationship of medical attention 
with both well-being and attitudes. 
By answering these questions we hope that women in the peri- and postmenopausal 
years who attend their doctors will find them better informed about the motives of their 
visit than perhaps before. 
SUBJECTS AND METHODS 
Recruitment 
This study is part of a larger study concerning climacteric, well-being, women's attitudes 
towards and knowledge about menopause and HRT. Recruitment and measurement of 
well-being is reported in detail elsewhere.8 In short, from the municipal authorities of 
Krimpen aan den IJssel, a commuter suburb of Rotterdam with approximately 28.000 
66 ATTITUDE, WELL-BEING AND MEDICALA TTENTION 
inhabitants, names and addresses of all 2729 women aged between 45 and 60 years 
were obtained. In May 1990 they were sent a questionnaire and 1947 women responded 
(response 71.3%). A random sample (N=55) was taken of the non-respondents in order 
to evaluate the representativity of the respondent group. They were approached by 
telephone and 52 participated (response 95%). The comparison between respondents 
and non-respondents revealed no statistically significant differences in age, menopausal 
status, hysterectomy, estrogen therapy, level of education, work outside the home or 
medical attention. The study received approval from the Medical Ethical Committee of 
the Erasmus University Medical School and Academic Hospital Dijkzigt in Rotterdam. 
Measurements 
Attitude towards menopause was measured using 28 items. Most items are taken from 
existing questionnaires to make comparisons possible. Twelve items are taken from a 
German study by Frick-Bruder." Six items are taken from the Menopause Attitude 
Questionnaire (MAQ), constructed by Leiblum4 Three items are derived from Ferguson.6 
Finally, we constructed another seven items. The women were asked to rate their 
opinion on all the 28 statements, on a scale ranging from 1 (totally agree) to 5 (totally 
disagree). 
To ascertain menopausal status women were classified into pre-, peri- and 
postmenopausal according to menstrual history. Premenopausal women were women 
having a regular menstruation pattern in the preceding twelve months. Women were 
considered perimenopausal when irregular cycles or amenorrhoe had developed in the 
twelve months prior to the questionnaire. Women were classified as postmenopausal in 
cases where the last menstrual bleeding occurred at least twelve months ago. Women 
who had undergone hysterectomy and women who used estrogen therapy within the six 
months preceding answering the questionnaire, were excluded from the analyses, 
because they could not be categorized according to menopausal status. 
The women were also asked to rate their climacteric phase themselves. They were 
asked to choose one ofthe following five categories: 'I have not reached the menopause', 
'I just have reached the menopause', 'I am in the middle of the menopause', 'I have 
reached the end of the menopause', 'I reached the menopause long ago'. If women 
agreed with the second, third or fourth category they were classified as 'women who 
perceive themselves as climacteric'. 
Well-being can be defined as a multifactorial construct. The relevant well-being 
dimensions include: (a) subjective experiences i.e. self-assessed health (b) functioning 
aspects in daily life like social duties and intellectual functioning (c) symptomatic 
aspects i.e. the effects of disease. '2 Well-being was measured in this study by two 
validated inventories that measure (b) and (c) respectively: the 'Inventory of Subjective 
Health' (ISH) and the 'Sickness Impact Profile' (SIP). 
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The ISH has proven to be a sensitive instrument to detect health problems. In recent 
years it has been used in several Dutch surveys to quantify subjective health status. 13,14 
In a large representative study in the Netherlands Cronbach's " equalled.87 and the ratio 
of the eigenvalues of the first and second principal component equalled 16.2/404=3.7, 
both reflecting a strong unidimensional scale.1S The ISH includes 49 items, concerning 
the experience in the past two weeks of complaints like pains in the chest, shaking hands, 
headache, sneezing and less appetite. On every item the respondent is asked whether 
she has experienced it during the last two weeks. All items must be answered with either 
'yes' or 'no'. The sum score of all responses is computed, the maxjmum score being 49. 
The SIP was developed in the United States as a behaviourally based measure of the 
impact of sickness. l6 The Dutch validated version was used in this study." Both SIP 
overall scores and SIP category scores can discriminate between subsamples. To limit 
the time needed for filling out the questionnaire we chose three category scores which 
measure psycho-social impact on well-being: emotions, feelings and sensations (9 
items), social interaction (18 items) and intellectual functioning (10 items). All items are 
rated a scaling factor. This scaling permits the calculation of three SIP percent category 
scores. A percentage of 1 00 means maximal impairment on the corresponding category 
score. 
To measure medical attention, the women were asked to answer the following 
question with either 'Yes' or 'No': "At this moment I am being treated by my general 
practitioner and/or specialist". 
Analysis 
To give a view of the women's attitudes towards menopause, mean scores and standard 
deviations for the 28 separate items were computed. By means of factor analysis (using 
principal component analysis) these items were clustered. Three factors were extracted. 
All items loading 0040 or more were considered potential items of a potential cluster. 
Subsequently for each cluster factor analysis and reliability analysis were executed. An 
item was definitely assigned to a definite cluster when (i) it loaded 0040 or more on the 
first factor and/or (ii) the deletion ofthe item resulted in a decrease of Cronbach's ofthe 
cluster. One item, "Psychological problems which women experience during the 
climacteric stand apart from coincidental life changes", did not meet either of the 
criteria and was excluded from further analyses. 
The first cluster contains 11 items reflecting the attitude towards disadvantages of the 
menopause (Cronbach's " =0.78). The second cluster comprises 11 items reflecting the 
attitude towards advantages of the menopause ( "=0.65). Finally, the third cluster 
encompasses 5 items reflecting attitudes towards (medical) treatment of the menopause 
( " =0.59). The mean total score per cluster was computed. Means were also computed 
for pre-, peri- and postmenopausal women separately. By means of analysis of variance 
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the differences between the menopausal categories were tested. 
Pearson's correlations were computed between measures of well-being and attitude 
clusters for all women and for each menopausal status separately. 
To determine the separate associations of menopausal status, well-being and attitude 
clusters with medical attention, logistic regression analyses were performed for each 
variable. As menopausal status inheres age, and as age can be related to attitude (e.g. 
"One starts to feel old in the climacteric"), age is always included in the regression 
equation. Dummy variables for menopausal status were constructed to detect possible 
non linear effects. Then logistic regression was performed entering all variables. As a 
result of the backward stepwise procedure only variables contributing on a p<.1 0 level 
are retained in the model. Finally, the extent to which the attitudes towards menopause 
are related to seeking of medical attention is probably dependent on the self-perceived 
climacteric status. Hence, an analysis restricted to women that perceive themselves as 
climacteric was performed. 
RESULTS 
After exclusion of all women with hysterectomy and/or estrogen therapy, 1343 women 
could be categorized according to menopausal status. The study population included 
274 premenopausal women, 309 perimenopausal women and 760 postmenopausal 
women. 
(i) The attitude of women in the climacteric years towards menopause 
In Table 1, the women's attitude towards several aspects ofthe climacteric is shown. On 
the disadvantage cluster the women have a neutral attitude (mean total score 3.0). 
However, women disagree with the two items concerning the loss of (sexual) attractiveness 
(item 5 and 9). Women tend to agree with the items included in the advantage cluster 
(mean total score 2.3). In particular, women agree with statements that emphasize the 
view on the climacteric as a natural development (item 17 and 20). Furthermore, the 
impossibility of a pregnancy and the absence of the menstruation are considered as a 
relief (item 15 and 21). On the treatment cluster the women express moderate agreement 
(mean total score 2.7). The women agree most with the statement that women have to 
consult their GP with problems in the climacteric (item 23). Towards HRT more neutral 
attitudes are reported. 
The relationship between the three attitude-clusters and the actual menopausal status 
of a woman according to the menstrual history is also shown in Table 1. 
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Table L Means and standard deviations of the items about the menopause and 
of the total scores of the three attitude-clusters. Figures for all women and for pre-, 
peri- and postmenopausal women separately'. 
Meant> S.D. Pco Peri Post P_valuec 
Disadvantage cluster 
(Items relating menopause with disadvantages) 
1. One starts to feel old in the climacteric 3.' 1.5 3.5 35 3.7 .582 
2. In the climacteric women can stand less stress 2.3 1.2 2.3 23 2.4 .176 
3. The climacteric coincides with bothersome complaints 25 1.3 2.5 2.4 25 .092 
4. In the (!'Imacteric a woman often has more psycho- 2.' 1.3 2.' 2.' 2.7 .690 
logical problems 
5. Partners of postmenopausal women regard them as less 4.0 1.2 4.0 4.0 4.1 .382 
sexual attractive 
6. For the woman the climacteric is an unpleasant period 2.3 1.3 2.3 2.1 2.4 .025 
7. During the ciim(lcteric one feels less like undertaking 3.1 1.4 3.0 3.0 32 ,119 
something 
8. In the climacteric one often feels unwell 2.3 12 2.4 22 2.4 .053 
9. A woman feels less attractive after the menopause 4.0 1.3 3.8 3.9 4.0 .543 
10. After the menopause women have less sexual needs 3.0 1.3 3.4 32 2.8 .002 
11. The cause of all problems in the climacteric is some- 3.0 1.3 3.1 3.0 3.0 .732 
thing that women can not control by themselves· 
something from outside 
Mean total 3.0 0.7 3.0 2.9 3.0 258 
, N ranges from 1314 to 1397 as the number of women who give a valid answer differs per question, 
b Opinions range from 1 = strongly agree, via 3 = neutral to 5 = strongly disagree. 
< p-value based on analysis of variance, adjusted for age. 
After adjustment for age the mean total score on the advantage cluster and the 
disadvantage cluster is comparable for the three menopausal categories. The mean total 
score on the treatment cluster is more negative from pre-, through peri-, to postmenopausal 
women (mean total score 2.5, 2.7 and 2.8 respectively; p=O.OOl). 
Viewing the separate items of the disadvantage cluster, peri menopausal women agree 
more than pre- and postmenopausal women with the statement that the climacteric is 
an unpleasant period (item 6). Postmenopausal women agree more than pre- and 
peri menopausal women with the statement that after the menopause women have less 
sexual needs (item 10). 
In the advantage cluster postmenopausal women agree more than pre- and 
peri menopausal women with the statement that the climacteric brings many positive 
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Table 1. (continued) 
Mean b S.D. Pee Peri 
Advantage duster 
(Items relating menopause with advilntages) 
12. The climacteric brings milny positive aspects 2.8 1.3 3.0 3.1 
13. Problems in the climacteric disappear spontaneously 2.1 12 2.4 22 
14. Women expecting complaints in the menopause will 2.3 1.4 2.2 2.4 
get them 
15. It is pleasant that pregnancy is not possible after the 1.7 1.2 1.9 1.8 
menopiluse 
16. After the climacteric sex is more pleasant 3.1 1.2 32 3.0 
17. Women in the climacteric must have the insight that 1.4 0.8 1.4 1.4 
physical changes are natural 
18. One grows mature and more self·confident in the 2.4 1.3 2.6 25 
climacteric 
19. After the menopause the sexual relationsh ip is better 3.3 1.1 3.3 32 
20. One should have a preference for natural approaches 1.5 0.9 1.5 1.3 
(i.e. attending to nutritional requirements, vitamin sup-
plements, exercise programmes) for menopausal pro-
blems 
21. The absence of the menstruation after menopause is a 1.7 1.1 1.9 1.7 
relief 
22. After the climacteric one feels more free and more 2.7 1.3 3.0 2.8 
independent 
Mean total 2.3 05 2.4 2.3 
Treatment duster 
(Items relating menopausal complaints with treatment) 
23. Women in the climacteric, with problems, should 1.8 1.1 15 1.7 
cOn!;ult their GP 
24. Complaints in the climacteric must not be treated 2.6 1.4 3.0 2.7 
With drugs· 
25. Women with bothersome climacteric complaints must 3.0 13 2B 2.9 
gH HRT 
26. The benefits of HRT outweigh the risk 3.1 12 3.0 32 
27. Phenomena in the climacteric must be treated medi- 25 1.3 2.4 2.5 
cally 
Mean total 2.7 0.8 2.5 2.7 
.1 Computing the mean total score for the treatment cluster the category scores were reversed for this item 
b Opinions range from 1 = strongly agree, via 3 = neutral to 5 = strongly disagree. 
< p-vaIue based on analys'is of variance, adjusted for age. 
Post P·valuec 
2.6 .002 
1.9 203 
2.3 ,148 
1.6 .111 
32 ,108 
1.4 ,105 
2.3 .336 
3.3 .179 
1.6 .082 
1.6 .005 
2.6 .296 
22 .184 
1.9 .002 
2.5 ,001 
3.1 ,093 
3.2 .105 
2.6 .008 
2.8 .001 
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aspects (item 12) and the statement that the absence of the menstruation after 
menopause is a relief (item 21). 
Three items of the treatment cluster show the same pattern: postmenopausal women 
disagree more than pre- and perimenopausa[ women with statements that promote 
medical attention of climacteric complaints: "Women in the climacteric, with problems, 
should consult their CP" (item 23); "Comp[aints in the climacteric must not be treated 
with drugs" (item 24: association is reversed); "Phenomena in the climacteric must be 
treated medica[[y" (item 27). 
Iii) The association between attitude towards menopause and weJl-being 
The correlations between the four measures of well-being and the three attitude clusters 
are reported in Tab[e 2 ('tota[' columns). The disadvantage cluster is moderately 
correlated to well-being for all women (r varies from -.31 to -.38, a[[ p<.Ol), whereas 
the advantage cluster is weakly correlated to well-being for a[[ women (r varies from .07 
to .13, a[[ p<.05). The treatment cluster is not statistically significant correlated to any 
of the measures of well-being. 
Tab[e 2 also shows whether these reported correlations are different for women in the 
three menopausal status according to the menstrual history. The correlation between the 
disadvantage cluster and well-being is [east strong for premenopausal women and 
strongest for postmenopausal women. This difference is most pronounced for the ISH 
and the SIP emotions, feelings and sensations. Only small differences are found for the 
SIP-socia[ interaction and the SIP intellectual functioning. Such a different pattern over 
menopausal status is not present in the relationship between the advantage cluster and 
the treatment cluster on the one side and well-being on the other. 
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Table 2. Correlations between four measures of well-being and three attitude 
clusters towards menopause for the total group and the three menopausal status'. 
Disadvantage duster Advantage cluster Treatment cluster 
Me<lsure of well-being Total Pee Peri Post Total Pee Peri Post Total Pee Peri Post 
ISH ·.38'" ·25"''' ·.26"'* ·.46** .OS ...... .02 .09 .08 .00 .0' -.13 .00 
SIP social interaction ·,34*" ·.29"" -.31"" _.38"'" .08* .09 .0' .13 -.03 .01 .00 .19"" 
SIP emotions, feelings -.31 ,.,. -.17*" -.26** -.37*" .13 u .01 .00 .19"" -.03 .16 -.03 .06 
and sensations 
SIP intellectual functio- -.31** -28*" -.3, ..... -.32*" .07" .16 -.03 .06 .00 .0' -.02 -.03 
ning 
"Significance:" P < .05; ** P < .01 
(iii) The relationship of medical attention with both well-being and attitude towards 
menopause 
In Table 3, the association of well-being and attitude with medical attention, adjusted 
for differences in age, is shown. Both the menopausal status according to the menstrual 
history and the self-perceived menopausal status are not related with medical attention. 
Well-being as measured by the ISH and the three SIP-scales is strongly related to medical 
attention. For example, an increase of 5 points on the ISH corresponds to a 1.47 higher 
use of medical attention. Finally, of the three different attitude clusters the disadvantage 
cluster and the treatment cluster are moderately related to medical attention: an increase 
(thus: disagree more) of 1 point corresponds to a 25% (odds ratio 0.75) and a 18% (odds 
ratio 0.82) lower use of medical attention respectively. 
The results of the multivariate logistic regression analysis are shown in Table 4. Of the 
three attitude clusters, only the treatment cluster, independent of age and well-being, 
is related to medical attention to a limited extent (odds ratio 0.78). When the analysis 
is restricted to women who perceive themselves as climacteric an increase of 1 point for 
the treatment cluster corresponds to a 37% lower use of medical attention (odds ratio 
0.63). 
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Table 3. The influence of determinants on medical attention: odds ratio of 
determinants, adjusted for age'. 
Vilriable 
Measures of menopausal status 
Menopausal status according to menstrual history' 
Peri menopausal 
Postmenopausal 
Selfperceived menopausal status' 
Peri menopausal 
postmenopausal 
Measures of well-being 
Odds 
Ratio 
0.88 
0.92 
1.05 
1.13 
ISH (per 5 points) 1.47 
SIP social functioning (per 5 points) 1.13 
SIP emotions, feelings and sensations (per 5 points) 1,12 
SIP intellectual functioning and alertness (per 5 points) 1.08 
Attitude measurement 
Disadvantages 0.75 
Advantages 1.08 
Treatment 0.82 
(0.61;128) 
(O.61;1.41) 
(0.74;1.50) 
(0.71;1.79) 
(1.33;1.62) 
(1.07;1.19) 
Cl .08;1.17) 
(',04;1.11) 
(0.63;0.90) 
(0.86;1.37) 
(0.70;0.97) 
• Results are based on logistic regression, where apart from the determinant age is included. 
b 95% confidence interval. 
C Premenopausal is used as reference category. 
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P-value 
.509 
.713 
.786 
.613 
.000 
.000 
.000 
.000 
.002 
.512 
,019 
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Table 4. Multivariate logistic regression analysis of medical attention' 
(Multiple R = 0.31; variance accounted for = 9.6%) 
Variable contained in the regression model Odds Ratio 95% Cl b 
Age (per 5 years) 1.48 (1.20;1.82) 
ISH (per 5 points) 1.27 (1.07;1.50) 
SIP emotions, feelings and sensations 1.09 (1.00;1.18) 
(per 5 points) 
SIP intellectual functioning and alertness 1.06 (1.00;1.13) 
(per 5 points) 
Attitude towards treatment 0.78 (0.62;0.99) 
• Backward stepwise procedure (variables that contribute on a p < ,10 level are retained in the model). 
b 95% confidence interval. 
P-value 
.000 
.005 
.047 
.065 
.041 
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DISCUSSION 
In the attitude of women towards menopause three clusters may be discerned: a 
disadvantage cluster, an advantage cluster and a treatment cluster. In general women 
answer neutrally to, or slightly agree with respectively the items on the disadvantage 
cluster and the advantage cluster. Notwithstanding this overall pattern, the answers on 
the items about sexuality reflect a positive view: the women in this study believe that 
their attractiveness and their sexuality is not influenced by menopause. This attitude is 
somewhat more positive for postmenopausal women, whereas these women agree more 
than pre- and perimenopausal women with the statement that they have less sexual 
needs after the menopause. Apparently menopause is related to a decrease in sexual 
interest, but sexuality is equally appreciated. On the treatment cluster postmenopausal 
women disagree more than pre- and peri menopausal women with statements that favour 
HRT. These findings are in accordance with those of Leiblum et al.4 
A possible explanation for the reported reluctance to the use of HRT may be found in 
the overall agreement with the statement that the absence of the menstruation after 
menopause is a relief. Another possibility is the strong agreement with statements that 
emphasize that the climacteric is a natural process. On the whole, the women report 
comparable means on the items taken from other studies in Germany and the USA.4.6.11 
In our study, well-being is significantly correlated to the disadvantage cluster. Avis and 
McKinley found a similar relationship between negative attitude towards menopause 
and a higher frequency of symptom reporting.s A consequence of this relationship could 
be an iatrogenic effect, especially in the light of the small effect of menopause on well-
being.'·18 It is surprising that the relationship between well-being and the disadvantage 
cluster is present even for women who have not yet experienced the climacteric. This 
relationship is strongest in postmenopausal women. This phenomenon could indicate 
that the attitude towards menopause is partly a consequence of experiences that are not 
associated with the menopause. This has also been demonstrated by Holte et al who 
reported that the mother's menopausal experiences affect those of the daughter.'· 
Another interesting result is the absence of a correlation between the (medical) 
treatment cluster and well-being. Evidently, women who experience a low level of wei 1-
being do not necessarily prefer to be treated. Similar results were found by Ferguson et 
al. In their study no relation between experiencing symptoms during menopause and use 
of HRT was reported.6 
In our study no relationship was found between the menopausal status according to 
either menstrual history or self-perceived menopausal status, with medical attention. 
Thus, a woman seems not to experience the menopause as a medical condition that 
should be treated as such. As expected, all measures of well-being are clearly related 
to medical attention. Next to well-being, both the disadvantage cluster and the treatment 
cluster are related to medical attention. As the treatment cluster is not associated with 
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well-being, this attitude seems to have a function in explaining the need for medical 
attention independent of well-being. This is supported by the multivariate analysis with 
all variables present in which the treatment cluster, independent of well-being, is 
associated with medical attention. Its relationship, however, is rather weak. In the 
analysis restricted to women who perceive themselves as climacteric this effect is seen 
more clearly. This is an important finding. Apparently if women perceive themselves as 
climacteric and if they experience the same level of well-being, more positive ideas 
about treatment correspond to an increase in medical attention. 
As to the generalization of the results, our study group encompasses a population at 
large and women were not selected according to the presence of medical complaints. 
The selection bias seems to be limited, given the minor differences between respondents 
and non-respondents and the response rate (71.3%). 
Only static associations can be studied (which is a limitation inherent to the cross-
sectional design), e.g. it remains undecided whether a low level of well-being leads to 
a more negative attitude towards menopause or vice versa among postmenopausal 
women. Causal relationships between attitude, well-being and medical attention can 
only be addressed in longitudinal studies. 
In this study, we measured medical attention irrespective ofthe presence of menopausal 
complaints. As a consequence, medical attention that is not perceived by women as 
menopause-related will be included. Therefore, the reported relationships between 
well-being, attitude clusters and medical attention may be diluted, by the inclusion of, 
for example, prescriptions for chronic diseases. It is however difficult to distinguish 
complaints that are perceived by women as climacteric from those that are not. 
In order to classify menopausal status correctly, hysterectomized women and women 
using estrogens or having used estrogens in the past six months were excluded. Hence, 
it is not known whether our findings may be extrapolated to these women. However, 
it may be assumed that women already using estrogens will, have a more positive view 
on medical treatment of menopausal complaints. 
In conclusion, women in the climacteric period report a neutral to positive view 
towards menopause. Agreement with items that reflect disadvantages towards menopause' 
is related to a low level of well-bei ng, whereas agreement with items that reflect 
advantages towards menopause is weakly associated with a high level of well-being. 
The woman's opinion regarding the treatment of menopausal complaints is not related 
to well-being. Of the variables used in this study, well-being and age play the most 
important roles in explaining medical attention of women in the climacteric years. Apart 
from these variables, also the woman's ideas about treatment are related to medical 
attention. 
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INTRODUCTION 
Hormone replacement therapy (HRT) is widely accepted as the appropriate treatment 
for the climacteric syndrome characterized by hot flushes and severe sweating. I 
Furthermore, HRT is used for the alleviation of atrophic symptoms of the urogenital 
tract.2 In the past decade, much attention has been paid to the prevention of osteoporosis 
. with oestrogen treatment' and more recently, epidemiologic studies have reported a 
beneficial effect of estrogens in the prevention of ischaemic heart disease.4 Although the 
efficacy of HRT in reducing the incidence of ischaemic heart disease has not been 
assessed in randomised controlled trials, the overall benefits of HRT are now widely 
accepted. 
For women with an intact uterus unopposed oestrogen therapy can not be advocated 
because of the increased risk of endometrial cancer and of the increased incidence of 
curettage and hysterectomy.5 There is consensus that oestrogen therapy has to be 
combined with periodic progestogens6 Such a combination induces withdrawal 
bleedings in most women.' It is generally felt that these withdrawal bleedings are a major 
disadvantage of HRT8.9, but there is literature on the opinion of the women 
themseJves.9-12 
Several modifications!:3-15 of HRT have been proposed to diminish the problem of 
monthly withdrawal bleedings. In the Netherlands, general practitioners often prescribe 
continuous estrogens with the addition of progestogens during 10-12 days once every 
three months. Little is known, however, about the attitude of the women regarding this 
policy. 
The aim of this study is to assess the opinion of women on the continuation or re-
induction of artificial cycles with hormone replacement therapy after menopause. 
METHODS 
This study is part of a larger study to measure well-being in the climacteric. The 
framework of this study is described in detail elsewhere. '6 In short, from the municipal 
authorities of Krimpen aan den IJssel, a commuter suburb of Rotterdam with approximately 
28.000 inhabitants, names and addresses of all 2729 women aged between 45 and 60 
years were obtained. In May 1990 they were sent a questionnaire and 1947 women 
responded (response 71.3%). A random sample (n~55) was taken of the non-respondents 
in order to evaluate the representativity of the respondent group. They were approached 
by telephone and 52 participated (response 95%). No differences between respondents 
and non-respondents could be demonstrated. 
The climacteric status was classified according to menstrual pattern characteristics 
and the number of months or years since the last menstrual bleeding. Women having had 
a menstruation within twelve months priorto the survey and a menstrual pattern which 
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did not change were included in the premenopausal group. Women who had had a 
change in the menstrual cycles in the preceding year were categorized in the 
peri menopausal group. Women whose last menstrual bleeding had occurred more than 
twelve months previous to the survey were categorized as postmenopausal. Women 
who had undergone hysterectomy (n=273) were not included in the analysis. Of the 
remaining 1674 women, 200 women who used oestrogen therapy were considered as 
a separate group and 131 women could not be classified according to their climacteric 
status because of missing data. The analysis was performed using the answers of 274 
premenopausal women, 307 peri menopausal women and 760 postmenopausal women. 
Measurement of attitude towards withdrawal bleedings with HRT 
At the end of the questionnaire we explained that estrogens could be helpful for 
climacteric complaints but that "When you still have your uterus, your menstrual cycle 
will continue or restart when using hormonal treatment". After that statement the 
following questions were asked: 
A: What is your opinion regarding hormonal treatment when your menstrual cycle will 
continue or restart when using this treatment? 
B: What is your opinion when this treatment leads to menstrual bleedings once every 
three months? 
There were five possible answers: no objection, little objection, much objection, 
unwanted, no opinion. 
Statistical methods 
To detect statistical differences between the opinion on withdrawal bleedings of pre-, 
peri- and postmenopausal women the Chi-square test was used. As menopausal age is 
closely related to age, it is necessary to evaluate whether an observed difference 
between women in the three menopausal categories can be contributed to age. To assess 
this, a linear regression analysis was performed for each menopausal category with age 
as independent variable and the opinion of withdrawal bleedings as dependent variable. 
For purpose ofthese analyses the opinion categories were dichotomized. The categories 
'no objection', little objection' and 'no opinion' were clustered, as were 'much 
objection' and 'unwanted'. 
The study received approval from the Medical Ethical Committee of the Erasmus 
University Medical School and Academic Hospital Dijkzigt in Rotterdam. 
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RESULTS 
The findings are summarised in the table. Only 17.2% of the women have no or little 
objection to monthly withdrawal after menopause with HRT. For trimonthly withdrawals 
this percentage is 22.4%. In addition, 28% of the women have no opinion on this subject. 
In general, premenopausal women have less objection than postmenopausal women 
against both monthly and trimonthly withdrawal bleedings. Approximately 60% of the 
postmenopausal women have problems with recurrence of withdrawal bleedings 
(60.8% and 58.4% in the case of monthly and trimonthly withdrawal bleedings, 
respectively), whereas approximately 30% of the premenopausal women have problems 
(30.2% and 34.8% respectively). The difference between pre-, peri- and postmenopausal 
women is highly significant (p<O.OOOOl for monthly, and p<O.OOOOl for trimonthly 
withdrawal bleedings). Of the current users of oestrogen therapy, 60.3% and 63.9% 
object to monthly and trimonthly withdrawal bleedings respectively. 
The influence of age on the opinion on withdrawal bleedings is significant only in the 
peri menopausal group. An age difference of 5 years results in a 13% higher score (95% 
confidence interval: 3% to 23%) in the categories 'much objection' and unwanted' for 
monthly withdrawal bleedings. This figure is 1 0% (95% CI-4% to 24%) for premenopausal 
women and -2% (95% CI -8% to 4%) for postmenopausal women. For trimonthly 
withdrawal bleedings the figures are similar. 
A similar opinion regarding the question about monthly and the question about 
trimonthly induced withdrawal bleedings was expressed by 84% of the women. Another 
12% had a preference for trimonthly cycles, whereas 4% preferred monthly withdrawals. 
Table - Opinion of women regarding continuation or re-inducing of withdrawal 
bleedings after menopause with HRT (in percentages) 
Question A: Question B: 
monthly withdrawals trimonthly withdrawals 
Menopausal categol)' All Pco Peri Post All Pee Peri Post 
" 
1166 256 298 612 1152 253 298 601 
No objection 6.3 14.8 7.0 2.3 9.5 21.7 11.4 3.5 
Little objection 10.9 17.6 13.4 6.9 12.9 19.4 16.8 8.3 
Much objection 12.4 12.1 14.4 11.6 102 9.1 9.4 '1,1 
Unwanted 41.7 28.1 37.9 492 40.1 25.7 37.9 47.3 
No opinion 28.7 27.3 27.2 30.1 272 24.1 24.5 29.8 
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DISCUSSION 
Hormone replacement therapy is gaining more acceptance in Europe. Currently, about 
10% of women between 45 and 60 years are using HRT in the Netherlands. This 
proportion is comparable to reports from the United Kingdom,17 and substantially lower 
than reported in Denmark '8 and the USA. '9 Trimonthly addition of progestogen to 
estrogen treatment is popular among general practitioners in The Netherlands. However, 
it should be stated that scientific proof for the safety regarding the risk of endometrial 
cancer is lacking. The experience with this kind of HRT is only anecdotal and cannot 
be advocated before more is known about its potential cancer risk. Nevertheless it seems 
of interest to know, if this reduction in the frequency of menstrual periods is appreciated 
by women. 
In our study among women aged 45-60, a considerable difference between the 
opinion of pre-, peri- and postmenopausal women exists. Whereas 32.4% of 
premenopausal women have no or little objection to continuation of monthly withdrawal 
bleedings, only 20.4% of the perimenopausal group and 9.2% of the postmenopausal 
group share that opinion. It should be underlined that this opinion was measured in 
women not currently taking oestrogens. Of women using oestrogens, 60.3% have no 
objection to monthly withdrawal bleedings. 
Trimonthly withdrawals are somewhat more acceptable to all groups of women. Of 
the premenopausal women 41.4% have no or little objection to continuation of their 
menstruations in such a pattern. However, the score in the postmenopausal group, 
although higherthan for monthly bleedings, is still low: only 11.8% are in favour of such 
a schedule and at least S8.5% have strong objections. 
The opinion on monthly withdrawals with HRT of the total study group is in agreement 
with other authors.8-1O·12 Draper et al8 in a postal survey in Cambridge reported that 18% 
of 84 women aged 50-52 perceived continuation of menstrual periods as a major 
disadvantage, 32% described it as a minor disadvantage and only 18% described it as 
neutral. In a study in a rural practice in Hampshire among 420 women aged 45-64, 40% 
of the women were deterred from using HRT by the thought of prolongation of periods 
after the menopause.9 Of the women 9% would consider a hysterectomy as an 
alternative. Hahn et al lO in a prospective follow-up study concluded that nearly all 
women discontinued therapy because of undesirable "physiologic" withdrawal bleedings. 
Ferguson et al.12 assessed the factors that influenced the decision of women to use 
oestrogen replacement therapy. Withdrawal bleedings scored as the most negative 
factor both in postmenopausal women currently taking HRT, in postmenopausal women 
who never had taken HRT and in premenopausal women. 
Our findings indicate that for some women, notably those in the premenopausal 
period, a HRT-schedule with trimonthly withdrawal bleedings contributes to their 
willingness to use oestrogens. For the majority of women (and especially for 
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postmenopausal women) monthly and trimonthly withdrawals are not acceptable. 
Research should continue on schedules of hormone replacement therapy without 
withdrawal bleedings. 
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INTRODUCTION 
Hormone replacement therapy has been available for about 40 years. The first placebo 
controlled efficacy study was reported in 1950.1 Since then, many other studies have 
argued the benefits of HRT. They have provided evidence that HRT is profitable for 
women in the climacteric years with vasomotor complaints, vaginal dryness and 
disturbances in menstruation pattern (the so-called typical complaints). Further, HRT is 
probably useful in the prevention of postmenopausal bone loss2-4 and death from 
coronary heart disease5-7 Nevertheless, several authors report a low prevalence of HRT 
use.$,9 
Several factors that influence the decision to use HRT have been reported in the 
literature. The regular withdrawal bleeding as a result of the cyclic oestrogen/progestagen 
therapy is often experienced as unacceptable. lO•il Also, fear of cancer seems to be an 
important reason to refrain from HRT.12 In contrast, women who are interested in health 
promotion and disease prevention measures are more willing to take estrogens. l3 
Furthermore, a higher rate of medical consultations, a belief in the efficacy of medical 
treatment (espeCially hormonal treatment), experience of hot flushes, women's overall 
experience of menopause, parity, education and smoking behaviour may influence the 
use of HRT.'4.'5 
Next to these factors which are related to the women, doctor-related factors may be 
equally important, e.g. the judgment of the phYSicians concerning HRT leads to 
considerable differences in prescribing behaviour and a clear inter-doctor variability has 
been documented. 16,17 
The aim of this study was to estimate the cumulative incidence of first HRT prescription 
and the influence of the woman's well-being, attitude towards menopause, menopausal 
status and other variables on first HRT prescription in a population at large during a 9 
month follow-up period. For women as well as their doctors the so-called typical 
complaints are probably the major indication for HRT.8.18.19 Therefore, the incidence and 
determinants of HRT were studied among women with and without these complaints. 
METHODS 
Recruitment 
This study is part of a larger study aimed at assessing the relationships between 
climacteric, well-being, women's attitude towards menopause and medical attention. 
The methods applied to measure well-being and attitude towards menopause have been 
reported in detail elsewhere.2021 In short, from the municipal authorities of Krimpen aan 
den Ijssel, a commuter suburb of Rotterdam with approximately 28000 inhabitants, 
names and addresses of all 2729 women aged between 45-60 years were obtained. In 
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May 1990 they were sent a questionnaire; 1947 women responded (response 71.3%). 
A random sample (N=55) was taken of the non-respondents in order to evaluate the 
representativity of the respondent group. They were approached by telephone and 52 
participated (response 95%). The comparison between respondents and non-respondents 
revealed no statistically significant differences in age, menopausal status, hysterectomy, 
estrogen therapy, level of education, work outside the home or medical attention. 
To measure the cumulative incidence offirst HRT prescriptions, assistance was given 
by the two pharmacies in Krimpen aan den IJssel. Both pharmacies are computerized. 
Of the women who returned the questionnaire, the 220 women (prevalence 11.5%) who 
had used estrogen therapy within six months preceding answering the questionnaire and 
the 7 women who used progestatives without estrogens were excluded. A further 31 
women could not be traced in the pharmacies' database. The remaining 1689 women 
were registered at the pharmacies, included in the study and followed for a period of 9 
months. The follow-up period lasted from July 1 st 1990 till April 1 st 1991. 
The study received approval from the Medical Ethical Committee of the Erasmus 
University and Academic Hospital Dijkzigt in Rotterdam. 
Measurements 
General well-being was measured by two validated inventories: the 'Inventory of 
Subjective Health' (ISH) and the 'Sickness Impact Profile' (SIP). The ISH has proven to 
be a sensitive instrument to detect health problems.22.'4 The ISH includes 49 items, 
concerning the experience in the past two weeks, for example of pains in the chest, 
trembling hands, headache, sneezing and loss of appetite. On every item the respondent 
is asked whether she has experienced this during the last two weeks. All items must be 
answered with either 'yes' or 'no'. The maximum score is 49. The SIP was developed in 
the United States as a behaviourally based measure of the impact of sickness.'s In this 
study, the Dutch validated version has been used.'6 Both SIP overall scores and SIP 
category scores can discriminate between subsamples of respondents. We have chosen 
three category scores which measure psycho-social impact on well-being: emotions, 
feelings and sensations (9 items), social interaction (18 items) and intellectual functioning 
(10 items). All items are rated a scaling factor. This scaling permits the calculation of 
three SIP percent category scores. A percentage of 100 means maximal impairment on 
the corresponding category score. 
Three attitude clusters towards menopause were distinguished: two clusters encompass 
items reflecting the idea that "menopause is advantageous" and "menopause is 
disadvantageous" and one cluster encompasses items reflecting the idea that "menopause 
should be treated (medically)"." The women were asked to rate their opinion on all 
items on a scale ranging from 1 (totally agree) to 5 (totally disagree). Per cluster mean 
scores were computed. 
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To ascertain menopausal status according to last menstrual bleeding, women were 
classified into pre- peri- and postmenopausal according to menstrual history. 
Premenopausal women were women having a regular menstruation pattern in the 
preceding twelve months. Women were considered perimenopausal when irregular 
cycles or amenorrhoe had developed in the twelve months prior to the questionnaire. 
Women were classified as postmenopausal if last menstrual bleeding occurred at least 
twelve months ago. Women who had undergone hysterectomy were categorized as a 
separate group. 
The women were also asked to rate their climacteric phase themselves by choosing 
one of the following five categories: 'I have not reached the menopause' (classified as 
premenopausal), 'I have just reached the menopause', 'I am in the middle of the 
menopause', 'I have reached the end of the menopause' (all three categories classified 
as peri menopausal), 'I reached the menopause long ago' (classified as postmenopausal). 
The methods used to measure the other potential determinants of the initial HRT such 
as body mass index, smoking behaviour, parity, age, general practice are shown in 
Table 1. 
Women were categorized as having typical (climacteric) complaints when they 
reported one or more of the following symptoms on the questionnaire: hot flushes, severe 
sweating, vaginal dryness or menstruation disturbances. The presence of severe 
sweating and vaginal dryness were assessed by using both a closed and an open 
question, whereas the presence of hot flushes and menstruation disturbances were 
assessed using an open question only. The closed questions were incorporated in a 
symptom checklist, where the women could encircle either yes or no when they had 
regularly experienced a symptom during the last two weeks. In the open question the 
women could indicate any symptom they experienced the during the last four weeks. 
Analysis 
The cumulative incidence of first HRT prescriptions during 9 months was computed. 
Linear variables were dichotomized around the median. The association between 
possible determinants and first HRT prescriptions was studied by means of the X '_test. 
Determinants that were associated with first HRT prescription on a p<O.10 level were 
then included in a logistic regression analysis to ascertain the relative contributions. For 
all ordinal and nominal variables dummy variables were constructed to detect nonlinear 
effects. The backward stepwise procedure was used retaining only variables that 
contributed on a p<O.10 level to the prediction of first HRT prescriptions. 
As the relationships between the determinants and first HRT prescriptions may be 
modified by the presence of typical (climacteric) complaints, subgroup analyses were 
performed for the women without and women with typical complaints. 
Table 1. Cumulative incidence within 9 months of first hormone replacement therapy among 1689 women aged 
'" 45-60 years (%). N 
All 
" 
Without , With , All Without With 
women typical typical women typical typical 
complaints complaints complaints complaints 
Total (n) 62 (104) 4.4 (37) 8.0 (67) Other variables 
Agegroup, years (1641) .000 .004 .014 
MeJsures of well-beingb 45-50 9.2 7.1 11.7 
ISH (1251) 
.001 .002 .260 51-55 5.0 3.1 6.5 
below median 4.4 2.9 6.7 56-60 3.5 1.8 5.3 
above median 9.0 8.6 9.2 Education (1651) .089 .910 .055 0 SIP-social interaction (1335) .316 .701 .700 low 3.5 3.9 3.0 m 
below median 5.5 3.9 7.7 middle 7.0 4.6 9.3 --i m 
above median 6.8 4.5 8.5 high 6.0 5.0 7.2 ;0 
SIP-emotions, feelings and senSiltions (1509) .005 .069 .082 Body mass index, kg/m2 (1585) .681 .751 .452 ~ 
below median 5.1 3.9 6.5 below median 5.9 4.8 7.0 Z 
above median 8.8 7.0 9.9 above median 6.4 4.3 8.5 » 
SIP-intellectual functioning (1454) 518 .668 .974 Smoking behaviour (1619) .004 .092 .039 Z 
--i 
below median 5.9 3.9 8.2 never/ever 5.8 4.2 7.5 V> 
above median 6.7 4.5 8.2 1 to 15 per day 4.4 1.6 7.0 0 ~ AWwde measurements > 15 per day 12.6 8.5 15.8 
'" Menopause is disadvantageous (1294) .217 .30B .674 Contraceptive pill (1643) .000 .037 .002 ~ more positive 6.9 5.2 8.2 never used 3.2 2.6 4.0 
more negative 5.3 3.5 7.3 formerly used 8.0 5.7 10.2 0 
Menopause is advantageous (1299) .16B 510 .221 Parity (1689) .714 .267 .B67 m V> 
more positive 5.1 3.6 6.5 no children 5.0 1.8 7.8 n 
more negative 7.0 4.7 9.1 one child 7.5 5.4 9.2 ;0 
Menopause should be treated (1424) 
.000 .182 .000 two children 6.2 3.6 8.7 ~ 
more positive 8.5 4.7 12.1 three children 6.8 7.0 6.6 is 
more negative 3.6 2.8 4.4 ;:::: four children 4.7 3.2 6.7 Z 
Menopausal staWs Hysterectomy (1659) .008 .109 .051 0 
Menopausal status according to last 00 5.5 4.0 6.8 ~ 
menstrual bleeding (1332) .401 .071 .877 yes, unilateral oophorectomy 11.3 9.3 12.9 I 
premenopausal 7.0 6.1 9.3 yes, bilateral oophorectomy 9.3 4.3 15.0 "'i 
perimenopausal 7.3 6.9 7.7 Medical attention last two weeks (1654) .932 .850 .725 
postmenopausal 5.5 3.0 7.6 00 6.3 4.4 8.3 
Menopausal status according to the women Y" 6.4 4.7 7.7 
themselves (1594) 
.027 .128 .065 General practice (1641) .036 .088 239 
premenopausal 7.0 5.0 14.8 A J.3 1.1 5.4 
perimenopausa! 7.1 5.5 8.0 8 3.5 2.1 4.8 
postmenopausal 3.3 2.1 5.2 C 8.1 6.1 9.8 
D 6.5 4.0 9.7 
E 6.7 7.1 6.3 
• P-value based on the .\2·tesl b 15H = Inventory of Subjective Health. SIP == Sickness Impact Profile. 
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RESULTS 
The 9 month cumulative incidence of first HRT prescriptions was 6.2% (104 women). 
This equals a one year cumulative incidence of 8.2%. The incidence of first HRT 
prescriptions among women without typical complaints at baseline was 4.4%, whereas 
the incidence for women with typical complaints was 8.0%. 
Determinants of first HRT prescriptions for all women 
Table 1 shows the relationship between first HRT prescriptions and possible determinants. 
Only statistically significant associations are reported below. Two measures of well-
being predicted first HRT prescriptions: women below the median of the ISH -i.e. the 
half of women that feels relatively well- had an incidence of 4.4% whereas the women 
above the median of the ISH had an incidence of 9.0%. For the SIP-emotions, feelings 
and sensations these figures were 5.1 % and 8.8% respectively. From the attitude 
measurements, the cluster "menopause should be treated (medically)" was related to 
HRT prescription. Women who thought more positively had an incidence of 8.5%, 
whereas the other women had an incidence of 3.6%. Only the menopausal status 
according to the women themselves was associated with first HRT. Of the premenopausal 
women 7.0%, of the peri menopausal women 7.1 % and of the postmenopausal women 
3.3% started using HRT within the 9 months. 
Furthermore, women who were younger, women who smoked more than 15 
cigarettes per day, women who formerly used the contraceptive pill and women who 
were hysterectomized were more often prescribed HRT. Women who were enlisted in 
general practice C had the highest incidence offirst HRT use (8.1 %), while women in 
general practice A had the lowest 9 month prescription rate (3.3%). 
The results of the multivariate logistic regression analysis are shown in Table 2. Within 
the 9 months of the study, women with typical complaints were prescribed HRT 1.7 
times ( 95% CI 0.9;3.0) more often than women without these complaints. The 
likelihood of HRT prescription for women above the median of the ISH was 2.0 (95% 
CI 1.1 ;3.6) times higher than for women below the median. For the WOmen who thought 
more positively about the attitude cluster "menopause should be treated" the odds ratio 
equalled 2.7 (95% CI 1.5;4.9) compared to the women who thought more negatively. 
Women who smoked more than 15 cigarettes a day had an odds ratio of 2.2 (95% CI 
1.1 ;4.6) compared to women who have never or ever smoked. The former use of the 
contraceptive pill resulted in a 2.3 (95% Cll.l ;4.6) times higher prescription rate of HRT 
within the 9 months compared to women who never used the pill. 
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Determinants of first HRT for women with and without typical complaints 
In the multivariate analyses (Table 2) all relationships between determinants and HRT 
prescription appeared to be modified by the presence of typical complaints. 
For women without typical complaints the ISH and the former use of the contraceptive 
pill were determinants of initial HRT prescription. Women above the median of the ISH 
had a 5.5 (95% CI 1.9;15.5) higher rate of HRT than women below the median, while 
for former users of the contraceptive pill the odds ratio was 4.6 (95% CI 1.0;20.5). 
For the women with typical complaints the attitude cluster "menopause should be 
treated" was related to HRT prescription. Women who thought more positively about 
treatment had an odds ratio of 3.8 (95% CI 1.8;8.0) compared to women who thought 
more negatively. 
Table 2. Sign ificant determinants from the multivariate logistic regression analysis 
of first hormone replacement therapy prescription among 1689 women aged 
45·60 years 
All women Women without Women with 
typical complaint5 typical complaints 
Variance accounted for by 3.8% 4.0% 2.8% 
the variables 
Variable contained in the Odds 95% CI" Odds 95%CI Odds 95%CI 
regression model Ratio Riltio Ratio 
Typical complaints 
not present 1.0 
present 1.7 (0.9;3.0) 
ISH b 
below median 1.0 1.0 
ilbove median 2.0 (1.1;3.6) 55 (1.9;15.5) 
Menopause should be treated 
more negative 1.0 1.0 
more positive 2.7 (1.5;4.9) 3.8 (1.8;8.0) 
Smoking behaviour 
never/ever 1.0 
1-15 cigarettes 1.0 (0.4;22) 
> 15 cigarettes 2.2 (1.1;4.6) 
Contraceptive pill 
never used 1.0 1.0 
ever used 2.3 (',1;4.6) 4.6 (1.0;20.5) 
"95% CI = 95% confidence interval. b ISH = Inventol)' of Subjective Health. 
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DiSCUSSiON 
in this follow-up study of 1689 women aged 45-60 years in an open population, the 9 
month cumulative incidence of first hormonal replacement therapy prescriptions was 
6.2%. When the independent effects of several determinants were studied by means of 
a logistic regression analysis this incidence appeared to be higher for women (i) with 
typical complaints, (ii) with a lower level of well-being as measured by the ISH, (iii) with 
a more positive attitude towards "the menopause should be treated", (iv) smoking more 
than 15 cigarettes a day and (v) who formerly used the contraceptive pill. 
In this 9 month study a cumulative incidence of 6.2% of first HRT was established, 
whereas the prevalence of HRT use at baseline was 11.5%. This implies that either the 
prevalence of HRT is rapidly increasing or that many women stop taking HRT. We were 
able to verify these options atthe two pharmaCies where the women were still registered. 
The pharmacies reported that one year and 9 months after the questionnaire 68 of the 
103 (66%) women were no longer prescribed HRT (one woman moved). Therefore, the 
problem of a low prevalence of HRT as stated by several studies.9.15 might be attributed 
to the problem of continuation rather than starting HRT. 
Several determinants of HRT prescription that have been found in our study are in line 
with previous findings. An association between general well-being and HRT has not 
been reported as a determinant of HRT in other studies. However, these studies were 
crossectional and therefore the level of well-being may already have been influenced 
by HRT.14.15 The relationship between attitude towards treatment and HRT has been 
found before.27 Apparently, the belief in the efficacy of medical treatment of the 
menopause is at least as important as the presence of typical complaints. The 
relationship between smoking behaviour and HRT was ascertained in one study'8, but 
absent in another study.'5 Perhaps women who smoke may therefore experience typical 
complaints more intensely. In several earlier studies, the former use ofthe contraceptive 
pill was a determinant of HRT use. '5 Probably, once a woman has decided to use 
hormones with a contraceptive purpose, she has less fear of cancer and other adverse 
effects. 
in our study, hysterectomy was, in contrast to other studies'529, a determinant in the 
univariate analysis only. Once well-being, smoking behaviour and/or former use of the 
pill were taken into account by means of the logistic regression analysis, the prediction 
of HRT prescription did not depend on hysterectomy. The same was found for the SIP 
emotions, feelings and sensations, the menopausal status according to the woman, age 
and general practice. 
The cumulative incidence for women with typical (climacteric) complaints was 8.0% 
versus 4.4% for women without typical complaints. Hence, for the majority of the 
women a therapeutic indication existed. For women without and with typical complaints 
it appears that the prediction of HRT use is determined by different factors, i.e. a lower 
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level of well-being and the former use ofthe contraceptive pill for women withoutthese 
complaints and a positive attitude towards "menopause should be treated" for women 
with these complaints. 
It is remarkable that a lower level of well-being as measured by the ISH determined 
HRT prescription (odds ratio equals 5.5) for women without typical complaints. As yet, 
no clear views exist about the beneficial effect of HRT on well-being in the absence of 
typical symptoms. From this we may tentatively conclude that a low level of well-being 
as measured by the ISH might be employed by the woman and/or her physician in the· 
process leading to HRT prescription. In a study of Hunt a considerable influence of 
patient's demand on HRT prescription was apparent (21 % of all prescriptions).'9 This 
conclusion is also supported by the divergence in HRT prescription rates between the 
general practices, especially for women without typical complaints. Ferguson also 
observed differences between physicians in HRT prescription.27 When typical complaints 
are present, the prescription of HRT mainly depends on the woman's attitude towards 
"menopause should be treated" and not on her experienced level of well-being. 
To our knowledge this is the first study to assess the cumulative incidence of HRT and 
its determinants in an unselected population. By gathering the data from the pharmacists, 
neither the women's nor the doctor's attention was drawn to HRT prescription. A 
limitation of this study is the possibility of a change in typical complaints during the 9 
month follow-up. Women were categorized as women with or without typical complaints 
according to the presence of these symptoms at the time of the questionnaire. 
Subsequent changes in the experience of these complaints, which were not measured, 
may have been of influence on the prescription of HRT. Most likely this resulted in an 
underestimation of the relationships reported in the separate analyses. Another limitation 
is the fact that we measured delivery of HRT prescriptions and not the actual use. 
Moreover, some women might have incidentally filled HRT prescriptions in other 
pharmacies than the two present in Krimpen aan den IJssel. As there is a considerable 
distance between this suburb and Rotterdam and only 31 out of 1947 women could not 
be traced at either pharmacy this will only have happened in few cases. Nevertheless 
a slight underestimation of the cumulative incidence of HRT may be present. Finally, 
although we evaluated most variables known to possibly influence the prescription of 
HRT, some other factors such as those related to the physician were not measured. 
It may be concluded that the cumulative incidence of first HRT prescription is high, 
but that the majority of the women stop taking HRT within two years, which implies that 
most indications are rather therapeutic than preventive. When typical complaints are 
absent, women with a level of well-being above the median are prescribed HRT five 
times more frequently. The question arises whether for these women the indication is 
therapeutic, preventive or equivocal. For women with typical complaints the doctor's 
prescription is primarily related to the woman's attitude towards (medical) treatment of 
the menopause. The process of decision-making about starting and continuation of HRT 
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is complex, depending on a variety of determinants modified by the presence of the 
typical climacteric complaints. Insight in this process may contribute to a more rational 
prescription of HRT. 
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INTRODUCTION 
In the USA the prescription of estrogens in menopausal women was more than doubled 
in the period 1960 to 1974. This may partly be attributed to Wilson's advocacy of 
estrogen therapy in his widely read book 'Feminine for ever'.' In Sweden the consumption 
trebled between 1973 en 1977.2 A drop in the use of estrogens appeared in the late 
seventies. This was probably due to the commotion about reports of a strong association 
between endometrial cancer and estrogen replacement therapy.3A Consensus exists that 
in addition to estrogens, women with an intact uterus should be given progestogens in 
order to prevent endometrial cancer.s As a consequence of the acclaimed beneficial 
effects of hormone replacement therapy on osteoporosis and cardiovascular disease, a 
renewed interest in HRT has emerged.6.7 In recent years, however, conflicting data has 
become available about an increased risk of breast cancer associated with these drugs.' 
Appropriate duration of HRT is about 6 to 12 months for short term beneficial effects 
(i.e. the alleviation of vasomotor symptoms) and at least 3 to 5 years to prevent 
osteoporosis and cardiovascular diseases.9- 11 Although only few studies have assessed 
the duration of use of HRT after its initiation, they indicate that estrogens are stopped 
earlier than the indication would require. '2 This has been attributed to the discomfort 
associated with the inherent withdrawal bleedings or side effects such as breast 
tenderness.'" Only few studies evaluated determinants of the duration of HRT use. 
The aims of our study were (i) to assess the mean duration of use of HRT and (ii) to 
determine which variables predict the duration of HRT use. 
METHODS 
Recruitment 
This study is part of a larger study aimed at assessing the relationships between 
climacteric, well-being, women's attitude towards menopause and medical attention. 
The methods applied to measure attitude towards menopause have been reported in 
detail elsewhere.'4 In short, from the municipal authorities of Krimpen aan den IJssel, a 
commuter suburb of Rotterdam with approximately 28000 inhabitants, names and 
addresses of all 2729 women aged 45 to 60 years were obtained. These women were 
all enlisted in one of the five group practices of general practitioners in Krimpen aan den 
IJssel. In May 1990 they were sent a questionnaire; 1947 women responded (response 
71.3%). A random sample (N=55) was taken of the non-respondents in order 10 evaluate 
the representativity of the respondent group. They were approached by telephone and 
52 participated (response 95%). The comparison between respondents and non-
respondents did not reveal any statistically significant differences in age, menopausal 
status, hysterectomy, estrogen therapy, level of education, work outside the home or 
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medical attention. 
To measure the incidence of first HRT prescriptions (i.e. women who had not used 
estrogen therapy within six months preceding answering the questionnaire), assistance 
was given by the two pharmacies in Krimpen aan den IJssel. Both pharmacies are 
computerized. Of the women who returned the questionnaire, the 220 women 
(prevalence 11.5%) who had used estrogen therapy within six months and the 7 women 
who used progestogens without estrogens were excluded. A further 31 women could not 
be traced in the pharmacies' database. The remaining 1689 women who were registered 
at the pharmacies, were included in the study and followed for a period of 9 months. The 
recruitment period lasted from July 1 st 1990 till April 1 st 1991. In total, 103 women 
(incidence in 9 months 6.2%) were prescribed HRT. These 103 women were all 
followed from the initiation of HRT for 2% years. 
The study received approval from the Medical Ethical Committee of the Erasmus 
University and Academic Hospital Dijkzigt in Rotterdam. 
Measurements 
The duration of HRT was assessed by using the data provided on the dispensions of HRT 
to the 103 women in the cohort. For each HRT dispension the expected final date of use 
was computed. If the interval between the computed final date and the date of the next 
dispension of HRT was less than 42 days, the use of HRT was considered to be 
continuous, irrespective of a possible change of application. Although 42 days is an 
arbitral interval, short-term beneficial effects may then be considered to have disappeared. 
When a next dispension occurred before the computed final date of the previous 
dispension the overlapping time was counted only once in the computation of the total 
period of HRT use. When a next dispension occurred more than 42 days after the 
computed final date of the previous dispension, the HRT use was considered as 
interrupted. Several variables that could influence the duration were measured. During 
the data analysis it became apparent that,an important variable, i.e. the indication for 
HRT was not measured adequately by questionnaire, i.e. many women did not fill out 
the question about the indication. Therefore it was measured retrospectively by asking 
the general practitioners for their reason for prescription, with the assistance of the 
patient's record. 
Th ree attitude cl usters towards menopause were distinguished: 14 two clusters encompass 
items reflecting the idea that "menopause is advantageous" and "menopause is 
disadvantageous" and one cluster encompasses items reflecting the idea that "menopause 
should be treated (medically)" . The women were asked to rate their opinion on all items 
on a scale ranging from 1 (totally agree) to 5 (totally disagree). Per cluster mean scores 
were computed. 
To ascertain menopausal status according to last menstrual bleeding, women were 
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classified into pre-, peri- and postmenopausal according to menstrual history. 
Premenopausal women were women having had a regular menstruation pattern in the 
preceding twelve months. Women were considered peri menopausal when irregular 
cycles or amenorrhoe had developed in the twelve months prior to the questionnaire. 
Women were classified as postmenopausal if the last menstrual bleeding occurred at 
least twelve months ago. Women who had undergone hysterectomy were categorized 
as a separate group. 
The methods used to measure the other variables such as type of application, 
education, hysterectomy, use of contraceptive pill, smoking and group practice are 
shown in table 1 and table 2. 
Analysis 
For each category of a possible determinant of the duration of HRT the mean duration 
of continuous HRT use was computed. The attitude measurements were dichotomized 
around the median. By means of analysis of variance it was tested whether the submeans 
differed Significantly from each other. 
RESULTS 
The mean duration of hormone replacement therapy use of the 103 women was 7 
months (standard deviation 7.1; range from 0.5 to 27 months). In table 1 the duration 
of use for all women and for the women on different applications of HRT is shown. In 
figure 1 the proportion of users is depicted as a function of the period elapsed since the 
initial HRT prescription. Within 6 months more than 60 % of the women stopped using 
HRT. Aftertwo years 8% ofthe women were still using HRT. Tibolon showed the highest 
withdrawal rate within 6 months, being 93%, whereas these figures are 79%, 69% and 
61 % are for creams, transcutaneous and oral applications other than Tibolon respectively. 
On average the oral application of HRT other than Tibolon is taken longer than the 
other applications. All indications for the prescription of HRT were primarily short term, 
i.e. to relieve vasomotor symptoms, dyspareunia caused by vaginal atrophy or 
menstruation disturbances. 
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Table 1. Mean duration in months of the continuous use of H RT according to type of 
application of HRT. 
All women (n = 103) 
Transcutaneous 
(n = 16) 
Oral 
(n =49) 
Creams 
(n =24) 
Tibolon 
(n = 14) 
100% 
80% 
60% 
40% 
20% 
<6 6-12 12-18 18-24 
months months months months 
64% 21% 4% 3% 
69% 31% 0% 0% 
61% 20% 4% 2% 
79% 21% 0% 0% 
93% 7% 0% 0% 
% of users 
<6 6·12 12·18 18·24 > 24 
Mean continuous use of HRT (months) 
- TIS -+ Oral "*" Creams ... Tibolon 0 Total 
>24 
months 
8% 
0% 
12% 
0% 
0% 
Figure 1. The mean duration in months of the continuous use of HRTaccording to 
the type of application (n = 103 women). 
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In table 2 the association between other variables and the mean duration of HRT use 
in months is shown. Three of these variables appear to be significantly related to the 
duration of HRT use. Women having a more positive attitude towards treatment stop 
using HRT 3.4 month later than women with a more negative attitude. Older women 
stayed on HRT less long than younger women. The mean duration of HRT use for women 
aged 45-50 years, 50-55 years and 55-60 years were 8.9, 6.0 and 4.4 months 
respectively. The mean duration of HRT appeared to vary according to the group 
practice from 4.4 months (group practice A) to 10.4 months (group practice D). 
Postmenopausal women as compared to pre and peri menopausal women tended to use 
HRT shorter. 
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Table 2. Mean duration in months of the continuous use of HRT for different 
possible determinants within a period of 2% year. 
Determinant Mean StandiHd 
deviation 
Attitudes 
Menopause is disadvantageous 
Below median" 6.3 6.1 
Above medianb 8.9 9.3 
Menopause is advantageous 
Below median· 7.7 8~ 
Above median b 72 7.0 
Menopause should be treated 
Below median" 8.7 8.4 
Above median b 5.3 5.9 
Sociodemographic variables 
Age group 
45-50 years 8.9 8.6 
51-55 years 6.0 6.0 
56-60 years 4.4 3.4 
Education 
low 6.6 7.4 
middle 6.7 7.0 
high 8.1 7.9 
Gynaecological variables 
Menopausal status according to last 
menstrual bleeding 
premenopausal 9.1 8.6 
perimenopausal 8.4 7.9 
postmenopausal 5.0 4.9 
Hysterectomy 
'0 7.3 7.3 
Y" 5.8 6.3 
Contraceptive pill 
never used 5.6 5.8 
formerly used 72 7.3 
Other variables 
Smoking 
never/ever 6.3 6.3 
1-15 per day 8.4 9.3 
> 15 per day 7.4 8.1 
Croup practice 
A 4.5 4.0 
8 9.3 8.3 
C 5.8 6.1 
D lOA 10.0 
E 5.0 3.3 
• Below median: the 50% of the women who agree most with the items. 
b Above median: the 50% of the women who di~gree most with the items. 
p-value 
0.14 
0.76 
0.03 
0.03 
0.78 
0.10 
0.36 
0.37 
0.61 
0.05 
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DISCUSSION 
In our follow-up study of 103 women who started using HRT in general practice more 
than 60% of the women stopped their HRTwithin 6 months and only 8% of the women 
remained on HRT for more than 2 years. The mean duration of use was 7 months. 
Determinants that predicted the duration of HRT use were type of application, age, 
attitude towards treatment of the menopause and the group practice. 
Very few studies have assessed the duration of use of HRT. Wren found that 61 % of 
100 women was still on therapy after one year. IS Barlow found that after 2 years only 
15% of the women were still on HRT.'6 We found the same pattern, although the 
percentage of women who stopped HRT is higher in our study. 
Many studies pointed outthat one of the main reasons for stopping HRT are withdrawal 
bleedingsY From this point of view one may expect hysterectomized women and 
women using preparations which do not result in withdrawal bleedings (i.e. tibolon), to 
use HRT for a longer period. We, however, could not confirm this in our study. Other 
studies also pointed out that the compliance with HRT of hysterectomized women was 
low. '6,18 Thus, withdrawal bleedings inherent to most HRT do not appear to be a leading 
factor in the decision to stop HRT use. When the indications in this and other studies 
would be more often preventive, thereby implying a longer use of HRT, withdrawal 
bleeding could as yet negatively influence the duration of HRT. 
Another main reason for early withdrawal from HRT was suggested by Draper. He 
found that 50% of the women judged the risks of HRT higher than the benefits.19 They 
were especially worried about the possibility of cancer. 
In our study the role of the physician was of influence on the duration of HRT use. 
Ferguson also found that a major factor influencing HRT duration was the physician.20 
Doctors probably vary in their opinion about the necessity of HRT.21.22 
The attitude towards treatment of the menopause was a strong predictor of the duration 
of HRT use, In an earlier study we established that this attitude was also a predictor of 
the initiation of HRT23 Sinclair also reported that a positive attitude towards treatment 
was related to HRT use.24 
Why younger women comply more with HRT use than older women remains 
unresolved, Harris found that menopausal women who used estrogens were relatively 
young.2S POSSibly, younger women often still have menstruations when they start using 
HRT and are therefore less troubled by the withdrawal bleedings accompanying HRT 
use, compared to older women who have experienced a period without menstruations.26 
This idea is also supported by our finding that pre- and perimenopausal women had a 
longer duration of HRT use compared to postmenopausal women. 
The majority of women in our study stopped using HRT within 6 months. This indicates 
that women take HRT for short term effects, notably to alleviate symptoms such as 
flushes, This was confirmed by the general practitioners. Roberts reported that eighty 
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percent of the women use HRT primarily to relieve menopausal symptoms, while only 
6% use it as a prophylaxis against osteoporosis.27 
A disadvantage of our study is that we could not measure the reasons for stopping HRT. 
Another disadvantage lies in the fact that we measured the indication retrospectively, 
using information from both the patients' records and the general practitioners. An 
advantage of our study concerns the opportunity to observe aspects of HRT use without 
being influenced by defined prescriptions, strict inclusion criteria and closed monitoring 
of drug compliance inherent to randomized trials which may influence the duration of 
HRT and hamper generalizability. Another limitation is the restricted possibility of 
generalization: the results of this study only apply to Krimpen aan den Ijssel in the 
Netherlands. Part of the relationship between group practice and the duration of use may 
be attributable to differences in age between the treated women in the practices. 
Adjustment for confounding variables however was not possible, as the total number of 
participants was 103, resulting in unstable estimates in multivariate analyses. Further 
research among larger populations is necessary to resolve these issues. 
In conclusion the mean duration of HRT was 7 months; more than 60% stopped using 
HRT within 6 months, while only 8% of the women still use HRT after two years. We 
conclude that the mean duration is short, even if all indications are short term, i.e. for 
the alleviation of menopausal symptoms. Apparently, women are presently unwilling to 
take H RT for longer periods. 
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GENERAL D[SCUSS[ON AND [MPLlCAT[ONS FOR THE PHYS[ClAN 
The studies described in this thesis focus on the relationship between well-being, 
attitudes towards menopause, HRT use and menopausal status of women aged 45-60 
years. The study was based on a literature review, a cross-sectional population based 
study and a longitudinal study. [n this chapter the main conclusions from our study are 
put into perspective with literature, and their implications for the practising physician 
will be discussed. 
Many studies have been performed to answer the question whether certain symptoms 
and complaints during the climacteric years could be classified in a well-defined entity, 
the so-called 'climacteric syndrome', caused by hormonal changes (chapter 1). During 
the last 1 0-15 years medical, psychological and sociological disciplines have carried out 
population based cross-sectional, as well as longitudinal studies among a large number 
of women in several countries, using an appropriate methodology and sophisticated 
statistics.
'
·
'5 The majority of these studies concluded that symptoms of the so called 
climacteric syndrome were mainly excessive sweating, hot flushes, vaginal dryness and 
menstrual disturbances. These studies point out that psychosocial factors have more 
impact on the presentation of symptoms and complaints than does the menopause per 
se. Our own cross-sectional study, which applied well-being as an overall measure 
instead of the mere presence of symptoms, resulted in similar findings (chapter 2). We 
also established a strong relationship between menopausal status, vasomotor symptoms 
and dryness of the vagina; whereas the independent relationship between the climacteric 
and well-being as measured by the Inventory of Subjective Hea[th (ISH) and the three 
subsca[es of the Sickness Impact Profile (S[P) is found a small negative association 
between behavioral functioning in the daily life of a woman and the menopausal status. 
Only a few studies have explored the association between vasomotor symptoms and 
atypical complaints. They reported that sleep disturbances, social dysfunction and other 
atypical complaints were related to vasomotor symptoms. We found that no linear 
association between vasomotor symptoms and well-being exists (chapter 3). Furthermore, 
in pre- and postmenopause women with vasomotor symptoms had an impaired well-
being compared to women without vasomotor symptoms. However, in the 
peri menopause, when the prevalence of vasomotor symptoms is at its highest level, 
there was no difference in well-being between women with or without vasomotor 
symptoms. [n our opinion, the relationship between well-being and vasomotor symptoms 
is complex and not only depends on their severity and frequency but probably also on 
the circumstances under which they occur. From this, we pose that women who 
perceive a symptom in the climacteric as 'normal' (perimenopausa[ women) do not 
experience an impaired well-being, whereas pre- and postmenopausal women do. This 
hypothesis is supported by our findings: when women classify themselves as 'in the 
middle of the menopause', the difference in well-being between women with and 
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without vasomotor symptoms is smaller than when women are classified according to 
their last menstrual bleeding. 
For the physician, some major conclusions can be drawn from this part of the thesis. 
Firstly, a woman with complaints in the climacteric years should not be stigmatized as 
a 'climacteric woman', in the sense of suffering from a disease or a syndrome entity. 
Aside from typical, but not pathognomonic symptoms (vasomotor symptoms, dry vagina 
and menstrual disturbances), there is not sufficient evidence to support the existence of 
a climacteric syndrome. Although a diagnosis is often defined as 'a provisional formula 
for action', it should not become a license to stop thinking about the nature of the 
patient's problem too soon.17 In addition, attribution of symptoms to a 'climacteric 
syndrome' by the doctor may hinder a integral approach, characteristic in family 
medicine i.e. to include somatical and psychosociological elements. In the appreciation 
of complaints, a preliminary attribution of symptoms to the climacteric may lead to 
serious doctor's and patient's delay. Therefore, it is better to speak of complaints and 
symptoms in the climacteric years in stead of 'climacteric complaints'. 
Secondly, as the level of well-being may depend on the perception of vasomotor 
symptoms as 'normal', this accentuates the need for the physician to explain to a woman 
the occurrence of these symptoms in pre- and postmenopausal women. Probably this 
explanation may give these women reassurance and this in turn may improve well-
being. 
To know the attitudes and beliefs of women towards menopause will help the 
physician to elicit and understand why and how a complaint is presented by a patient. 
From literature (chapter 7) and our own study (chapter 3) some attitudes and beliefs can 
be discerned. Brody stated, that physicians are prone to transmit to a patient the accepted 
scientific explanation for a symptom or condition and may pay little attention to the 
explanatory model that the patient may have devised. The extent to which the 
physician's and patient's understanding of a given symptom differs, influences the 
quality of the communication between doctor and patient. 16 
Most women have a neutral to positive attitude towards menopause. They especially 
agree that sexuality is not impaired in the climacteric years. An important conclusion 
of this thesis is that a more negative attitude towards menopause is related to a lower 
level of well-being. This relationship is strongest in premenopausal women, who (by 
definition) have not experienced the menopause. As impaired well-being can not be 
explained by menopausal status per se, this attitude may facilitate wrong attribution of 
complaints to the climacteric and may lead to either patient's delay or to extra medical 
attention. Indeed, in our study we confirmed that, next to age and impaired well-being, 
the women's idea about treatment towards menopause is related to medical attention 
in the climacteric years. 
This part of the study illustrates that the physician should be aware of the existence of 
a subgroup of women who express a more negative attitude towards menopause, since 
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they will, in general, have a lower level of well-being compared to women with a less 
negative attitude towards menopause. The physician should provide more comprehensive 
health information to these women in order to avoid misattribution to the climacteric. 
Furthermore, the physician should realise that when he also misattributes the complaints 
this could result in iatrogenic effects. As the association between a negative attitude 
towards menopause and the level of well-being is most pronounced in premenopausal 
women, the risk of a self-fulfilling prophecy is present. 
A limitation of our study lies in the cross-sectional design of parts of the study. Such 
an design often leads to the 'chicken-and-egg' problem, e.i. it remains undecided 
whether a low level of well-being leads to a more negative attitude, or vice versa. 
Another limitation is the restricted possibility of generalisation: the results of this study 
only apply to Krimpen aan den IJssel in the Netherlands. The advantages of our study 
were that we included a large population (N=2729) and adjusted for confounding 
variables. In contrast, most earlier studies were performed among women visiting clinics 
and data were not adjusted for potential confounding variables. Furthermore, several 
earlier studies used inadequate criteria to classify menopausal status. 
Hormone replacement therapy (HRT) is accepted as the appropriate treatment for hot 
flushes and severe sweating, as well as for the alleviation of atrophic symptoms of the 
urogenital tract and the regulation of menstrual disturbances. As yet, no clear opinion 
exists about the beneficial effects of HRT in the absence of the above mentioned typical 
complaints. This can be ascribed to design difficulties, i.e especially blinding is a main 
problem (chapter 7). This is without dispute necessary to rule out the placebo effect." 
If any beneficial effects of estrogens on other symptoms and complaints in the 
climacteric years exist, they are probably of modest proportion. 
More recently, epidemiological studies report the beneficial effects of estrogens in the 
prevention of demineralization of bones and ischaemic heart disease. Some disadvantages 
of HRT are (i) the withdrawal bleeding caused by the combination of estrogen therapy 
with progestogens for women with an intact uterus to prevent endometrial cancer (ii) 
other side effects like breast tenderness, edema (iii) worries about cancer, espeCially 
breast cancer among physicians and women. 19,20,21 
Our study provides more insight into some aspects of HRT use e.g. women's opinion 
as to withdrawal bleedings, the determinants of initiating HRT and the determinants of 
the duration of HRT use. We found (chapter 4) a considerable difference in the opinions 
of pre-, peri- and postmenopausal women with respect to continuation or re-induction 
of withdrawal bleedings. Whereas 32.4% of the premenopausal women have no or little 
objection to continuation of monthly withdrawal bleedings, only 20.4 % of the 
perimenopausal women and 9.2% of the postmenopausal group share that opinion. 
Trimonthly withdrawal bleedings are somewhat more acceptable to all groups of 
women. 
Seemingly, withdrawal bleedings may to some extent influence the decision of 
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women to take hormone replacement therapy. Initiating HRT before the cycles stop and 
regimens without withdrawal bleedings will possible augment compliance with HRT. 
However, for the majority (and especially for the postmenopausal women) monthly or 
trimonthly withdrawals are not acceptable. 
In a longitudinal part of our study (chapter 6 and chapter 7) we established the 
incidence of initiation and duration of HRT use and their determinants. Here, we discuss 
these two studies together. The 9 month cumulative incidence for women with typical 
complaints is 8.0% and for women without typical complaints 4.4%. This indicates that 
prescription is dominated by the typical complaints e.g. vasomotor symptoms, vaginal 
dryness and menstrual disturbances. Other determinants were well-being, attitude 
towards 'menopause should be treated' and former use of oral contraceptives. 
Contrary to our expectations, hysterectomy appeared not to be a determinant for the 
initiation of HRT. Moreover, the duration of HRT use was not related to hysterectomy. 
Obviously, other factors in the decision to take HRT playa more important role than 
withdrawal bleedings. This is also supported by our findings that (i) trimonthly 
withdrawal bleedings hardly increase the women's willingness to take HRT and (ii) the 
duration of usage of preparations which give little or no withdrawal bleeding is not 
longer than that for other H RT products. 
From literature it is known that fear of cancer is a major reason not to start HRT. Sixty 
percent of the respondents in a UK study expressed concern about side effects, including 
the risk of cancer, even though it is known that endometrial cancer can be prevented by 
progestogens and that any increase in breast cancer is controversial and probably offset 
by a reduction in cardiovascular mortality and fracture risk.19.22 
Another finding in this study is, that when typical complaints are absent, well-being 
as measured by the ISH plays an important role in starting HRT. The odds ratio for women 
with a relatively low level of well-being to starting HRT as compared to women who feel 
relatively well is 5.5 (95% CI 1.9;15,5). As we know from our data that the general 
practitioners do not prescribe HRT exclusively for preventive purposes and that well-
being is only slightly influenced by the menopausal status, the giving of HRT to this group 
of women is debatable. In the presence of vasomotor symptoms only, the attitude 
towards 'menopause should be treated' is a determinant. The available research suggests 
that, in case of vasomotor symptoms a concrete indication is present, but the attitude 
of the woman plays the decisive role in the actual initiation of HRT. Our findings show 
a short mean duration of usage of HRT. More than 60% of the women ceased within 6 
months and only 8% of these women still used HRT after 2 years. These data are in 
accordance with the fact that general practitioners seldom prescribe HRT for preventive 
measures only. In conclusion, the majority of the women start HRT for the alleviation 
of typical complaints. Some of the women may use HRT for other unspecified reasons, 
which can not be explained either by indication of typical complaints or by preventive 
measures. These women are probably prescribed HRT to test whether the complaints are 
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related to estrogen deficiency. 
As yet, it appears that both women and physicians are not ready to use or prescribe 
HRT as a means of prevention for osteoporosis and cardiovascular disease. Future 
research should further explore the determinants of compliance with HRT. Furthermore, 
well-designed studies of the effects of HRT on well-being in the absence of typical 
complaints remain necessary. 
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Chapter 1 
In reviewing the literature we tried to answer the following questions (i) is there a 
climacteric syndrome in terms of symptoms and complaints, exclusively and 
independently connected with the climacteric status (ii) is there an association between 
serum hormone levels and a possible climacteric syndrome (iii) does estrogen replacement 
therapy bring about relief in symptoms and complaints of this feasible syndrome and 
improves well-being (iv) what are the attitudes and beliefs towards menopause among 
the women themselves (v) what is known about the usage of hormone replacement 
therapy among women. 
Most studies found that vasomotor symptoms and vaginal dryness are significantly 
related to menopausal status. Hot flushes and night sweats are strongly associated with 
menopausal status in Western research literature. These symptoms have a relatively low 
prevalence among Japanese women. In general these studies showed that the menopausal 
transition does not have an important impact on well-being, including the experience 
of sexuality. Most complaints in the climacteric years were not associated with 
menopausal development, but could be explained by a mixture of other variables. Given 
the avai lable recent evidence, apart from typical complaints, there are too few 
indications to speak of a well-defined climacteric syndrome. Some studies have reported 
a relationship between complaints (sleepingdisturbances, social dysfunction) and the 
presence of vasomotor symptoms. 
Although the drop in estrogen production at menopause is characteristic, levels of all 
hormones are similar in flushers and non-flushers. 
The best scientifically accepted design to establish the effect of estrogen therapy in 
relieving symptoms, complaints and improving well-being is a randomized double-
blind placebo controlled trial. The major problem in the design is blinding, caused by 
the presence of withdrawal bleedings as a result of the combination of estrogens with 
progestogens. To maintain blinding, some studies were performed in hysterectomized 
women, of which the generalizability of the results are questionable. Other studies used 
estrogen only. In conclusion, from the few randomized double blind control trials it is 
apparent that estrogen therapy (i) has a significant and substantial effect in relieving 
vasomotor symptoms and vaginal dryness (ii) has a modest beneficial effect on mood, 
sleep problems, sexual functioning and well-being; however, these may be reduced by 
adding progestogens (iii) has an outspoken placebo impact on these symptoms, 
complaints and well-being. 
Most 'women have a neutral to positive attitude towards menopause. Obviously, 
women who have already experienced menopause are more positive than premenopausal 
women. Negative attitudes are clearly related to complaints. Women generally believe 
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that sexuality is not influenced negatively by the menopause. Only women who view 
menopause as a medical condition show a clear tendency to start the use of HRT. 
Hormone replacement therapy use rates, especially in Europe, are in general low and 
vary between countries from 3 to 13%. Less than 25% of the GPs in the UK, the 
Netherlands and Finland stated hormones should be given preventively. Surgical 
menopause, educational level, former use of anticonceptiva, menopausal status and 
vasomotor complaints are determinants for HRT use. The compliance with HRT is low; 
most studies indicate that more than 50% of women take HRT for a year or less. 
Chapter 2 
The climacteric is accompanied by many changes in life, which may give rise to a variety 
of complaints. Thus, it may be difficult to discern to what extentthe climacteric is related 
to well-being. 
The association between menopausal status and well-being was determined in a 
population of 2729 women aged 45 to 60 years. A self-administered questionnaire was 
filled out and returned by 1947 women (response 71.3%). Well-being was measured by 
the Inventory of Subjective Health and the three subscales of the Sickness Impact Profile: 
(i) social functioning, (ii) emotions, feelings and sensations and (iii) intellectual 
functioning. The relationship between menopausal status and well-being was estimated 
using linear regression analysis, while adjusting for age and other potential confounding 
variables, including Body Mass Index, smoking behaviour, education, work outside the 
home, parity, way of cohabitation, difference in age with the partner and partner's 
employment. 
The results show that early peri menopausal women report a lower level of well-being 
as compared to premenopausal women on all three SIP scales. Early postmenopausal 
women report a lower level of well-being on the SIP emotions, feelings and sensations. 
Intermediate postmenopausal women have a lower level of well-being on the ISH only. 
Finally, late postmenopausal women have a lower level of well-being on the SIP social 
functioning and SIP emotions feelings and sensations. We tentatively conclude that the 
influence of the climacteric on well-being independent of confounders is primarily 
found in behavioural functioning in the daily life of a woman. 
Chapter 3 
There are equivocal conceptions of the association between vasomotor symptoms and 
well-being. The aim of our study was to determine more closely the relationship between 
vasomotor symptoms, well-being and climacteric status according to the last menstrual 
bleeding and according to the women themselves. 
This relationship was investigated in a population of 2729 women aged 45-60 years. 
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A self administered questionnaire was filled out and returned by 1947 (71.3%) women. 
Well-being was measured by the Inventory of Subjective Health (ISH) and three 
subscales of the Sickness Impact Profile (SIP). Women were categorized as having 
vasomotor symptoms when they reported severe sweating and/or hot flushes. A logistic 
regression analysis was performed using dichotomized well-being scores as dependent 
variable and the presence of vasomotor symptoms as independent variable, adjusting for 
selected confounders. 
In this cross-sectional study we found that the relationship between vasomotor 
symptoms and well-being was dependent on the climacteric status. Pre- and (middle and 
late) postmenopausal women with vasomotor symptoms more often experienced a 
relatively lower level of well-being compared to women without these symptoms. 
However, in the peri menopause there was no difference in well-being between women 
with or without vasomotor symptoms, when the prevalence of vasomotor symptoms is 
at its highest level. In conclusion we suggest that, next to hormone replacement 
treatment, well-being may improve conSiderably when women are better informed 
about the presence and significance of vasomotor symptoms in pre- and postmenopause. 
Chapter 4 
This study aims to answer the following questions: (i) what is the attitude of women in 
the climacteric years towards menopause (ii) what is the association between attitude 
towards menopause and well-being (iii) to what extent is medical attention determined 
by both well-being and attitude towards menopause. 
All 2729 women aged 45-60 years living in a suburb of Rotterdam were sent a 
questionnaire. Of these 1947 (71.3%) were returned. Attitude was measured on 5 point 
rating scales using 28 items that have been used in other studies. Well-being was 
measured by the Inventory of Subjective Health and the three subscales of the Sickness 
Irnpact Profile. Medical attention was measured by asking the women whether they 
were currently being treated by GP or specialist. 
Results show that three clusters of attitudes towards menopause exist: two clusters 
encompass items reflecting attitudes towards disadvantages and advantages of the 
menopause, one cluster encompasses items reflecting attitudes towards (medical) 
treatment of the menopause. On the whole, women answer neutrally to items relating 
menopause with disadvantages and tend to agree with items relating menopause with 
advantages. The women slightly agree, premenopausal women more than others, with 
items that are in favour of treatment of menopausal complaints. Agreement with items 
on the disadvantage cluster is moderately associated with a low level of well-being, 
whereas agreement with items on the advantage cluster is slightly associated with a high 
level of well-being; the treatment cluster is not associated with well-being. Both relative 
low well-being and agreement with items on the treatment cluster are statistically 
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significantly associated with medical attention. 
Chapter 5 
The objective of the study was to assess the opinion of women aboutthe use of hormone 
replacement therapy (HRT) in relation to continuation or re-induction of menstrual 
cycles after menopause. 
The study was population-based cross-sectional using a postal questionnaire in 
Krimpen aan den IJssel, a commuter suburb of Rotterdam. 
The participants were all 2729 women living in Krimpen aan den IJssel aged 45-60 years, 
of whom 1947 (71.3%) responded. The main outcome measure was an opinion on 
monthly or trimonthly withdrawal bleedings with HRT. 
The results showed 16.9% of all women have no or little objection to use of HRT with 
monthly withdrawal bleedings. There is a marked difference between premenopausal 
women (32.4% have no or little objection) and postmenopausal women (only 9.2% have 
no or little objection). Trimonthly cycles during HRT tend to be perceived as more 
acceptable (41.4% of premenopausal women and 11.8% of postmenopausal women 
have no or little objection). 
It is concluded thata reasonable proportion of premenopausal women accept continuation 
of the menstrual cycle with HRT. There is a preference for trimonthly cycles above 
monthly withdrawal bleedings. Mostpostmenopausal women object to havingwithdrawal 
bleedings with HRT, irrespective of a monthly or trimonthly cycle. Research should 
continue on schedules without withdrawal bleedings. 
Chapter 6 
The aim of the present study was to ascertain the cumulative incidence of first hormone 
replacement therapy (HRn and the factors that predict its prescription. 
In a general population 1689 women were followed for 9 months in orderto trace first 
HRT prescriptions. Determinants (well-being, attitude towards menopause, menopausal 
status and another 9 variables) were measured by means of a questionnaire. Data 
analyses were performed for all women and for women with or without typical 
climacteric complaints. 
The cumulative 9 month incidence of HRT was 6.2%. For women without typical 
complaints a lower level of well-being (odds ratio 5.5; 95% CI 1.9-15.5) and the former 
use of the contraceptive pill (odds ratio 4.6; 95% CI 1.0-20.5) were independently 
associated with HRT prescription. For women with typical complaints a positive attitude 
towards "menopause should be treated" (odds ratio 3.8; 95% CI 1.8-8.0) was a 
determinant of HRT prescription. The cumulative incidence of HRT prescription is high, 
but from additional data it is apparent that within a period of one year and nine months 
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the majority of women stop taking HRT. For women without typical complaints, 
physiCians prescribe HRT five times more often to those with a lower level of well-being. 
For women with typical complaints the physician's prescription is primarily related to 
the woman's attitude towards (medical) treatment of the menopause. 
Chapter 7 
Little is known about the duration of the use of HRT. The aim of this study is (i) to assess 
the mean duration of use of HRT in general practice and (ii) to determine which variables 
predict the duration of HRT use. 
A general population of 1689 women aged 45-60 years and enlisted in 5 group 
practices of general practitioners were followed for 9 months to trace first HRT 
prescriptions. The 103 women who were presented HRT were all followed for a period 
of 2114 year. Duration of HRT was assessed by using the data provided on the dispension 
of HRT. Possible determinants of duration of use such as attitude towards menopause, 
menopausal status and another 6 variables were measured by means of a questionnaire. 
The 103 women were hardly ever prescribed HRT with a preventive purpose. More 
than 60% of the women stopped their HRT within 6 months and only 8% of the women 
remained for more than 2 years on HRT. The mean duration of use was 7 months. 
Determinants that significantly predicted the duration of HRT use were age, attitude 
towards treatment of the menopause and the group practice. We conclude that the mean 
duration is very low, even if all indications are short term, i.e. for the alleviation of 
menopausal symptoms. Apparently, women are presently unwilling to take HRT for 
longer periods. 
Chapter 8 
In the conclusive chapter the findings of the previous chapters are discussed, especially 
the implications for the physician are given. 
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Hoofdstuk 1 
Middels literatuurstudie trachtten we een antwoord te vinden op de volgende vragen: 
(i) bestaat er een climacterieel syndroom in termen van symptomen en klachten, 
uitsluitend en onafhankelijk gerelateerd aan de menopauzale status (ii) bestaat er een 
associatie tussen serum hormoonspiegel en een climacterieel syndroom (iii) verbetert 
oestrogene substitutietherapie symptomen, klachten en welbevinden vaneen mogelijk 
climacterieel syndroom (iv) welke zijn de attitudes en verwachtingen van de vrouwen 
zelf ten aanzien van de overgang (v) wat is er bekend over het gebruik van hormonale 
substitutietherapie onder vrouwen. 
De meeste studies stelden vast dat vasomotorische symptomen en vaginale droogte 
significante gerelateerd zijn aan de menopauzale status. Onderzoek in Westerse landen 
laat een duidelijk verband zien tussen de prevalentie van opvliegingen en nachtelijk 
zweten enerzijds en menopauzale status anderzijds. De prevalentie van deze symptomen 
is relatief laag onder Japanse vrouwen. In het algemeen blijkt uit studies dat de overgang 
een geringe invloed heeitopwelbevinden en seksualiteitsbeleving. Sommigeonderzoeken 
rapporteerden dat in het climacterium een relatie bestaat tussen vasomotorische 
klachten en atypische klachten (slaapstoornissen, minder sociaal functioneren). De 
meeste klachten in de overgangsjaren zijn niet geassocieerd met de overgang per se, 
maar worden verklaard door een diversiteit aan andere factoren. Uitgaande van recente 
gegevens kan gesteld worden dat, los van typische klachten, er weinig aanwijzingen zijn 
om te kunnen spreken van een goed gedefinieerd climacterieel syndroom. 
Of schoon een duidelijke vermindering in oestrogeenproduktie karakteristiek is voor 
de menopause, bestaat er geen verschil in hormoon spiegels tussen vrouwen met of 
zonder opvliegingen. 
Een gerandomiseerdedubbel blind en placebo gecontroleerdestudie is de geaccepteerde 
wetenschappelijke methode om vast te stellen dat behandeling met oestrogen en 
symptomen en klachten vermindert en het welbevinden verbetert. 
Onttrekkingsbloedingen, een gevolgvan de combinatievan oestrogenen met progestativa, 
vormen een groot probleem bij blindering van het onderzoek. Om blindering te kunnen-· 
bereiken werden sommige onderzoekingen verricht onder vrouwen zander baarmoeder, 
waarbij uiteraard de generaliseerbaarheid van de resultaten in het gedrang komt. Andere 
studies gebruikten aileen oestrogenen. Uit de weinige gerandomiseerde en dubbel blind 
uitgevoerde trials kunnen we concluderen dat therapie met oestrogenen: (i) een 
significant en substantieel effect heeit op het verlichten van vasomotorische symptomen 
en vaginale droogte (ii) een matige verbetering geeit van stemming, slaapstoornissen, 
seksueel functioneren en welbevinden; hoewel deze verbeteringen worden gereduceerd 
door het toevoegen van progestagenen (iii) een uitgesproken placebo effect heeit ten 
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aanzien van deze symptomen, klachten en welbevinden. 
De meeste vrouwen hebben een neutrale tot positieve attitude ten opzichte van de 
overgang. Vrouwen die de overgang al hebben ervaren, zijn een meer positieve attitude 
toegedaan dan premenopauzale vrouwen. Het hebben van negatieve attitudes is 
duidelijk gerelateerd met klachten. Over het algemeen menen vrouwen dat de 
seksualiteit door de overgang niet negatief wordt beinvloed. Slechts vrouwen die de 
overgang als een medische conditie beschouwen vertonen een duidelijke neiging om 
HST te gaan gebruiken. 
Vooral in Europa zijn de cijfers over gebruik van hormoon substitutietherapie (HST) 
over het algemeen laag en varieren van land tot land van 3 tot 13%. Minder dan 25% 
van de huisartsen in Engeland, Nederland en Finland zijn de mening toegedaan dat HST 
om preventieve redenen moet worden voorgeschreven. Chirurgische menopause, 
opleidingsniveau, eerder gebruik van orale anticonceptiva, menopauzale status en 
vasomotorische klachten zijn determinanten van HST gebruik. De compliantie met HST 
is laag; de meeste studies laten zien dat meer dan 50% van de vrouwen HST niet langer 
dan een jaar gebruikt. 
Hoofdstuk 2 
De overgang wordt vergezeld door vele veranderingen in het leven, welke een 
verscheidenheid aan klachten kunnen oproepen. Het kan derhalve moeilijk zijn te 
bepalen in welke mate de overgang op zichzelf samenhangt met het welbevinden. 
Het verband tussen de menopauzale status en welbevinden werd onderzocht in een 
populatie van 2729 vrouwen in de leeftijd van 45 tot 60 jaar. Een zelf ingevulde 
vragenlijst werd teruggestuurd door 1947 vrouwen (response 71,3%). Welbevinden 
werd gemeten met de VOEG (Vragenlijst Onderzoek Ervaren Gezondheid) en drie 
subschalen van de SIP (Sickness Impact Profile): (i) sociale interactie, (ij) emotioneel 
gedrag en (iii) alertheid en intellectueel functioneren. De relatie tussen menopauzale 
status en welbevinden werd bepaald middels lineaire regressie analyse, waarbij 
gecorrigeerd werd voor leeftijd en andere verstorende variabelen zoals Quetelet index, 
roken, opleiding, werk buitenshuis, aantal kinderen, samenlevingsvormen, verschil in 
leeftijd met de partner en werkstatus van de partner. 
De resultaten laten zien dat vroeg perimenopauzale vrouwen een lager niveau van 
welbevinden rapporteren vergeleken met premenopauzale vrouwen op de drie subschalen 
van de SIP. Vroeg-postmenopauzale vrouwen rapporteren een lager niveau van 
welbevinden op de SIP emotioneel gedrag. Vrouwen halverwege de postmenopauze 
hebben een lager niveau van welbevinden gemeten met de VOEG. Tenslotte hebben 
vrouwen die de overgang achter zich hebben een lager welbevinden op de SIP sociale 
interactie en de SIP emotioneel gedrag. Met enige terughoudendheid concluderen wij, 
dat de invloed van de overgang op het welbevinden, onafhankelijk van verstorende 
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variabelen, voornamelijk aanwezig is in het dagelijks functioneren van de vrouw. 
Hoofdstuk 3 
Er bestaan tegenstrijdige opvattingen over het verband tussen vasomotorische klachten 
en welbevinden. Het doel van onze studie was de relatie vast te stellen tussen 
vasomotorische klachten, welbevinden en de climacteriele status bepaald naar de 
laatste menstruatie en bepaald naar de indeling van de vrouwen zelf. 
Oit verband werd onderzocht in een populatie van 2729 vrouwen in de leeftijd van 
45 tot 60 jaar. Een zelf ingevulde vragenlijst werd door 1947 (response 71,3%) vrOuwen 
teruggestuurd. Welbevinden werd gemeten middels de VOEG (Vragenlijst Onderzoek 
Ervaren Gezondheid) en drie subschalen van de SIP (Sickness Impact Profile). Vrouwen 
werden ingedeeld in de groep met vasomotorische klachten wanneer zij ernstig zweten 
en/of opvliegers rapporteerden. Een logistische regressie met correctie voor geselecteerde 
verstorende variabelen werd uitgevoerd; hierbij vormden de gedichotomiseerde scores 
op de 4 schalen van welbevinden de afhankelijke variabelen. De onafhankelijke 
variabele was het al dan niet aanwezig zijn van vasomotorische symptomen. 
In deze dwarsdoorsnede studie vonden we dat het verband tussen vasomotorische 
symptomen en welbevinden afhankelijk was van de climacteriele status. Pre- en 
(midden en laat) postmenopauzale vrouwen met vasomotorische symptomen ervaren 
vaker een relatief lager niveau van welbevinden dan vrouwen zander deze symptomen. 
Echter, in de perimenopauzale fase, wanneer de prevalentie van vasomotorische 
klachten het hoogst is, bestond er geen verschil in welbevinden tussen vrouwen met of 
zonder vasomotorische klachten. Het is aannemelijk dat vasomotorische symptomen 
door andere dan farmacologische middelen kunnen worden bernvloed. Samenvattend 
stellen wij dat naast hormonale substitutietherapie het welbevinden aanzienlijk kan 
verbeteren wanneer vrouwen beter worden ge';nformeerd over de aanwezigheid en de 
betekenis van vasomotorische symptomen in de pre- en postmenopauze. 
Hoofdstuk 4 
Oeze studie wil de volgende vragen beantwoorden: (i) wat is de attitude ten aanzien van 
de overgang van vrouwen in de overgangsjaren (iO wat is het verband tussen de attitude 
ten aanzien van de overgang en welbevinden (iii) in welke mate dragen welbevinden, 
alswel attitude bij aan de verklaring van doktersbezoek. 
Aile 2729 vrouwen in de leeftijd van 45 tot 60 jaar, welke in een voorstad van 
Rotterdam wonen, kregen een vragenlijst per post toegezonden; van hen stuurden 1947 
(71,3%) vrouwen deze vragenlijst terug. Attitude werd gemeten op een 5-punts schaal 
bestaande uit 28 vragen, welke ook in andere studies werden gebruikt. Welbevinden 
werd gemeten middels de VOEG (Vragenlijst Onderzoek Ervaren Gezondheid) en drie 
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subschalen van de Sickness Impact Profile. Doktersbezoek werd gemeten door de 
vrouwen te vragen of zij onlangs door de huisarts of medisch specialist behandeld 
werden. 
De resultaten laten zien dat er drie groepen items bestaan: twee groepen omvatten 
items die ofwel een positieve ofwel een negatieve houding ten aanzien van de overgang 
weergeven, de derde groep omvat items welke een (medische) behandeling van de 
overgang voorstaan. Over het algemeen antwoorden vrouwen neutraal op items welke 
een negatieve voorstelling van de overgang geven en neigen zij het eens te zijn met de 
items welke een positief beeld van de overgang geven. Vrouwen zijn het matig eens met 
de items welke een voorkeur weerspiegelen voor behandeling van overgangsklachten, 
hetgeen sterker tot uitdrukking komt bij premenopauzale vrouwen. Instemming met 
items welke een negatief beeld van de overgang geven is geassocieerd met een laag 
niveau van welbevinden, terwijl instemming met items welke een positief beeld van de 
overgang schetsen in geringe mate geassocieerd is met een hoog niveau van welbevinden; 
de items welke een behandeling van overgangsklachten voorstaan zijn niet gerelateerd 
aan welbevinden. Zowel een laag welbevinden als instemming met items dat 
overgangsklachtenbehandeld moeten worden zijn statistisch significant geassocieerd 
met doktersbezoek. 
Hoofdstuk 5 
Het doel van de studie was de mening te bepalen van vrouwen over het gebruik van 
hormoon substitutietherapie (HST), waarbij het effect bezien werd van de voortzetting 
of het weer beginnen van de menstruele cyclus na de menopause. 
De studie was een dwarsdoorsnede van een populatie in Krimpen aid IJssel, een 
voorstad van Rotterdam, waarbij gebruik werd gemaakt van een per post opgestuurde 
vragenlijst. 
Aile 2729 vrouwen in de leeftijd tussen 45 en 60 jaar wonende in Krimpen aid IJssel 
werden benaderd, hiervan deden er 1947 (71.3%) mee. De mening overeen maandelijkse 
of een driemaandelijkse onttrekkingsbloeding als gevolg van HST werd gemeten. 
De resultaten Iieten zien dat 16,9% van aile vrouwen geen of weinig bezwaar hadden 
tegen gebruik van HST met maandelijkse onttrekkingsbloedingen. Een duidelijk verschil 
bestaat er tussen premenopauzale vrouwen (32,4% heeft geen of weinig bezwaar) en 
postmenopauzale vrouwen (slechts 9,2% heeft geen of weinig bezwaar). 
Geconcludeerd kan worden dat een redelijk gedeelte van de premenopauzale 
vrouwen accepteert dat de menstruele cyclus doorgaat. Een lichte voorkeur van 
driemaandelijkse cycli boven maandelijkse onttrekkingsbloedingen is aanwezig. De 
meeste postmenopauzale vrOuwen hebben bezwaar tegen onttrekkingsbloedingen ten 
gevolge van HST of dit nu maandelijks dan wei driemaandelijks is. Onderzoek naar 
behandelingsstrategieen zonder onttrekkingsbloedingen wordt aanbevolen. 
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Hoofdstuk 6 
Het doel van deze studie was het vaststellen van de cumulatieve incidentie van het 
eerste gebruik van hormonale substitutietherapie (HST) en de lactoren welke dit 
bepalen. 
Om de eerste HST recepten te bepalen werden in een algemene populatie 1689 
vrouwen gedurende 9 maanden gevolgd. Determinanten (welbevinden, attitude ten 
0pzichtevan deovergang, menopauzalestatusen 9 andere persoonsgebonden variabelen) 
werden gemeten middels een vragenlijst. Data analyse werd uitgevoerd voor aile 
vrouwen en alzonderlijk voor vrouwen met 01 zonder typische ciimacteriele klachten. 
De cumulatieve 9-maands incidentie van HST was 6,2%. V~~r vrouwen zander 
typische klachten waren een laag niveau van welbevinden (odds ratio 5.5;95% CI 1.9-
15.5) en het gebruik van de anticonceptieve pi! in het verleden (odds ratio 4.6;95% CI 
1.0-20.5) onalhankelijk geassocieerd met HST recepten. Voor vrouwen met typische 
klachten was een positieve attitude ten aanzien van "de overgang moet worden 
behandeld" (odds ratio 3.8; 95% CI 1.8-8.0) een determinant van HST voorschriften. De 
cumulatieve incidentie van HST voorschriften is hoog, maar uit aanvullende gegevens 
over een periode van 1 jaar en 9 maanden blijkt het merendeel van de vrouwen al gestopt 
te zijn met HST. Artsen schrijven vrouwen zonder typische klachten en met een laag 
niveau van welbevinden vijfmaal vaker HST voar. Daarnaast wordt voar vrouwen met 
typische klachten het voorschrijven van HST het sterkst bepaald door de attitude van de 
vrouw betreffende (medisch) behandelen van de overgang. 
Hoofdstuk 7 
Over de duur van het gebruik van HST is weinig bekend. Het doel van deze studie is: 
(i) de gemiddelde gebruiksduur van HST in de algemene praktijk vast te stellen en (ii) 
te bepalen welke variabelen de gebruiksduur van HST voorspellen. 
Een algemene populatie van 1689 vrouwen in de leeftijd van 45 tot 60 jaar behorende 
tot vijl huisartsgroepspraktijken werd gedurende 9 maanden gevolgd om zodoende 
eerste HST recepten te traceren. De 103 vrouwen, welke een HST recept meekregen, 
werden allen 2% jaar gevolgd. De duur van het gebruik van HST werd gemeten aan de 
hand van hoeveelheid en dosering van de verstrekte middelen op het recept. Mogelijke 
determinanten van de duur van het gebruik, zoals attitude ten opzichte van de overgang, 
menopauzale status en een ander zestal variabelen, werden gemeten middels een 
vragenlijst. 
De 103 vrouwen kregen zelden HST voorgeschreven voor preventieve doeleinden. 
Meer dan 60% van de vrouwen stopt hun gebruik van HST binnen 6 maanden, slechts 
8% van de vrouwen gebruikt HST langer dan 2 jaar. De gemiddelde gebruiksduur 
bedroeg 7 maanden. Leeftijd, de attitude "de overgang dient behandeld te worden" en 
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de huisartsgroepspraktijk waren determinanten welke significant de gebruiksduur van 
HST voorspelden. Wij concluderen dat de gemiddelde gebruiksduur kort is, zelfs als aile 
indicaties voor de korte termijn zijn, dat wil zeggen voor de verlichting van menopauzale 
symptomen. Blijkbaar gebruiken vrouwen op dit moment HST niet vOOr een langere 
periode. 
Hoofdstuk 8 
In het slothoofdstuk worden de resultaten uit de vorige hoofdstukken bediscussieerd. 
Daarnaast wordt aandacht geschonken aan de betekenis van de resultaten voor de arts. 
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APPENDIX I 
LEDER TO ALL WOMEN AGED 45-60 YEARS LIVING IN KRIMPEN AAN DEN IjSSEL 
ERASMUS UNIVERSITEIT ROTTERDAM 
Afd. Huisartsgeneeskunde 
Afct. Vrouwenziekten 
Krimpen aid IJssel, April 1990 
Dear Madam, 
In Krimpen aan den IJssel, I want to examine women's health and their 
opinion as to health and medical care. This study will take place with the 
support of the Department of General Practice (Read Prof. Dr. H.J. Dokter) 
and the Department of Gynaecology and Obstetrics (Read: Prof. Dr. A.C. 
Drogendijk), both of the Erasmus University Rotterdam. The group of women, 
now being approached for this, are in the age group 45-60 years, as you are. 
Your cooperation is indispensable for the success of this study. Enclosed you 
will find a questionnajre. 
I would appreciate it very much, if you would answer the questions. It takes 
about half an hour of your time. By means of the enclosed envelope, you can 
sent back the questionnaire free post. 
Later on it may perhaps be necessary to acquire additional data, therefore the 
questionnajre is sent to you by name. The questionnaire will be processed 
anonymously and only the undersigned knows the number and the name 
belonging to it. 
If you would like a summary of the results of the study, please indicate this on 
the last page of the questionnaire. 
Your sincerely, 
F.P.M.J. Groeneveld, general practitioner 
Meerkoetstraat 79 
2922 GM Krimpen aid IJssel 

APPENDIX II 
QUESTIONNAIRE 
ERASMUS UNIVERSITY ROTTERDAM 
DepartmentofGeneral Practice 
Department of Obstetrics and Gynaecology 
Women's Health Questionnaire 
APPENDIXII 143 
144 APPENDIXII 
A. If you regularly experienced the item concerned the PAST TWO WEEKS. please answer the question with circling 
'Ycs' or 'No' exclusively. 
1. Feeling of tiredness ............................ . 1. YES/NO 
2. Listlessness ...................................... . 2. YES/NO 
3. Sooner fatigued than normaL. ............... . 3. YES/NO 
4. Not rested in the morning .................... . 4. YESINO 
5. Not tired after a strenuous day .............. . 5. YES/NO 
6. Fit ................................................. . 6. YES/NO 
7. Stomach upset ............................. " .... . 7. YES/NO 
8. Stomach trouble ................................ . 8. YES/NO 
9. Pains in stomach region ....................... . 9. YES/NO 
10. Full and bloated fcclinS in the stomach .... . 10. YESINO 
11. Belly upset ...................................... . 11. YES!NO 
12. Bowel motion every day ...................... . 12. YES/NO 
13. Less appetite ................................... . 13. YES/NO 
14. Feeling hungry ..................... . 14. YES/NO 
15. Excessive thirst ............. . 15. YES/NO 
16. Unpleasant sweet ta.stc .. 16. YES/NO 
17. Loss of hair ..................................... . 17. YES/NO 
18. Too thin ......................................... . 18. YES/NO 
19. Overweisht .................................... . 19. YES/NO 
20. Acnelboils ....................................... . 20. YES/NO 
21. Scvere sweating ................................ . 21. YES/NO 
22. Nervous ........................................ .. 22. YES/NO 
23. Excited .......................................... .. 23. YES!NO 
24. lrrita.ted ......................................... . 24. YES!NO 
25. Tight in the chest. ............................. . 25. YES/NO 
26. Short, of breath ................................. . 26. YES/NO 
27. Pains in the chest ............................. . 27. YES/NO 
28. Heart palpita.tions ............................ .. 28. YES/NO 
29. Watering eyes ................................ .. 29. YES/NO 
30. Pains around the cyes ....................... .. 30. YES/NO 
31. Headache ...................................... .. 31. YES/NO 
32. Dizzy ............................................. . 32. YES/NO 
33. Roaring in thc cars ............................ . 33. YES/NO 
34. Dry vagina ..................................... . 34. YES/NO 
35. Itching ........................................... . 35. YES/NO 
36. Accident prone ............................... .. 36. YES/NO 
37. Bad cffect of alcoholic bevcrascs ........... . 37. YES/NO 
38. Sleepy/sluggish ................................ .. 38. YES/NO 
39. Sleeplessness .................................... . 39. YES/NO 
40. Fall asleep at once ............................. . 40. YES/NO 
41. Fall asleep at home from tiredness .... . 41. YES/NO 
42. Ache in bones 3.nd muscles ......... .. 42. YES/NO 
43. Backache .................... .. 43. YES/NO 
44. Numbed fee1inss in the limbs ................ . 44. YES/NO 
45. ShakinS hands ................................. . 45. YES/NO 
46. Weak aching feet .............................. . 46. YES/NO 
47. Cold fingers and toes ........................ . 47. YES/NO 
48. Coughing ........................................ . 48. YES/NO 
49. Sneezing ......................................... . 49. YES/NO 
SO. Clearing the throat ............................ .. 50. YESfNO 
51. Blocked nose ................................... . 51. YES!NO 
52. Feeling a lump in the throat ............... .. 52. YES/NO 
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B. 1. My height is .......... m 2. My weight is .... , ..... kg 
3. AT THIS MOMENT I am under the treatment of my general practitioner andlor specialist (circle the right 
answer). 
1. NO 
2. YES 
if yes, forwhat? ........................... . 
Are you being prescribed medicines momentarily for this? 
(circle). 
1. NO 
2. YES 
4. IN THE PAST 12 MONTHS I have been under treatment from my general practitioner and/or specialist. 
(circle). 
1. NO 
2. YES 
Was medicine prescribed for this? 
if yes, for what? ........................ . 
5. DURING THE PAST T'NO WEEKS. I have used medicines (including Homeopathic and chemists remedies 
such as stomach tablets, pain~killcrs etc. I.e all the medicines, which you have taken the past two weeks, wether 
or not prescribed by a doctor. 
(circle), 
1. NO 
2. YES 
if yes, which ones (write what is on the box) 
6. This question concerns your smoking habits 
(circle) 
1. I HAVE NEVER SMOKED (OR ONLY ONE PER 'WEEK) 
2. r HAVE SMOKED IN THE PAST 
3. I DO SMOKE MOMENTARILY 
if you smoke 
(circle) 1. 1-5 PER DAY 
2. 6-15 PER DAY 
3. MORE THAN 15 PER DAY 
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B. 7. This question encloses several parts and concerns YOUR MENSTRUATION. 
a) My last menstruation took place on .............................. . 
(date or only the year) 
b) During THE LAST 12 MONTHS I have had onc or more menstruations 
(circle your answer) 
1. NO 
2. YES, (if circled, please answer c d and e) 
c) My menstruation cycles have CHANGED the last year as compared to the preceding year. 
1. NO 
2. YES 
d) Last year I have had .......... times a menstruation 
e) If you have had menstruations during the past year, were these menstruations REGULAR 
(please circle your answer)? 
1. NO 
2. YES 
8. This question is about a possible HYSTERECTOMY you have undergone 
a) My uterus has been removed (circle) 
1. NO 
2. I DON'T KNOW 
3. YES 
if removed in which year 19 
Have both your ovaries been removed? 
1. NO 
2. I DON'T KNOW 
3. YES 
9. This question encloses the usc of ORAL ANTICONCEPTIVA (THE PILL') 
Have you used this? 
(circle) 
1. NO, NEVER USED 
2. YES 
if yes (circle one or more possibilities) 
1. USED IN THE PAST SHORTER THAN 3 MONTHS 
2. USED IN THE PAST LONGER THAN 3 MONTHS 
STOPPED 19 ........... (fill in the year). 
3. I USE IT MOMENTARILY 
SINCE 19 ........... (fill in the year). 
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C. By the following questions, answer the statcmcnL~ you think arc applicable to your PRESENT SITUATION and that 
arc also connected to your health and wc!1~bein£ (Circle YES or NO) 
1. I continWllly say how inferior and useless I feci ....................................... " .......... . 
Eg. that I am an inconvenience to others 
2. I began to cry or laugh without reason ............ " .................................. ,,', .......... . 
3, I often complain of/groan with pain an discomfort ...... . 
4. I have tried to end my life .. " .... " .. " .. 
5. 
6. 
I am nervous or restless................................ . ........................ . 
I continually rub or hold/grip parts of my body that hurt or feel unplcas~ 
ant/ache .................................................................................................. .. 
7. I reaet irritably or impatiently with my~clf ................ " ...................................... .. 
Eg. I say bad/evillwicked thing~ about myself, give myself the blame for things that 
happen 
8. I ~peak of the future w'ithout hope .................................................................. .. 
9: I "ddonly bocomo rcad"I...................... . .................. . 
10. I don't go out visiting/socially ......................................................... .. 
11. I go out socially less often ...................................................................... . 
12. I am less interested in other peoples' problems, 
Eg. I don't listen when told about them or offer to help .... 
13. I am often irrita.ble w'ith people around me 
Eg. r tum on them, answer sharply. criticize c:J.~ily .... 
14. I don't show my feelings c:J.~ily . 
15. I take part less often in group activitie~ ... 
16. I don't stay as long when visiting friends. 
17. I avoid having vi~itors ........................ .. 
18. I am less active sexually .................................. . 
19. I often show that I am concerned about what could happen to my 
health ...................................................................................................... .. 
20. I talk less to the people around me .................................................................... . 
21. I am more demanding of others ....................................................................... . 
22. Most of the time I remain alone .................................................. .. 
23. I am disagreeable to my nearest relations/family mcmbers/housc~ 
maids .............................. . 
24. I regularly turn on my relatives/housemaids. 
Eg I hit them, scream, throw things at them. 
25. r isolate myself from the rest of my nearest relatives/family members/housemaids 
26. I no longer have thc nonnal concern or interest in my children or fam~ 
ily..... ........................... . .............................. .. 
27. I joke less than usual with nearest relatives/family members/housemaids .. . 
28. I'm confused and begin several things simultaneously ....................... .. 
29. I have more small accidents ego I drop things/stumble etc .. .. .............. .. 
30. I react slowly to what is said and done ............................................................. . 
31. I don't fmish things that I start ...................................................................... . 
32. I have difficulties thinking things through and solving problems.... .. .......... .. 
33. I sometimes act as though I'm confused, have no knowledge of place and time etc 
Eg I don't know where I am, who is with me, in which direction I am going, I don't 
know which day it is 
34. I'm forgetful. .... 
Eg Where I've left things, appointments I have made 
35. I ean't concentrJ.te on things for long ..... 
36. I make more mistakes/errors than usual. 
37. I have difficulty doing things which I have to concentrate or think about ...... 
1. YES/NO 
2. YES/NO 
3. YES/NO 
4. YES/NO 
5. YESINO 
6. YES/NO 
7. YES/NO 
8. YES/NO 
9. YES/NO 
10. YES/NO 
11. YES/NO 
12. YES/NO 
13. YES/NO 
14. YES/NO 
IS. YES/NO 
16. YES/NO 
17. YES/NO 
18. YESINO 
19. YES/NO 
20. YESINO 
21. YES/NO 
22. YESINO 
23. YES/NO 
24. YES/NO 
25. YES/NO 
26. YES/NO 
27. Y;SINO 
28. YES/NO 
29. YES/NO 
30. YES/NO 
3.1. YES/NO 
32. YE$INO 
33. YES/NO 
34. YES/NO 
35. YES/NO 
36. YES/NO 
37. YES/NO 
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D. This Women Health Questionnaire has been scnt to all women in Krimpcn aid IJsscl between the ages of 4S and 60 
years. As during this period most women experience the menopause, we would like to hear THE WOMEN'S OWN 
OPINION, irrespective of whether YOu have begun the menopause or not. 
Give, by marking a figure, your opinion about the next statements. 
1 = completely agree 
2= a little agree 
3= neutral 
4= do not agree a little 
5 = completely do not agree 
For example: 
During the menopause the hair in the face augments ...................... agrcc (1) IX! (3) (4) (5) not agree 
By marking fi£ure 2 you are a little agreed with the statement the hair grows in the face. but you are not quite 
convinced, as you would mark 1. 
AGREE DISAGREE 
1. The climacteric brings many positive aspects (I) (2) (3) (4) (5) 
2. Problems in the climacteric disappear spontaneously (1) (2) (3) (4) (5) 
3. Women expccting complaints in the menopause will get them (1) (2) (3) (4) (5) 
4. It is pleasant that prcgnancy is not possible aftcr the menopause (1) (2) (3) (4) (5) 
5. One starts to fcel old in the climacteric (1) (2) (3) (4) (5) 
6. Women in the climacteric. with problems. should consult their GP (1) (2) (3) (4) (5) 
7. In the climacteric women can stand less stress (1) (2) (3) (4) (5) 
8. The climacteric coincides with bothersome complaints (1) (2) (3) (4) (5) 
9. Complaints in the climacteric must NOT be treatcd with drugs (1) (2) (3) (4) (5) 
10. Women with bothersome elimacteric complaints must get hormone therapy (1) (2) (3) (4) (5) 
11. The benefits of hormonc therapy outweigh the risk (1) (2) (3) (4) (5) 
12. After the climacteric sex is more pleasant (1) (2) (3) (4) (5) 
13. In the climacteric a women often has more psychological problems (1) (2) (3) (4) (5) 
14. Women in the climacteric must have the insight that physical changes are (1) (2) (3) (4) (5) 
natural 
15. One grows mature and more self-confidcnt in the climactcric (1) (2) (3) (4) (5) 
16. Partners of postmenopausal women regard thcm as less scxual attractive (1) (2) (3) (4) (5) 
17. Phenomena in the climacteric must be treated medically (1) (2) (3) (4) (5) 
18. For the women the climacteric is an unpleasant period (1) (2) (3) (4) (5) 
19. During the climacteric one feels less like undertaking something (1) (2) (3) (4) (5) 
20. After the menopause the sexual relationship is bcttcr (1) (2) (3) (4) (5) 
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AGREE DISAGREE 
21. One should have a preference for natural approaches (i.e. attending to nutri~ (1) (2) (3) (4) (5) 
tional requirements. vitamin supplements, exercise programs) for mcnopau~ 
sal problems 
22. In the climacteric one often feels unwell (1) (2) (3) (4) (5) 
23. The absence of the menstrua.tion after menopause is a relief (1) (2) (3) (4) (5) 
24. A women feels less attractive after the menopause (1) (2) (3) (4) (5) 
25. Psychological problems women experience during the climacteric stand (1) (2) (3) (4) (5) 
apart from co-occurring changes in life i.e. children leaving home, the de-
ath of parent..'> 
26. After menopause a women have less sexual needs (1) (2) (3) (4) (5) 
27. The cause of all problems in the climacteric is something that women can (1) (2) (3) (4) (5) 
not control by themselves~something from outside 
28. After menopause one feels more free and more independent (1) (2) (3) (4) (5) 
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E. The following questions concern complaints and treatment during and after the menopause 
1. In which phase, your own opinion, would you place yourself AT THIS MOMENT? 
(circle your answc'r) 
1. I HAVE NOT REACHED THE MENOPAUSE 
2. I HAVE JUST REACHED THE MENOPAUSE 
3. I AM IN THE MIDDLE OF THE MENOPAUSE 
4. I HAVE REACHED THE END OF THE MENOPAUSE 
5. I REACHED THE MENoPAUSE LONG AGO 
Please will you answer the following questions. even if you have not reached the menopause! 
2. Which complaint.s or symptoms do you think that arc prescnt during menopause, arc REALLY caused by the 
menopause? 
(please write in capital letters) 
3. Which of the above mentioned complaints (question 2) have you YOURSELF experienced during the last four 
weeks. 
Please will you state after the complaint, whether this has occurred regularly or only occasionally? 
COMPLAINT REGULAR SOMETIMES 
For example: coughing x 
4. When the periods stop, several changes arise in a woman's body, which could be caused by a deficiency of 
female hormones and of which symptoms only become clear after many years. 
A. Which complaints and disease DO YOU KNOW that are linked to a deficiency of female (estrogens) 
hormones? 
(again write in capital letters please) 
B, If you have filled out 4A, please will you indicate, if you would Cake hormones FOR THE PREVENTION of 
the diseases and complaints mentioned by yourself 
(circle your answer). 
1. UNDER NO CIRCUMSTANCES WOULD I WANT HORMONE TREATMENT FOR PREVEN 
TION THE ABOVE MENTIONED DISEASES AND COMPLAINTS. 
2 .. , I WOULD 9NLY DO THIS. WHEN AFTER CONSULTATION WITH MY GENERAL 
PRACTmONER THERE IS AN AUGMENTED CHANCE OF THE DISEASES AND 
COMPLAINTS MENTIONED BY MYSELF 
3. HORMONE TREATMENT FOR THE PREVENTION OF THE COMPLAINTS AND DIS 
EASES, AS :MENTIONED BY MYSELF, APPEALS TO ME VERY MUCH. 
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4. I DON'T HAVE A CLEAR OPINION ABOUT THIS. 
F. Complaints during the climacteric years can sometimes be treated benefIcially with estrogens. The following 
questions refer to this. 
1. Do you want to take hormonal treatment for climacteric complaints? 
(circle your answer), 
1. UNDER NO CIRCUMSTANCES WOULD I WANT HORMONE TREATMENTPOR CLIMAC~ 
TERIC COMPLAINTS. 
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2. I WOULD ONLY TAKE HORMONE TREATMENT IF SUFFERING GREATLY FROM CLIMAC-
TERIC COMPLAINTS. 
3. I SHOULD TAKE HORMONE TREATMENT ALSO IN THE CASE OF LESS SERIOUS 
CLIMACTERIC COMPLAINTS TOO. 
4. I DONT HAVE A CLEAR OPINION ABOUT THIS. 
2. a) 'When you still have got your uterus. your periods will continue (or restart) after menopause as a conse-
quence of hormone treatment. 
What is your opinion of hormonal treatment when your menstrual cycle will continue or restart once a 
month when using this treatment. 
(circle onc answer) 
1. I HAVE NO OBJECTION. 
2. I HAVE UTILE OBJECTION. 
3. I HAVE MUCH OBJECTION. 
4. I DON'T WANT THAT. 
5. I HAVE NO OPINION ABOUT IT. 
2. b) And when your menstrual bleedings would continue or restart once every three months (circle one_answer) 
1. I HAVE NO OBJECTION. 
2. I HAVE LITTLE OBJECTION. 
3. I HAVE MUCH OBJECTION. 
4. I DOWT WANT THAT. 
S. I HAVE NO OPINION ABOUT IT. 
3. Please indicate how you experience (or experienced) your periods by circling one of the following numbers 
1. I HAVE/HAD VERY MUCH DISCOMFORT DURING MY MENSTRUATIONS. 
2. I HAVE/HAD MUCH DISCOMFORT DURING MY MENSTRUATION. 
3. I HAVE/HAD SCARCELY ANY DISCOMFORT DURING MY MENSTRUATIONS. 
4. I HAVE/HAD NO DISCOMFORT DURING MY MENSTRUATIONS, 
4. DO YOU TAKE AT THIS MOMENT estrogens for the treatment of climacteric complaints? 
1. NO 
2. YES 
If yes: WHICH ONES: ...................................................... . 
SINCE HOW MANY MONTHS: ................................. . 
S. Apart from treatment with hormones, there are other possibilities to lessen or prevent complaints eaused by the 
transition. 
We think hereby of discussion groups. homeopathic medicines and other non-hormonal medicines. 
Could you indicate below which treatmcnt(s) you prefer and why? 
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G. We start now with THE LAST PART of the questionnaire. This deals with some general data about yourself: 
1. I was BORN: DAy ........ MONTH ........ YEAR ....... . 
2. My MARITAL STATUS is: 
(circle one answer) 
1. MARRIED 
2. SINGLE 
3. DrvORCED 
4. WIDOWED 
3. 'Nhich EDUCATION(S) did you follow? 
(morc answers arc possible, circle) 
1. PRIMARY SCHOOL 
2. VOCATIONAL SCHOOL (LOWER SECONDARy) 
3. LOWER SECONDARY SCHOOL 
4. SECONDARY SCHOOL 
5. HIGHER SECONDARY EDUCATION 
6. VOCATIONAL SCHOOL (ADVANCED LEVEL) 
7. UNIVERSITY 
4. I am a HOUSEWIFE. 
(circle). 
1. YES 
2. NO 
5. a) I have a PROFESSION 
(circle). 
1. NO 
2. YES--> Which PROFESSION ......................... . 
b) do you work, apart from being a housewife, outside the home 
(circle). 
1. NO 
2. YES--> 
6. llive 
(circle). 
1. ALONE > GO T0 QUESTION 10! 
2. WITH HUSBAND/PARTNER. 
3. WITH CHILD(REN). 
4. WITH HUSBAND/PARTNER AND CHILDREN. 
7. The age of my husband/partner is ........ years 
8. The health of my husband/partner is: 
(circle) 
1. GOOD. 
2. BAD. 
3. NEITHER GOOD NOR BAD. 
if yes: 
a) HOW MANY HRS/WK ................ . 
b) which JOB: 
G.9. My husband/partnerworks 
(cirde) 
1. YES 
2. NO 
if no 
(circle) 
1. 
2. 
3. 
4. 
RETIRED 
UNEMPLOYED 
WAD 
HOUSEMAN 
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10. I have CHILDREN (own, step--, or adopted children). 
(circle) 
1. NO 
2. YES------>if yes: a) HOW MANY .................. " ........... . 
b) AGES ....•.............................•...... 
c) HOW MANY STILL AT HOME ....... . 
11. I have gained INFORMATION AND KNOWLEDGE about the climacteric years. 
(circle one or more numbers). 
1. FROM TALKS WITH FRIENDS, FAMILY MEMBERS. ACQUAINTANCES. 
2. FROM THE GENERAL PRACTITIONER. 
3. FROM MAGAZINESINEWSPAPERS, 
4. TV. 
5. FROM OTHER SOURCES, WHICH ONES? ......... " ............. . 
6. I HAVE NOT (YET) PAID ATTENTION TO THIS PERIOD OF LIFE 
12. 1 am in need of extra information 
(circle) 
1. NO 
2. YES 
if yes, about which subjcct(s) would you like to gain information? 
(circle one or more numbers). 
1. THE CAUSE OF MENOPAUSE. 
2. COMPLAINTS DURING THE MENOPAUSE. 
3. (LATER) CONSEQUENCES AFTER MENOPAUSE. 
4. REDUCING COMPLAINTS WITH HORMONAL TREATMENT. 
S. OTHER MEANS OF REDUCING COMPLAINTS DURING MENOPAUSE. 
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6. PREVENTION OF LATER CONSEQUENCES OF HORMONE (OESTROGEN) DEFICIENCY I.E. 
OSTEOPOROSIS. 
7. RISKS AND BENEmS OF HORMONAL TREATMENT. 
13. WHO IS YOUR GENERAL PRACTITIONER: ...................... . 
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14. For a limited group of women we want to complete dat:l from the questionnaire with questions about medical 
attention and usc of medicines. Would you agree to us contacting your family physician and/or pharmacists 
concerning THIS SUBJECT. 
(circle). 
1. No, I object 
2. Yes, no objection 
---> Signature 
15. DO YOU WANT TO HAVE A SUMMARY OF THE RESULTS LATER ON? 
(circle), 
1. NO 
2. YES 
THANK YOU VERY MUCH FOR YOUR EFFORTS 
Room for remarks: 
NOTES 
NOTES 
NOTES 
NOTES 


